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The major part of this thesis describes studies of human ubiquitin-specific protease 7 (USP7), a
deubiquitinating enzyme that regulates cellular levels of key oncoproteins and tumor suppressors.
Inactivation of USP7 has recently emerged as a new approach to treatment of malignancies. However,
design of potent and specific small-molecule compounds requires detailed understanding of the molecular
mechanisms of USP7 substrate recognition and regulation of its catalytic activity. The goal of this work
was to explore these mechanisms using solution nuclear magnetic resonance spectroscopy in combination
with other methods. In our studies of USP7 substrate recognition, we structurally characterized its
interaction with ICP0 protein from Herpes Simplex virus 1 and identified a novel USP7 substrate-binding
site harbored within its C-terminal region. To address the question of USP7 activity regulation, we
investigated its interaction with ubiquitin, which was believed to cause structural rearrangement of USP7
active site from an unproductive to a catalytically competent conformation. Surprisingly, we showed that
in solution USP7 – ubiquitin interaction alone is not sufficient for activation of the enzyme as was
previously postulated. Finally, we uncovered a previously unknown mechanism of USP7 inactivation by
two of its known inhibitors. We found that these compounds bind to the active site of USP7 and inactivate
the enzyme via covalent modification of a catalytic cysteine residue. The efficacy of the inhibitors was
confirmed in cells. Altogether, these results advance our understanding of the mechanisms of substrate
specificity, activation and inhibition of USP7 and open new strategies for rational structure-based drug
design.
Chapter 4 describes another example of using NMR spectroscopy in studies of complex biological
systems. REV1 is a translesion synthesis (TLS) DNA polymerase that plays a key role in replication
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across the sites of DNA damage. Beyond its catalytic activity, its major role is to recruit other TLS
polymerases to DNA lesions. The goal of this work was to structurally characterize protein – protein
interactions mediated by the C-terminal region of REV1 (REV1-CT). We determined a solution NMR
structure of REV1-CT alone and in complex with TLS polymerase η, and unraveled the molecular
mechanism by which REV1 recognizes other Y-family TLS polymerases.
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CHAPTER 1

Introduction
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1.1. USP7 – a complex, pharmaceutically relevant biological system
1.1.1. Overview of ubiquitin – proteasome system
As a part of their metabolism cells constantly synthetize new proteins and, at the same time,
break down proteins that are misfolded, aggregated or no longer needed. Eukaryotic cells
developed two major systems responsible for protein degradation: lysosomal proteolysis and the
ubiquitin – proteasome system (UPS). While the first system is specialized in degradation of
membrane and endocytosed proteins, UPS is versatile and accomplishes degradation of the
majority of cellular proteins (1). In this pathway a polyubiquitin chain is conjugated to a protein
substrate. This chain serves as a signal for the substrate recognition and degradation by the 26S
proteasome. Protein ubiquitination is a multi-step process, involving consecutive action of three
enzymes: ubiquitin-activating enzyme E1, ubiquitin-conjugating enzyme E2 and E3 ligase
(Figure 1.1). First, E1 uses ATP to form a thioester bond between a cysteine residue in its active
site and the C-terminal glycine of ubiquitin. Activated ubiquitin is then transferred to E2 with the
formation of second thioester intermediate. In the final step, ubiquitin is transferred to a protein
substrate with help of E3 ligase (2). There are two families of E3 ligases that act through
different mechanisms. RING E3 ligases bind both the E2 – ubiquitin complex and a substrate
bringing them together and, thereby, promoting the attack of the substrate lysine residue on E2 –
ubiquitin thioester (3). E3 ligases of the HECT family receive ubiquitin from E2 with formation
of the third thioester intermediate and then transfer it to the substrate (4). The process described
above can be repeated several times to generate a polyubiquitin chain that consists of ubiquitin
monomers attached to each other through a linkage between one of seven lysine residues (Lys6,
Lys11, Lys27, Lys29, Lys33, Lys48, and Lys63) of one monomer and the C-terminal glycine of
another. Chains linked through N-terminal methionine can also be formed (5). Interestingly, only
2

Lys48- and Lys11-linked chains are known to target proteins to proteasome (6) while other
linkage types are involved in signaling pathways distinct from protein degradation. Specifically,
K63-linked chains play a role in regulating signal transduction, DNA repair and endocytosis
(7,8), and linear polyubiquitin (Met1-linked) is important in inflammatory cytokine signaling (9).
In addition to polyubiquitination, protein monoubiquitination often takes place in various cellular
pathways such as intracellular and membrane trafficking, DNA transcription and DNA repair
(10). Overall, the functions of protein ubiquitination are not limited to mediating proteasomedependent degradation. The ability of ubiquitin to form various polymers adds a complexity to
UPS in which mono- and polyubiquitination as well as diverse chain linkage types determine
different functional outcomes for protein substrates.
1.1.2. Deubiquitinating enzymes and their role in the ubiquitin – proteasome system
Protein ubiquitination can be reversed by action of deubiquitinating enzymes (DUBs) that
cleave ubiquitin moieties from their substrates. Nearly 100 DUBs identified in human genome
can be classified into two mechanistically distinct classes: metalloproteases and cysteine
proteases (11). Metalloproteases coordinate a zinc ion and a water molecule in the active site.
During catalysis, a hydrogen atom from the water molecule is abstracted by a neighboring
glutamate residue and the resulting hydroxyl ion attacks the carbonyl carbon of the isopeptide
bond. In humans, metalloproteases are represented by a family of JAB1/MPN/MOV34 domain
containing proteases (JAMM) that consists of 12 members (12). The catalytic mechanism of
cysteine proteases is analogous to that of well-studied plant enzymes papains (13). All cysteine
peptidases share a catalytic triad consisting of cysteine, histidine and aspartate/asparagine
residues. The role of the histidine is to deprotonate the thiol group of the cysteine and initiate its
nucleophilic attack on the isopeptide bond, while the aspartate restricts side-chain rotation of the
3

histidine and polarizes it. Based on the architecture of the catalytic core, cysteine proteases can
be subdivided into five families (Figure 1.2). Four families including ubiquitin-specific proteases
(USPs) ubiquitin carboxyl-terminal hydrolases (UCHs), ovarian tumor proteases (OTUs) and
Machado-Joseph (Josephin) domain containing (MJD) proteases have been extensively studied
(14). The fifth family of MINDY proteases (motif interacting with ubiquitin-containing novel
DUB family) was recently discovered and, to date, contains only one characterized protein
MINDY-1 (15). Structurally, proteins of UCH family are relatively small and do not have
domains other than the catalytic core while DUBs from other families often have varying
numbers of additional domains with distinct structures and functions. These domains often
participate in protein – protein interactions such as assembly in macromolecular complexes or
DUB binding to substrates and substrate adaptors (16).
DUBs perform a variety of functions in the UPS (Figure 1.1). They remove polyubiquitin
chains from their substrates thus preventing their proteasomal degradation. Furthermore, DUBs
recycle ubiquitin by disassembling the chains. These enzymes are also involved in maturation of
ubiquitin, which is synthetized as a linear fusion protein. DUBs cleave the precursor and
generate a pool of ubiquitin monomers. Finally, DUBs can redirect the fate of a substrate by
editing the conjugated ubiquitin chains. For example, they can transform polyubiquitinated
protein into monoubiquitinated and vice versa. In some instances, they disassemble a chain of
one linkage type so a chain of a different linkage could be formed (17). Interestingly, some
DUBs, including many USPs, recognize ubiquitin chains of several linkage types while others
demonstrate linkage specificity (16). For example, proteases of the JAMM family cleave K63linked chains only (18,19). In contrast, OTU family members vary in their linkage preferences.
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Thus, OTUD4 and OTUB1 are specific to Lys48, Cezanne and Cezanne2 – to Lys11, OTUD1 –
to Lys63 and OTULIN – to Met1 (14).
Given the number of cellular pathways involving protein deubiquitination, it is not surprising
that DUBs activity is tightly regulated. To date, a few mechanisms of DUBs regulation have
been discovered that function independently or in combination, depending on the particular
enzyme. These mechanisms include post-translational modifications, recruitment to substrates
and/or proteasome, inner structural rearrangements upon substrate binding and, finally,
interactions with other proteins that can either activate or inhibit the enzyme (20). In turn,
dysregulation of DUBs activity was linked to prostate, colon, ovary and other cancers as well as
to neurodegenerative diseases such as Parkinson disease and ataxia (21,22).
Overall, protein ubiquitination and deubiquitination are two highly dynamic processes that
maintain a delicate balance between protein stabilization and degradation, and mediate numerous
signaling pathways in the cell. Interest in studying DUBs rapidly developed in recent years due
to their contribution to almost every cellular process and their role in human pathologies. Despite
some progress made in elucidation of DUBs activity and regulation, only a small fraction of
these enzymes has been well characterized. The substrates, mechanisms of regulation as well as
three-dimensional structures of many DUBs are still not known and many questions remain
unanswered even for those enzymes that have been extensively studied. How do DUBs
distinguish between ubiquitin chains of different linkage types? What are the general
mechanisms of controlling DUBs activity that are applied within and across the families?
Multiple layers of regulation were described for several enzymes but in order to generalize these
mechanisms we need further studies of many other DUBs. The same is true for defining the
determinants of DUBs substrate specificity. The lack of information about protein targets for
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many enzymes prevents determination of common substrate features. Finally, we do not know
how DUBs are regulated in the context of macromolecular complexes since such studies are
complex and limited by modern technology.

1.1.3. Introducing USP7: functions, substrates and regulation
Human ubiquitin-specific protease 7 (USP7) also known as Herpes virus associated protease
(HAUSP) belongs to the largest DUB family of USPs. Located in the nucleus, it regulates the
stability of many proteins involved in multiple cellular processes (Table 1.1) (23). One such
process is the DNA damage response where USP7 performs several functions. First, it
deubiquitinates both transcription factor p53 and E3 ligase HDM2 responsible for
polyubiquitination of p53 and targeting it to the proteasome (24-26). Interestingly, USP7
preferably binds HDM2 preventing its degradation (27). In turn, HDM2 ubiquitinates p53 and
maintains low cellular levels of this tumor suppressor during normal homeostasis. DNA damage
causes ATM-dependent dephosphorylation of USP7 by PPM1G that decreases the affinity of the
enzyme towards HDM2 (28). Consequently, USP7 associates with p53 and protects it from
ubiquitination. This interaction results in p53 stabilization and initiation of the p53-dependent
DNA damage response. Second, USP7 is involved in regulation of nucleotide excision repair.
Specifically, it prevents degradation of the XPC protein that recognizes helix-distorting DNA
lesions and initiates the repair (29). Furthermore, USP7 plays a significant role in the ATR-Chk1
branch of the DNA damage response pathway where it deubiquitinates and stabilizes Chk1, an
important checkpoint kinase (30), and clapsin, an adapter protein (31). Another interesting
substrate of USP7 is UVSSA, one of the initiating factors of UV-induced transcription-coupled
DNA repair (32). Finally, in response to genotoxic stress, USP7 stabilizes HLTF that regulates
error-free replication through DNA lesions (33).
6

On the other hand, USP7 is also involved in DNA damage tolerance pathways. It controls the
stability of E3 ligase Rad18 that monoubiquitinates a proliferating-cell nuclear antigen (PCNA)
in response to the presence of DNA lesions stalling the replication fork (34). PCNA
monoubiquitination facilitates recruitment of specialized translesion synthesis (TLS) DNA
polymerases, which can efficiently bypass DNA lesions, thereby allowing replication to proceed
(35). The stability of at least one TLS polymerase, polymerase η, is also controlled by USP7
(36). In addition, USP7 plays a role in conventional DNA replication. First, its complex with
MCM-BP unloads the minichromosome maintenance protein complex from chromatin at the end
of S-phase (37). Second, it was recently suggested that USP7 might regulate replication fork
progression through creating SUMO-rich environment at sites of DNA replication (38). Finally,
USP7 controls protein levels of replisome components UHRF1 and methyltransferase DNMT1
that function together in maintaining tissue-specific DNA methylation patterns (39,40).
There are many other cellular pathways that require the deubiquitinase activity of USP7. For
instance, this enzyme associates with chromatin and participates in epigenetic control of gene
expression. Specifically, USP7 interacts with BMI1, MEL18, SCML2 and E3 ligase RING1B –
components of the PRC1 complex responsible for monoubiquitination of histone H2A, which
results in gene repression (41-43). It also stabilizes several other histone-associated proteins such
as acetyltransferase TIP60 (44), demethylase PHF8 (45), methyltransferase MLL5 (46) and E3
ligase RNF168 (47). Furthermore, USP7 functions in the immune response where it regulates the
transcription activity of master transcription factor NF-kB via stabilization of its subunit p65
(48).
Although USP7 is mostly known for removing polyubiquitin chains from its substrates, it is
also capable of deubiquitinating monoubiquitinated proteins. Thus, USP7 forms a complex with
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GMPS in Drosophila and removes monoubiquitin from histone H2B thereby contributing to
gene silencing (49). In humans, USP7 deubiquitinates monoubiquitinated transcription factors
PTEN and FOX(O)4 (50,51). In this case, the activity of USP7 is a part of a mechanism
negatively regulating the transcription activity of these proteins since deubiquitination of both
PTEN and FOX(O)4 causes their translocation from the nucleus to cytoplasm and, therefore,
their inactivation. As a side note, some functions of USP7 do not require its deubiquitinase
activity at all. In particular, the enzyme negatively regulates PML nuclear bodies and the
mechanism relies only on USP7 interactions with other proteins (52).
In addition to numerous cellular processes, USP7 is known to play a role in viral infection.
Originally, it was discovered as an enzyme associated with ICP0, an immediate-early protein
from Herpes Simplex Virus-1 (53). ICP0 is the E3 ligase required for efficient lytic infection
(54). Its binding to USP7 prevents its auto-ubiquitination and proteasomal degradation (55).
Later studies revealed that USP7 interacts with proteins from three other viruses of the
Herpesviridae family. Thus, binding of USP7 to LANA from Kaposi’s sarcoma-associated
herpes virus (KSHV) and its functional homologue EBNA-1 from Epstein-Barr virus (EBV) has
a regulatory effect on latent viral replication (56,57). Furthermore, EBNA-1 – USP7 interaction
blocks the interaction of the latter to p53 and, therefore, diminishes p53 stabilization (58). The
similar viral mechanism that disrupts the p53-mediated antiviral response was proposed for
another USP7 substrate, the vIRF4 protein from KSHV (59), while the significance of interaction
between USP7 and UL35 from human cytomegalovirus (HCMV) remains elusive (60). Finally,
besides the role in infections mediated by Herpesviruses, USP7 also promotes adenoviral
replication via interaction with viral multifunctional protein E1B-55K (61).
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USP7 is an important component of UPS and its activity in the cell is tightly regulated to
avoid uncontrolled stabilization of its multiple substrates. There are several levels of USP7
regulation including intermolecular mechanisms, post-transcriptional modifications and protein –
protein interactions. Intramolecular mechanisms include the domain reorganization required for
the enzyme activation and the active site rearrangement upon ubiquitin binding (described in
chapter 1.1.4). Post-transcriptional modifications further tune USP7 activity. In particular, the
enzyme was shown to be phosphorylated at Ser18 and Ser963, and ubiquitinated at Lys869 (62).
Phosphorylation at Ser18 by protein kinase CK2 alters affinity of USP7 towards its substrates
HDM2 and p53 in such a way that the phosphorylated enzyme preferably binds to HDM2 while
its dephosphorylation results in higher affinity to p53 (28). USP7 ubiquitination at Lys869 by E3
ligase TRIM27 promotes TNF-α-induced apoptosis through deubiquitination of RIPK1 (63) and
the role of phosphorylation at Ser963 remains to be determined. In addition, USP7 is aberrantly
phosphorylated at Tyr243 by chimeric protein p210 BCR-ABL in chronic myeloid leukemia
(CML) cells. This post-translational modification enhances deubiquitinase activity of the enzyme
towards tumor suppressor PTEN, whose dysregulation is critical for CML pathogenesis (64). The
highest level of USP7 regulation is mediated by several proteins that interact with the enzyme
and mediate its activity. Thus, Daxx binds to USP7 and HDM2 facilitating deubiquitination of
the latter (65). Daxx – USP7 complex also regulates stability of E3 ligase CHFR and Aurora-A
kinase involved in mitosis progression (66). In the Wnt/β-catenin signaling pathway USP7
mediated stabilization of β-catenin depends on E3 ligase RNF220 that forms a tertiary complex
with both USP7 and β-catenin and promotes deubiquitination of the latter (67). Another protein,
MBD4, recruits USP7 to heterochromatin foci in order to co-localize it with UHRF1 and
DNMT1 thus promoting their interaction (68). Finally, at least one protein, TRAF4 negatively
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regulates USP7 activity. It binds to the same region of USP7 as p53 blocking p53 accesses to the
enzyme. This inhibition mechanism was shown to play an important role in breast cancers where
TRAF4 overexpression prevents USP7-mediated p53 stabilization and diminishes cytotoxic
stress response (69).

1.1.4. Structure of USP7
Schematic representation of USP7 domain organization is shown in Figure 1.3A. USP is a
large 1102 residue (135 kDa) protein that consists of seven domains including an N-terminal
TRAF (tumor necrosis factor receptor – associated factor)-like domain, a central catalytic core
and five C-terminal ubiquitin-like domains (UBLs) (70,71). The N-terminal TRAF-like domain
encompasses the protein residues 53-205 and has a characteristic for all TRAF domains fold
(58). Specifically, it adopts a conformation of an eight-stranded, antiparallel β-sandwich (Figure
1.3B). The function of the USP7 TRAF-like domain is to bind USP7 substrates. Transcription
factor p53 was the first protein shown to be recognized by this region of USP7 (72) and later
studies revealed many others such as HDM2, UbE2E1 and MCM-BP. Interestingly all these
interactions occur through the same molecular mechanism. Briefly, all the substrates contain a
Pro/Ala-X-X-Ser motif in their protein sequences that binds to a shallow grove on the surface of
the TRAF-like domain (Figure 1.3C) (27,37,73,74). The almost identical manner of the binding
in all cases allows some substrates to compete for interaction with USP7 as was shown, for
example, for p53 and HDM2 (27).
The function of the DUB catalytic core is to bind ubiquitin and to cleave the isopeptide bond
between ubiquitin and a modified protein substrate. The catalytic core of USP7 is the largest
domain within the protein (residues 208-560) and is centrally located between the TRAF-like
and UBL domains (Figure 1.3A). It has characteristic for all USP enzymes fold that resembles a
10

right hand (Figure 1.3D). Residues Cys223, His464 and Asp481 form the catalytic site of the
enzyme that is located in a cleft between the two protein regions referred to as Thumb and Palm.
The third region, Fingers, is responsible for binding to ubiquitin (72,75). Remarkably, the
structure of isolated USP7 catalytic domain differs from available structures of other USPs in the
conformation of its active site. While the catalytic residues are properly positioned for catalysis
in USP4, USP8, USP14 and CYLD (76-79), the USP7 catalytic triad is found in an unproductive
conformation. The catalytically competent conformation of the active site is formed only upon
binding to ubiquitin as was shown in the crystal structure of USP7 in complex with ubiquitin
aldehyde (72) (Figure 1.3E). These intramolecular rearrangements represent a hypothetical
mechanism of USP7 autoregulation, which ensures the inactive state of the enzyme in the
absence of a substrate.
The C-terminal region of USP7 (C-USP7) encompasses residues 564-1102 and consists of
five ubiquitin-like domains (UBLs 1-5) that are arranged in the following manner: UBL1 closely
interacts with UBL2 (UBL12 tandem), UBL4 – with UBL5 (UBL45 tandem) and UBL3 is
separated from UBL2 and UBL4 by linkers (Figure 1.4A) (71). These domains adopt a
characteristic β-grasp ubiquitin fold consisting of β-β-α-β-β-α-β secondary structure elements
(Figure 1.4B). Besides USP7, UBL domains are found in many cellular proteins and play roles in
diverse biological processes (80). Within the USP family, 19 enzymes are predicted to have
UBLs (16). Interestingly, the numbers of the domains varies from one in USP9X/Y, USP19,
USP31 and several others to five in USP7, USP40 and USP47 (Figure 1.5). A position of the
UBLs can also be different within a protein with some domains located either N- or C-terminally
and others embedded in the catalytic core. The reason for such divergence within one protein
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family is unclear since functions of the UBLs have been elucidated for only a couple of USPs
(76,81,82).
The functions of USP7 UBL domains remained unknown until recently. The new findings
indicate that C-USP7 constitutes an additional substrate-binding region along with the Nterminal TRAF-like domain. Interestingly, despite overall structural similarity, the protein
sequences of USP7 UBLs significantly vary from ubiquitin and from each other resulting in
surface charge distributions unique for each domain. The presence of these differently charged
surfaces implies that in contrast to the TRAF-like domain that contains a single substrate-binding
site, several distinct sites might be harbored within the C-USP7. Indeed, mounting evidence
suggests that different USP7 substrates are recognized by its C-terminal region that bind
different UBL domains. Thus, ICP0 from HSV-1 interacts with the first three UBL domains and
human XPC, and RNF168 bind to UBL12 tandem (29,47,70). UBL3 and UBL45 were recently
shown to contain second binding sites for HDM2 and p53 respectively (83), and UBL45 was also
reported to recognize FOX(O)4 (50). However, the mechanism of substrate binding to C-USP7
remains to be defined since no structural information is available for any of these complexes.
In addition to five UBL domains, C-USP7 contains a conserved 23 amino residue peptide
located at the extreme C-terminus (residues 1080-1102). Intriguingly, this non-structured peptide
is required for activation of USP7 as its deletion significantly decreases the deubiquitinase
activity of the enzyme (71,83). The molecular mechanism of activation, however, raised
controversy in the literature. First, according to the crystal structure, five UBLs are in the
extended conformation (Figure 1.4A), which positions the extreme C-terminus ~80 Å away from
the active site. Next, as reported in the same study, the isolated USP7 C-terminal peptide does
not directly interact with the catalytic core and only slightly restores its enzymatic activity in
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trans (71). In contrast, another study found that a USP7 construct containing the C-terminal
peptide attached to the catalytic domain through a 10 amino residue linker has almost full
deubiquitinase activity, compared to the full-length protein (84). Furthermore, according to the
crystal structure of this USP7 construct in complex with ubiquitin aldehyde, USP7 C-terminal
peptide binds to a cleft on the surface of its catalytic core formed after active site rearrangement
upon ubiquitin binding. Nevertheless, both groups highlighted the significance of UBL domains
in activation of the enzyme. They proposed a model of the full-length protein where UBLs
rearrange from an extended conformation into a more compact structure upon activation of USP7
in order to bring the C-terminal peptide towards the catalytic domain (Figure 1.4C). In support of
this hypothesis, it was recently shown that UBLs 1-3 can adopt a conformation that is more
compact than previously reported in the structure of C-USP7 (85).

1.1.5. USP7 in human disease
USP7 expression is often dysregulated in human malignancies. Its overexpression contributes
to tumor progression through aberrant changes in cancer related signaling pathways such as the
DNA damage response, apoptosis and cell cycle control. In particular, overexpression of USP7
in human prostate cancer correlates with tumor aggressiveness. This correlation is at least
partially explained by USP7-dependent deactivation of tumor suppressor PTEN (51). USP7 is
also overexpressed in breast carcinomas (45) as well as in lung squamous cell carcinoma and
large cell carcinoma (86). Its dysregulation in non-small cell lung cancers leads to disruption of
the HDM2 – p53 axis and is associated with induced cell epithelial mesenchymal transition,
metastasis and overall poor prognosis (86). Similarly, high USP7 expression in patients with
epithelial ovarian cancer was found to induce cell invasion ability and correlate with poor
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survival (87,88). Finally, USP7 expression was shown to gradually increase with tumor
progression form grade I to grade IV in glioma patients (89).
Because of USP7 aberrant expression in many human cancers and its role in important
signaling pathways, this enzyme recently emerged as a promising pharmaceutical target.

1.1.6. Pharmaceutical potential of USP7
Manipulating the stability of proteins that are mutated, overexpressed or downregulated in
human malignancies represents a promising therapeutic strategy for cancer treatment. Between
the two protein degradation pathways, lysosomal proteolysis and UPS, the latter is highly
selective and, therefore, its inhibition has a potential for development of highly specific targeted
therapies. E3 ligases and DUBs are of special interest since they determine the selectivity of
UPS, although other components of UPS such as E2s and proteasome have also emerged as
pharmaceutical targets (90).
USP7 pharmaceutical potential emerged in recent years because of its role in cellular
pathways involving oncogenes and tumor suppressors as well as evidence of its aberrant
expression in various cancer cell lines. Early studies searching for small-molecule inhibitors of
USP7 led to discovery of compound HBX 41,108, a cyano-indenopyrazine derivative, that
inhibits USP7 in an uncompetitive and reversible manner and induces p53-dependent apoptosis
in HCT116 colon cancer cells. However, HBX 41,108 activity against USP7 is relatively low
(high nM range) and its specificity is modest (91). More recently, specific USP7 compounds
HBX 19,818 and HBX 28,258 were reported. Treatment with HBX 19,818 leads to p53
stabilization and G1 cell cycle arrest in HCT116 colon cancer cells (92). Finally, a family of dual
USP7/USP47 inhibitors (compounds 1 - 14) was recently discovered (93). The lead compound 1
(P5091) was shown to induce apoptosis in multiple myeloma cells resistant to bortezamib and to
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prolong survival in mouse xenograft models (94). The mechanism of P5091 cytotoxic activity is
p53-independent and at least partially relies on endoplasmic reticulum stress caused by
accumulation of polyubiquitinated proteins (95). In contrast, compound 4 (DUB inhibitor VI,
P22077) induces p53 stabilization and inhibits cell growth in neuroblastoma cell lines with
intact, but not with the mutant p53 (96). Overall, all the reported USP7 inhibitors exhibit
cytotoxic activity in several cancer models but their further optimization is needed in order to
create highly specific and more potent compounds.
It is worth mentioning that to date, over 30 proteins have been described as substrates of
USP7 (Table 1.1) but, given the fact that only ~100 DUBs in humans deubiquitinate thousands
of different proteins, it is likely that new USP7 substrates will be discovered in the near future.
Importantly, all the above compounds target the catalytic core of USP7 and, therefore, affect
ubiquitination status of its numerous binding partners. Such full inhibition of the enzyme might
result in severe side effects due to changes in stability of multiple cellular proteins. Another
potential way to manipulate USP7 activity is to block its interactions with a particular substrate
such as oncogene HDM2 or viral protein ICP0. The discovery of such compounds would allow
controlling deubiquitinase activity of the enzyme towards a specific protein without affecting
others.
In conclusion, although the design of compounds capable of breaking protein-protein
interactions was considered to be challenging for a long time, recent advances in technology
have allowed the pharmaceutical industry to successfully pursue this goal (97). However, the
development of substrate-specific therapeutics for USP7, first, requires deep understanding of
the molecular mechanisms of its activity and regulation as well as structural characterization of
USP7/substrate binding interfaces. In this light, solution nuclear magnetic resonance
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spectroscopy (NMR) might be a useful tool for studying this enzyme. NMR is the state-of-the-art
structural biology method that might provide valuable information about USP7 itself and its
interactions with either substrates or small-molecule compounds. Furthermore, only NMR may
provide insight into USP7 dynamic behavior such as conformational changes upon enzyme
activation or binding to a substrate.

1.2. NMR spectroscopy as a powerful method for studies of proteins and protein-protein
interactions
1.2.1. Basics of NMR
Several methods including NMR spectroscopy, X-ray crystallography, electron microscopy
and small-angle X-ray scattering are widely used to gain structural information about
macromolecules. However, only two of these methods, X-ray crystallography and NMR
spectroscopy, provide information about the three-dimensional structure of proteins at the atomic
level. Among those, only NMR spectroscopy can be used to determine protein structure in
solution, which closer resembles physiological conditions. Moreover, NMR spectroscopy is the
only method sensitive to very weak and transient intermolecular interactions invisible to other
techniques. Finally, in contrast to X-ray crystallography, NMR can provide information about
protein dynamics and folding.
The method of NMR relies on interaction of the magnetic moment of a nucleus (µ) with an
external magnetic field. The nuclear magnetic moment is an intrinsic property of a nucleus such
as charge and mass and is proportional to the spin angular momentum:
𝜇⃗ = 𝛾ħ𝐼⃗
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where γ is gyromagnetic ratio, a fundamental property of a given isotope, ħ = h/2π (h is Plank
constant) and I is spin angular momentum quantum number. The nuclei with I = ½ (such as 1H,
15

N, 13C, 19F and 31P) have the most favorable for NMR magnetic properties and are commonly

observed in studies of biomolecules.
When placed in a magnetic field (B0), nuclear spins precess about the direction of B0 with a
characteristic frequency:
ω0 = -γB0,
which is called the Larmor frequency. As it follows from the above equation, ω0 is different for
different nuclei and is proportional to the applied magnetic field. The orientation of the magnetic
moments of a spin ½ nucleus may be either parallel or antiparallel to the field. The parallel
orientation is characterized by a magnetic quantum number m = +½ (referred to as α-spin state)
and antiparallel orientation is characterized by m = -½ (referred to as β-spin state). Importantly,
while the energies of α- and β-spin states are the same in the absence of an external magnetic
field, in the presence of the magnetic field they are slightly different (effect called Zeeman
splitting):
1

𝐸𝛼 = − 2 ħ𝛾𝐵0

𝐸𝛽 =

1
2

ħ𝛾𝐵0 .

The energy difference ∆E is given by
𝐸𝛽 − 𝐸𝛼 = ħ𝛾𝐵0 = ħ𝜔0
and is proportional to the resonance frequency of a nucleus ω0 = γB0. In NMR spectroscopy,
radio-frequency pulses (rf-pulses) and/or irradiation are applied to a nucleus placed in a static
magnetic field B0 at a carrier frequency ω matching ∆E.
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Notably, the low energy spin state is only slightly more populated in the magnetic field
relative to the high energy state, with a ratio of spins in α- and β-spin states, Nα and Nβ,
respectively, given by Boltzmann distribution:
𝛥𝐸
𝑁𝛽
−
= 𝑒 𝑘𝑏 𝑇
𝑁𝛼

where kb is Boltzmann’s constant and T is the temperature. The modest excess of spins in the low
energy state results in only a small fraction of spins excited during NMR experiments and
contributing to the NMR signal, which explains the relatively low sensitivity of the NMR
method (98).
Critical for structural biology, in context of biomolecules, Larmor frequency depends on the
electronic environment of a nucleus. In proteins, adopting a three-dimensional structure
electronic environment is unique for every nucleus. Elections induce currents and produce local
magnetic fields that oppose B0 or, in other words, shield the nucleus from the field. Because of
this chemical shielding, nuclei of the same type experience slightly different magnetic fields,
which results in a range of resonance frequencies for each nucleus in an NMR spectrum. These
frequency differences normalized to resonance frequency of the nucleus are referred as to
chemical shifts.
The above description explains principles of NMR spectroscopy using an example of a single
spin ½ system. Biological macromolecules contain complex multi-spin systems where spins of
different nuclei are coupled through bonds (J-coupled spins) and through space (dipole-dipole
coupled spins). Therefore, NMR experiments use various sequences of rf-pulses applied to nuclei
of one or different types. Beyond recording one dimensional (1D) 1H, 15N or 13C NMR spectra,
one can collect multi-dimensional (2D, 3D and 4D) NMR experiments to observe different types
of correlations between coupled nuclei.
18

1.2.2. Protein structure determination using NMR spectroscopy
NMR data does not immediately provide direct structural information about a protein unlike,
for example, protein images obtained using electron microscopy. Instead, a set of structure
related parameters including dihedral angles and distances between atoms within the molecule
can be derived from analysis of NMR data and then this indirect experimental information can be
used for protein structure calculation. In brief, the NMR structure determination process consists
of the following steps: 1) sample preparation; 2) NMR data acquisition, illustrated in Figure 1.6A
and described elsewhere (98); 3) NMR data analysis, including NMR resonance assignment and
obtaining distance restraints based on NOEs (Nuclear Overhauser Effect) as well as dihedral
angle restraints, and 4) calculation of the structure satisfying the restraints.
Sample preparation is a first and important step. As mentioned above, only nuclei with spin
½ are routinely observable in NMR spectroscopy meaning that a protein sample has to be
produced using spin – ½
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N,

13

C and in some cases spin – 1 2H isotope labeled precursors as

sources for nitrogen, carbon and hydrogen. The bacterium E. coli is the most suitable protein
expression system for NMR purposes since it allows introducing isotopes and obtaining a protein
of interest in high quantities in a relatively short time. Proteins overexpressed in E. coli must be
purified prior NMR experiments, which sometimes can be difficult due to low expression levels
or insolubility of certain proteins in solution. Another challenge is that not all proteins are stable
at high concentration (e.g. ~ 1mM) and/or for the time necessary to perform NMR
measurements. Overall, all the requirements can make protein sample preparation a time
consuming and challenging task.
NMR resonance assignment includes chemical shift assignments of backbone atoms, sidechain carbons and all the hydrogens.
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Assigning resonances for backbone

15

N, 1H,

13

Cα,

13

CO and, additionally,

13

Cβ atoms is

called the backbone chemical shift assignment. The first spectrum collected for the backbone
assignment is usually 2D 1H-15N HSQC (Heteronuclear Single-Quantum Correlation) that
correlates directly bonded N and H atoms (99). The majority of peaks in this spectrum
correspond to the backbone amide groups. The number of amide peaks should be the same as the
number of residues minus prolines and the first amino acid residue. Signals from the
pair of tryptophan indole groups and

15

15

Nε-1Hε

N1H2 groups of asparagine and arginine side-chains are

also visible (Figure 1.6B). Importantly, the number of peaks and the range of resonance
frequencies in the 1H-15N HSQC spectrum provides valuable information about whether the
protein is folded or disordered (100). Also, the 1H-15N HSQC spectrum can be used to monitor
protein – ligand interactions (described in subchapter 1.2.3). In addition to conventional 1H-15N
HSQC,

1

H-15N TROSY-HSQC spectrum (TROSY – transverse relaxation optimized

spectroscopy) was designed for large macromolecules (101).
The commonly used 3D triple-resonance spectra for backbone resonance assignment are:


HNCACO and HNCO that correlate amide Hi-Ni chemical shifts with COi and COi-1

chemical shifts, and COi-1 chemical shifts, respectively;


HNCA and HNCOCA that correlate amide Hi-Ni chemical shifts with Cαi and Cαi-1 chemical

shifts, and Cαi-1 chemical shifts, respectively;


HNCACB and HNCOCACB that correlate amide Hi-Ni chemical shifts with Cαi, Cβi, Cαi-1,

and Cβi-1 chemical shifts, and Cαi-1 as well as Cβi-1 chemical shifts, respectively;
where i is a residue in the protein sequence and i-1 is the preceding residue (102). During the
process of backbone resonance assignment, first, sequential chains of strips (parts of the
spectrum showing the particular frequencies in 1H and
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15

N dimensions but the whole range of

frequencies in

13

C dimension) are build using information in 3D spectra (Figure 1.6C). Briefly,

one looks for a strip with

13

C resonances for residue i of the same frequency as

13

C resonances

for residue i-1 in the analyzed strip (Figure 1.6D). As a next step, assignment of resonances to
specific amino-residues in the protein sequence is done based on the fact that

13

Cα and

13

Cβ

chemical shifts differ between various amino-acids (103). Finally, Hα and Hβ atoms are assigned
using experiments HNCAHA and HN(CO)CAHA that correlate Hi-Ni pairs with Hαi and Hαi-1
chemical shifts, and Hαi-1 chemical shifts, respectively; and experiments HBHA(CO)NH and
HAHBNH that correlate Hi-Ni pairs with Hαi-1 and Hβi-1 chemical shifts, and Hαi, Hβi, Hαi-1 and
Hβi-1, respectively (98).
Once the backbone resonance assignment is complete, side-chain assignment is performed
using 3D double-resonance experiments H(C)CH-TOCSY and (H)CCH-TOCSY that provide
correlations of 1H-13C pairs to all the 1H and

13

C atoms in the same amino residue sidechain,

respectively (104).
Importantly, chemical shifts contain information about secondary structure of a protein that
can be derived using several available algorithms.

13

Cα,

13

Cβ and

13

CO chemical shifts can be

used to predict secondary structure elements present in the protein fold using the Chemical shift
index (CSI) method (105). This approach is based on the finding that the chemical shifts of Cα
and CO nuclei located in α-helices and β-strands shift downfield and upfield, respectively
(compared to the chemical shifts in random coil) and the resonances of Cβ nuclei shift in the
opposite direction. Also, given the fact that secondary chemical shifts are dependent on local
secondary structure, assigned backbone resonances can be used for prediction of dihedral angle
restraints for angles φ and ψ (Figure 1.6E). The prediction is often made in program TALOS+
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(106) that compares chemical shifts of a given residue and its adjacent neighbors to a database of
high resolution protein structures with known secondary chemical shifts and torsion angles.
Another set of restraints is obtained from the analysis of 3D 15N- and

13

C-edited NOESY

(Nuclear Overhauser Effect Spectroscopy) spectra that correlate protons from amide groups and
C-H groups, respectively, with all nearby protons located within distance up to 5Å (102). Since
inter-proton distances are limited by protein secondary and tertiary structure, 1H – 1H distance
restraints obtained from NOEs are pivotal for structure calculation (Figure 1.6F). Briefly, NOE
effect is a magnetization transfer between adjacent nuclei caused by cross relaxation in a dipolar
coupled spin system. Important for structural biology, the cross relaxation rate is inversely
proportional to the sixth power of the distance between the two interacting protons (98). Thus,
the inter-proton distances in principle can be estimated from intensities of cross-peaks in
NOESY spectra. However, because of the internal protein motions and complexity of the 1H-1H
interaction network, it is impossible to measure the distances precisely, instead the peak
intensities are clustered in three groups of strong, medium and weak. Each group is associated
with upper distance limits: strong – 2.7 Å, medium – 3.3Å and weak – 5Å (103).
Because of the complexity of the 15N- and 13C- edited 3D NOESY spectra, their assignment
is done automatically in the beginning of the protein structure calculation process. Briefly, one of
several available programs including CYANA, XPLOR-NIH, ARIA or UNIO (107-111) uses the
resonance assignments to generate preliminary assignments for NOE peaks followed by their
conversion into distance restraints. Then, a program generates an initial set of structures, which
is used to confirm the NOE assignments that are satisfied in these structures and to discard ones
that are violated. Once NOEs are unambiguously assigned and upper limits for inter-proton
distances are defined, a program attempts to fold the protein structure in a way that every atom
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will have space coordinates satisfying the given restraints. Fitness of the structure is
characterized by its potential energy with lower energy indicating a smaller amount of the
restraints violated. In practice, structure determination is an iterative process, in which one
examines the distance (angle) restraints that have been violated during calculation, corrects the
resonance and NOEs assignments and repeats the calculation. Importantly, NMR based restraints
do not provide exact values but rather define the range of permitted distances and angle rotations.
Thus, NMR structure calculation cannot result in the protein structure adopting a single
conformation. Usually, 100 to 200 structures are calculated and 20 structures of the lowest
energy are chosen for final water refinement (103).

1.2.3. NMR studies of protein dynamics
Knowing protein structure often helps one to elucidate functions. However, atomic
coordinates do not provide insight into internal motions and conformational exchange inherent
for all the proteins. Studying time-dependent changes in protein structure (referred to as protein
dynamics) is important for understanding key biological processes including catalysis, ligand
binding as well as protein folding/misfolding and aggregation. Solution NMR spectroscopy is a
powerful tool for studying protein dynamics and to date many NMR experiments have been
developed to probe protein motions on time scales ranging from femtoseconds to seconds (112).
NMR spin relaxation, Carr-Purcell Meiboom-Gill relaxation dispersion (CPMG) and rotating
frame relaxation (R1ρ) methods used in this work are briefly discussed below.
Heteronuclear spin system excited by an rf-pulse will relax, e.g. return to equilibrium, with
characteristic times T1 (recovery of M0) and T2 (loss of coherence between individual spins
persessing perpendicular to the magnetic field). R1 = 1/T1, R2 = 1/T2 rate constants and the values
of heteronuclear NOEs (hrNOEs) related to the rate of dipole-dipole cross-relaxation between
23

nuclei, are widely used to elucidate ps – ns protein dynamics. The reason is that the protein
random tumbling occurring on ns time scale and internal motions such as rotation of torsion
angles and loop motions occurring on ps – ns time scale cause fluctuations in local magnetic
fields generated by spins that lead to relaxation of 1H-X pairs (X –
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N or

13

C). Two major

mechanisms relating these motions to time-dependent oscillating fields at MHz frequencies are
dipolar coupling and chemical shift anisotropy, which is the dependency of chemical shift on
orientation of the molecule relative to the applied magnetic field. R1, R2 rate constants and
hrNOEs are given by:
𝑅1 = (𝑑 2 /4)[𝐽(𝜔𝐻 − 𝜔𝑋 ) + 3𝐽(𝜔𝑋 ) + 6𝐽(𝜔𝐻 + 𝜔𝑋 )] + 𝑐 2 𝐽(𝜔𝑥 )
𝑅2 = (𝑑 2 /8)[4𝐽(0) + 𝐽(𝜔𝑋 − 𝜔𝐻 ) + 3𝐽(𝜔𝑋 ) + 6𝐽(𝜔𝐻 ) + 6𝐽(𝜔𝐻 + 𝜔𝑋 )]
+ (𝑐 2 /6)[4𝐽(0) + 3𝐽(𝜔𝑋 )] + 𝑅𝑒𝑥
𝑁𝑂𝐸 = 1 + (𝑑 2 /4𝑅1 )(𝛾𝑋 /𝛾𝐻 )[6𝐽(𝜔𝐻 + 𝜔𝑋 ) − 𝐽(𝜔𝐻 − 𝜔𝑋 )]
−3 〉/(8π2
where d = μ0hγXγH〈𝑟𝑋𝐻
); c = ωXΔσ/√3, µ0 is the magnetic permeability of free space; γH

and γX are the gyromagnetic ratios of spins 1H and X, respectively; ωH and ωX are the Larmor
frequencies of spins 1H and X, respectively; rXH is the X-1H bond length; ∆σ is the chemical shift
anisotropy of spin X; Rex is conformational exchange term due to μs – ms time scale processes
accompanied by changes in chemical shifts and J(ω) is spectral density function that quantifies
the amplitude of local field fluctuations at frequency ω (113). J(ω) is obtained by a cosine
Fourier transform of correlation function, C(t), which describes how rapidly bond vector
“forgets” its prior orientation:
𝐶(𝑡) = ⟨𝑃2 (𝜇(0) ∙𝜇(𝑡))⟩
where μ(0) and μ(t) are orientations of a bond vector at time zero and t, respectively and P2 =
(3x2 - 1)/2 is the Legendre polynomial of rank 2 (114).
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Obtained backbone

15

N NMR relaxation data are most commonly interpreted using model-

free data analysis originally introduced by Lipari and Szabo (115), and later extended by Clore et
al. (116). This approach describes molecular motion using the correlation function, C(t), given
by a product of two correlation functions Co(t) and CI(t) describing overall molecular tumbling
and internal motions, respectively, that are assumed to be independent of each other:
𝐶(𝑡) = 𝐶𝑜 (𝑡)𝐶𝐼 (𝑡).
Co(t) for a spherical molecule is given by:
𝐶(𝑡) = 𝑒 −𝑡/𝜏𝑅
where 𝜏𝑅 is the effective overall rotational correlation time. CI(t) depends on the timescale of the
internal motions. If the internal motions, 𝜏𝑒 , are much faster than the overall rotation of the
molecule and are in the extreme narrowing limit (ωτe ≪ 1), CI(t) is given by:

𝐶𝐼 (𝑡 ) = 𝑆 2 + (1 − 𝑆 2 )𝑒 −𝑡/𝜏𝑒
where τe is effective correlation time and S2 is a generalized order parameter that describes a
range of main chain motions and varies from 1 to 0 for completely restricted and unrestricted
isotropic motion, respectively (115). The spectral density function J(ω) in this case is:
(1 − 𝑆 2 )𝜏𝑒′
𝑆 2 𝜏𝑅
𝐽(𝜔) =
+
1 + (𝜔𝜏𝑅 ) 1 + (𝜔𝜏𝑒′ )2
where 𝜏𝑒′ = 𝜏𝑅 𝜏𝑒 /(𝜏𝑅 + 𝜏𝑒 ). If the internal motions are not in the extreme narrowing limit and
fast, 𝜏𝑓 , and slow, 𝜏𝑠 , components significantly differ, CI(t) is given by:

𝐶𝐼 (𝑡 ) = 𝑆 2 + (1 − 𝑆𝑓2 )𝑒 −𝑡/𝜏𝑓 + (𝑆𝑓2 − 𝑆 2 )𝑒 −𝜏/𝜏𝑠
where 𝑆 2 = 𝑆𝑓2 𝑆𝑠2 (116). J(ω) in this case is:
𝐽(𝜔) =

𝑆𝑓2 𝑆𝑠2 𝜏𝑅
(1 − 𝑆𝑓2 )𝜏𝑓′ 𝑆𝑓2 (1 − 𝑆𝑠2 )𝜏𝑠′
+
+
1 + (𝜔𝜏𝑅 ) 1 + (𝜔𝜏 ′ )2
1 + (𝜔𝜏𝑠′ )2
𝑓
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where 𝜏𝑓′ = 𝜏𝑅 𝜏𝑓 /(𝜏𝑅 + 𝜏𝑓 ) and 𝜏𝑠′ = 𝜏𝑅 𝜏𝑠 /(𝜏𝑅 + 𝜏𝑠 ) . Parameters of internal motions are
obtained from least square fit of relaxation data to equations for R1, R2 rates and hrNOEs (113)
constructed using spectral density functions appropriate for the particular case. For more detailed
and comprehensive explanation of the model-free approach and the description of a case of
anisotropic motion see (114).
CPMG and R1ρ experiments are used to study relatively slow μs-ms protein dynamics (114).
Conformational exchange in this time range accompanied by changes in chemical shifts is
known to contribute to R2 rates:
𝑅2 = 𝑅20 + 𝑅𝑒𝑥
where 𝑅20 is the R2 rate in the absence of chemical exchange and Rex is the contribution from
conformational exchange. A CPMG experiment exploits the dependence of Rex on repetition rate
of series of refocusing 180° pulses. In the constant relaxation time CPMG experiment, a number
of spin-echo refocusing elements (δ-180°-δ) are applied during a fixed relaxation period T with
different values of delay δ (117). A R1ρ experiment measures longitudal relaxation in the doubly
rotating frame as a function of the strength of the spin-locking field and the offset of nucleus
resonance frequency from the carrier frequency of the rf-pulse, ω0 (118,119). In either case,
exchange rates kex and/or populations of states A and B, pA and pB, respectively, are obtained by a
least square fit of measured R2/R1ρ rates to theoretical two-state or more complex models of
exchange process as described in (114,120).
1.2.4. NMR titration experiments in studies of protein –ligand interactions
NMR spectroscopy is widely used for probing protein – ligand interactions with the ligand
being another protein, DNA/RNA or a small-molecule compound. NMR titration experiments,
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also called chemical shift perturbation experiments, are based on the fact that chemical shifts are
extremely sensitive to the electronic environment of a nucleus. The most common NMR method
for testing the binding includes gradual addition of an unlabeled ligand to a 15N-labeled protein
and recording 1H-15N HSQC spectra of the protein at each point of titration. In the case of direct
interaction, the proximity of the ligand and subtle conformational changes in the binding site
lead to local changes in the electronic environment of the protein residues directly involved in
binding. Therefore, corresponding peaks move in the NMR spectrum. In addition, if ligand
binding induces a structural rearrangement in the protein, chemical shift perturbations for
residues not involved in interaction but participating in conformational changes may also be
observed. It is notable that strong dependence of chemical shifts on the electronic environment
makes NMR spectroscopy sensitive to even very weak interactions with millimolar affinities that
cannot be observed by other methods.
For a simple case of the ligand L reversibly binding to a single site within the protein P,
interaction can be described by 𝑃 + 𝐿 ↔ 𝑃𝐿. Importantly, the exchange rate between free (P)
and bound states (PL) of the protein kex = kon + koff (kon and koff are rates of the association and
dissociation reactions, respectively) affects the observable chemical shift changes in 1H-15N
HSQC spectra. If the binding process is fast on the NMR timescale (kex ≫ Δω) meaning that the
complex association and dissociation occur rapidly during NMR signal detection, the resonances
at each titration point will gradually move with increasing amount of the ligand. The frequency
of each signal is the population weighted average of the chemical shifts for free and saturated
protein states (Figure 1.6G, top). If the interaction is slow (kex ≪ Δω), the peaks corresponding to
the free protein will gradually disappear and the peaks corresponding to the bound state will
appear. Thus, in this case, two separate sets of the peaks are observed for the free protein and its

27

complex with the ligand, and the intensity of the signals reflects relative concentrations of the
free and bound protein (Figure 1.6G, bottom). Finally, if exchange is in the intermediate regime
(kex ~ Δω), the peaks will gradually move and broaden at the same time (Figure 1.6G, middle).
Notably, NMR spectroscopy is the only method that allows estimation of the dissociation
constant KD and the mapping of the binding site from a single experiment, provided that the
structure and the backbone resonance assignment of the protein are available. The binding site
identification is straightforward. First, one maps residues exhibiting most significant chemical
shift perturbations upon ligand binding on the protein structure. Next, considering the nature of
interaction (hydrophobic or electrostatic) and the size of the ligand, one looks for a cluster of
residues affected by binding, which is thought to form the binding site. The presence of more
than one cluster may be indicative of two or more binding sites or allosteric conformational
changes occurring upon interaction. The dissociation constant KD for a two-state binding process
in thermodynamic equilibrium is equal to
𝐾𝐷 =

[𝑃][𝐿]
[𝑃𝐿]

where [P], [L] and [PL] are concentrations of the protein, the ligand and the complex,
respectively. KD can be estimated for protein – ligand interactions in the fast to intermediate
regime on the NMR time scale by nonlinear least-square fitting of observed chemical shifts Δωobs
as a function of ligand concentration to the following equation:
∆ωobs

(𝐾D + [L]t + [P]t ) − √([𝑃]t + [L]t + 𝐾D )2 − 4[P]t [L]t
= ∆ωmax
2[P]t

where [P]t and [L]t are the total protein and ligand concentrations and Δωmax is the maximum
chemical shift difference at saturation (121).
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1.3. Thesis objectives
USP7 is a deubiquitinating enzyme involved in regulation of several oncogenic pathways and
its inhibition represents a promising pharmaceutical strategy for treatment of human
malignancies. All existing USP7 inhibitors target its catalytic core and, therefore, may affect
protein levels of its numerous substrates leading to unpredictable side effects. Blocking USP7
interaction with a specific substrate may present a better strategy for manipulating the enzyme
activity but given that USP7 deubiquitinates dozens of proteins, it is unclear how its substrate
specificity is achieved. Several previously identified binding partners of USP7 share a Pro/AlaX-X-Ser motif recognized by its N-terminal TRAF-like domain, while others lack this sequence
and are recognized by non-homologous C-terminal UBL domains. Interestingly, different UBL
domains can recognize different substrates, suggesting that the C-USP7 may serve as a substratespecific binding platform. However, the precise location of the binding sites harbored within CUSP7 is unknown. Furthermore, it is unclear whether the substrates recognized by C-USP7 share
any common structural features or motifs recognized by USP7. In addition, USP7 is the only
enzyme among USPs that has the catalytic triad in an unproductive conformation. The
rearrangement into a catalytically competent conformation is thought to occur upon binding to
ubiquitin as seen in the crystal structure of the USP7 catalytic core in a complex with ubiquitin
aldehyde, but such an active site rearrangement has not been demonstrated for USP7 interacting
with free ubiquitin and in solution. Answering the questions of “What determines USP7 substrate
specificity?” and “How is USP7 activated?” will provide a structural basis for rational
development of potent and highly targeted cancer therapeutics.
Although all reported USP7 inhibitors are known to target its catalytic domain, no structural
information characterizing their binding to the enzyme is currently available, which hinders
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further optimization of the lead compounds. Thus, the third question we addressed here is: “What
is the molecular mechanism of USP7 inhibition by small-molecule compounds that show antitumor potential in cancer cell lines?” In order to answer these questions, we, for the first time,
utilized NMR spectroscopy to study this fascinating and pharmaceutically relevant biological
system. The overall goal of this thesis was to provide structural insights into the molecular
mechanisms of USP7 substrate specificity, regulation and inhibition using solution NMR in
combination with other biophysical and biological methods. The specific aims were the
following1:
Aim 1. Structurally characterize the C-USP7 interaction with viral ICP0 protein that is missing
the conventional USP7 recognition motif in order to identify new determinants of USP7
substrate specificity.
a) Identify domains/regions of C-USP7 responsible for binding to ICP0.
b) Map the binding site for ICP0 on the USP7 structure.
c) Explore the significance of ICP0 interaction with USP7 during HSV-1 lytic infection in
vivo.

Aim 2. Identify the molecular mechanism of USP7 activation upon ubiquitin binding in order to
provide new means for manipulating the enzyme.
a) Test binding of ubiquitin to USP7 in solution.
b) Track conformational changes occurring in the catalytic domain of USP7 upon
interaction with ubiquitin.

1

Note that in order to reflect the work described in the thesis, the overall goal and the specific aims were modified

from those presented in the prospectus.
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Aim 3. Identify the molecular and chemical mechanism of USP7 inhibition by small-molecule
compounds to allow rational optimization of inhibitors targeting the enzyme.
a) Map the binding site for USP7 inhibitors P22077 and P50429 on the structure of the
USP7 catalytic core.
b) Characterize the mode of action of USP7 inhibitors P22077 and P50429.

In addition, chapter 4 of the thesis is not related to the USP7 project and represents another
example of using solution NMR spectroscopy in studies of complex large biological systems. It
describes structural studies of Y-family polymerase REV1 essential for DNA damage tolerance
pathway translesion synthesis (TLS) and explores the mechanisms of REV1 interactions with
other TLS polymerases.
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Table 1.1. List of USP7 substrates.
Substrate function

Substrate name

Refs

Epigenetic control
of gene expression

Transcription
factors

MEL18

(42)

RING1B

(41)

p53

(24)

Bmi1

(42)

HDM2

(25)

Histone H2B

(49)

Rb

(122)

DNMT1

(129)

FOX(O)4
FOX(O)3
PTEN

(50)

UHRF1

(39)

RNF168

(47)

β-catenin

(67)

MLL5

(46)

PPARγ

(123)

Tip60

(44)

N-Myc

(124)

UbE2E1

(74)

PHF8

(45)

TPP1

(130)

NFκB

(48)

TRAF6

(131)

IKKγ

(131)

TRIM27

(132)

(51)

DNA replication/
Cell cycle

Telomere proteins
CHFR

(125)

Bub3

(126)

Sumo

(38)

Immune response

DNA damage
response/
DNA repair
DAXX

(127)

Polymerase η

(36)

HLTF

(33)

EBNA1 from EBV

(56)

Rad18

(34)

ICP0 from HSV-1

(55)

Clapsin

(31)

vIRF4 from KSHV

(59)

Chk1

(30)
(32)

Mule/ARF-BP1

(128)

LANA from
KSHV
UL35 from HCMV

(57)

UVSSA
XPC

(29)

E1B from
Adenovirus

(61)

Viral proteins
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(60)

Figure 1.1. Functions of DUBs in the ubiquitin-proteasome system. A protein substrate
mono- and polyubiquitination is catalyzed by consecutive activity of E1, E2 and E3 enzymes.
The polyubiquitination targets the substrate for proteasomal degradation while
monoubiquitination results in a different functional outcome. DUBs deubiquitinate both polyand monoubiquitinated proteins and redirect their fate. Also DUBs edit polyubiquitin chins and
recycle them Finally, DUBs participate in maturation of free ubiquitin. Ub – ubiquitin; E1 –
ubiquitin activating enzyme; E2 – ubiquitin conjugating enzyme; E3 – ubiquitin Ligase; DUB –
deubiquitinating enzyme.
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Figure 1.2. Human DUBs. DUBs are classified into two classes of cysteine proteases and
metalloproteases. Cysteine proteases are further subdivided into five families of ubiquitinspecific proteases (USPs) ubiquitin carboxyl-terminal hydrolases (UCHs), ovarian tumor
proteases (OTUs), Machado-Joseph (Josephin) domain containing (MJD) proteases and MINDY
(motif interacting with Ub-containing novel DUB family). Adapted from (133). The class of
metalloproteases consists of the only family of JAB1/MPN/MOV34 domain containing proteases
(JAMMs).
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Figure 1.3. USP7 domain organization. A. Schematic representation of USP7 domains with
borders specified. UBL – ubiquitin-like domain. B, C. Crystal structures of free USP7 TRAFlike domain (PDB ID: 2F1W) and its complex with a p53364-367 peptide shown in yellow (PDB
ID: 2FOJ) (27,73). D, E. Crystal structures of free USP7 catalytic core (PDB ID: 1NB8) and its
complex with ubiquitin aldehyde (PDB ID: 1NBF) (72). The side-chains of the catalytic residues
Cys223, His464 and Asp481 are shown in green. The distances between the Cγ atom in Cys223
and the Nε2 atom in His464 are also shown. In E ubiquitin is shown in cyan.
35

Figure 1.4. C-terminal region of USP7. A. Crystal structure of the C-terminal region of USP7
(PDB ID: 2YLM) consisting of five ubiquitin-like domains (UBL1 – 5) (71). Here and later,
UBL1 is colored in blue, UBL2 – in green, UBL3 – in grey, UBL4 – in orange and UBL5 – in
red. B. Overlay of the UBL1 NMR structure (PDB ID: 2KVR) (134) onto the structure of
ubiquitin (PDB ID: 1UBQ) (135). C. Current model of USP7 activation by its C-terminal UBL
domains. The model was adapted from (71,84).
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Figure 1.5. Human USPs predicted to have at least one ubiquitin-like domain. The protein
domains are drawn approximately to scale. The catalytic domain is colored in red, UBL – in
green and DUSP (domain present in ubiquitin-specific protease) – in yellow. Other domains are
also indicated. Adapted from (16).
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Figure 1.6. NMR spectroscopy in structural biology. A. Schematic representation of a basic
NMR experiment. d1 – relaxation delay, pw – pulse width, at – acquisition time and FID –free
induction decay. B. Schematic representation of a 1H-15N HSQC spectrum. Amide peaks are
shown in blue, side-chain NH2 groups of asparagines and glutamines are shown in green and NεHε pairs of tryptophans are shown in magenta. C. Schematic representation of 3D HNCA
spectrum where CA peaks (colored in red) of a given and preceding residue are visible in every
strip shown in orange. D. Representation of the sequential backbone assignment process. E.
Backbone torsion angles. F. NMR Structure of UBL1 (PDB ID: 2KVR) with all inter-proton
distances less than 5 Å shown. G. Examples of the chemical shift perturbations in 1H-15N
TROSY-HSQC spectra caused by binding to a ligand. Three different experiments are shown
with binding in fast (top), intermediate (middle) and slow (bottom) regimes on the NMR
timescale. The direction of chemical shifts movement is indicated by arrows.
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2.1. Abstract
Human ubiquitin-specific protease 7 (USP7) is a deubiquitinating enzyme that prevents
protein degradation by removing poly-ubiquitin chains from its substrates. It regulates stability
of a number of human transcription factors and tumor suppressors and plays a critical role in the
development of several types of cancer, including prostate and small cell lung cancer. In
addition, human USP7 is targeted by several viruses of the Herpesviridae family and is required
for effective Herpesvirus infection. The USP7 C-terminal region (C-USP7) contains five
Ubiquitin-Like domains (UBL1-5) that interact with several USP7 substrates. Although
structures of the USP7 C-terminus bound to its substrates could provide vital information for
understanding USP7 substrate specificity, no such data has been available to date.
In this work we have demonstrated that the USP7 UBL domains can be studied in isolation
by solution NMR spectroscopy and have determined the structure of the UBL1 domain.
Furthermore, we have employed NMR and viral plaque assays to probe the interaction between
the C-USP7 and HSV-1 immediate-early protein ICP0 (infected cell protein 0), which is essential
for efficient lytic infection and virus reactivation from latency. We have shown that depletion of
the USP7 in HFF-1 cells negatively affects the efficiency of HSV-1 lytic infection. We have also
found that USP7 directly binds ICP0 via its C-terminal UBL1-2 domains and mapped the USP7
binding site for ICP0. This study, therefore, represents a first step toward understanding the
molecular mechanism of C-USP7 specificity toward its substrates and may provide the basis for
future development of novel anti-viral and anti-cancer therapies.
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2.2. Introduction
Conjugation of ubiquitin to target proteins is important in multiple cellular processes,
including signaling cascades, proteasomal degradation and protein localization. Mono- and
polyubiquitination can be reversed by deubiquitinating enzymes (DUBs), which cleave the
isopeptide bond between ubiquitin and a substrate. Ubiquitin-specific protease 7 (USP7), also
known as Herpes virus-associated ubiquitin-specific protease (HAUSP), is a 135 kDa cysteine
isopeptidase (11). Misregulation of USP7 was linked to multiple human pathologies, including
prostate and non-small cell lung cancers (51,136).
A number of USP7 substrates have been identified, and USP7 knockdown was shown to
affect cellular levels of at least 36 proteins in LS174T colon carcinoma cells (23). Among a
variety of substrates, USP7 deubiquitinates both p53 tumor suppressor and its main regulator E3
ligase Hdm2 (human double minute 2) and thus plays a central role in maintaining an appropriate
p53 level in the cell (24-27). Other important targets of USP7 include several transcription
factors such as FOX(O)4, PTEN, NF-kB and HLTF; DNA replication and repair proteins such as
UbE2E1, claspin and MCM-BP; and proteins involved in epigenetic control of gene expression
such as DNMT1 and PRC1 (33,37,39,41,48,50,51,74).
In addition to cellular substrates, USP7 is known to interact with proteins from all three
subfamilies of the Herpesviridae family of viruses. Specifically, it interacts with immediate early
protein ICP0 from Herpes Simplex Virus-1 (HSV-1), which is required for efficient lytic
infection and reactivation of latent and quiescent viral genomes (53). USP7 also binds two
proteins from Kaposi’s sarcoma-associated herpes virus (KSHV) LANA and vIRF4 (57,59).
LANA is the major viral protein expressed in all forms of KSHV-associated malignancies, and
vlRF4 is the key player in the switch from latency to lytic reactivation. USP7 also interacts with
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the EBNA1 protein from Epstein-Barr virus (EBV), which competes with the p53 transcription
factor for USP7 binding (58,70). Thus, USP7 binding to EBNA1 results in p53 destabilization
and blockage of the DNA damage response caused by EBV infection. Finally, USP7 binds the
UL35 protein from cytomegalovirus essential for viral replication and particle formation (60). In
addition to Herpesvirus targets, USP7 was recently shown to interact with at least one adenoviral
protein, E1B-55K, a component of the E1B-55K/E4-orf6 E3 ligase complex that degrades a wide
range of intracellular proteins. Downregulation or specific inhibition of USP7 destabilizes E1B55K and negatively affects viral replication (61,137). Due to the central role USP7 plays in viral
infection and cancer development pathways, it represents an attractive target for the design of
new anti-viral and anti-cancer therapies. Although knowledge of molecular mechanisms of USP7
specificity towards its diverse substrates is essential for drug development, to date these
mechanisms remain poorly understood.
Structurally, USP7 consists of an N-terminal substrate-binding TRAF-like domain followed
by a ubiquitin-binding catalytic domain and a large 64 kDa C-terminal region (C-USP7, residues
557-1102) that contains five ubiquitin-like domains (UBL 1-5) shown in Figure 2.1A
(70,71,138). USP7 complexes with several substrates have been previously characterized,
including peptides derived from p53, Hdm2, HdmX, UbE2E1, MCM-BP, vlRF4 and EBNA1
(27,37,58,59,73,74). Remarkably, all these substrates share a common USP7-binding Pro/Ala-XX-Ser motif and interact with the same site located in the TRAF-like domain. On the other hand,
the function of the USP7 C-terminal UBL domains remains largely unknown. Interestingly, UBL
domains were found in at least 16 members of the USP family. All of them share a characteristic
β-grasp ubiquitin fold, although their sequence similarity to ubiquitin may be very limited.
Although a few of these UBLs have been characterized, the functions of others, including UBLs
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of the USP9, USP24, USP34, USP47 and USP48 remain elusive (139). The ICP0 E3 ligase from
HSV-1 is the first USP7 substrate shown to interact with C-USP7, suggesting that the UBL
domains may function as a platform for substrate binding. Recent studies revealed that the USP7
C-terminal region contains additional binding sites for p53 and Hdm2, as well as for the
transcription factor FOX(O)4, which interacts exclusively with the C-terminus (50,83). However,
at this time no structural data is available for any of these C-USP7 complexes.
Here, we report a structural study of the C-USP7 – substrate interaction. With the use of
NMR spectroscopy we have shown that individual USP7 UBL domains and/or two-domain
constructs are stable in isolation and can be studied independently in solution. Furthermore, we
have determined solution NMR structure of the USP7 UBL1 domain and demonstrated that it is
nearly identical to the crystal structure of the UBL1 in the context of the intact C-terminus (71).
Finally, we have characterized the interaction between C-USP7 and the ICP0 protein from HSV1 virus and mapped the ICP0 binding interface on the surface of the UBL1-UBL2 domains. Our
work represents the first structural study of the USP - substrate recognition mediated by its UBL
domains. Since many of the USPs contain multiple UBLs (139), it is likely that substrate
recognition by the UBL domains may prove to be a common feature shared among a class of
UBL-containing USPs.

2.3. Experimental procedures
In vitro studies:
Protein expression and purification. Sequences encoding UBL1 (residues 537-664), UBL12
(residues 535-775), UBL3 (residues 775-888) and UBL45 (residues 884-1102) domains of the
human USP7 were sub-cloned into pET28a-LIC Vector (Structural Genomics Consortium). All
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proteins were purified following the same protocol. Plasmids containing recombinant proteins
with the N-terminal His6-Tag were transformed into Escherichia coli BL21 (DE3). Proteins were
expressed in M9 minimal medium containing
15

N/13C-labeled UBL1).

15

15

NH4Cl (and

13

C-glucose for production of the

N/13C-labeled deuterated UBL12 was expressed in 100% D2O-based

M9 medium using uniformly 13C/2H-glucose as the sole carbon source. Transformed cells were
grown at 37°C to an OD600 of 0.6-0.8. Protein expression was induced by adding 1mM IPTG
followed by incubation overnight at 20°C. Cells were harvested, resuspended in buffer
containing 20 mM NaH2PO4, 250 mM NaCl, 10 mM imidazole, 1 mM PMSF, pH 7.4, lysed by
sonication and centrifuged at 15000 rpm for 45 min. The supernatant was applied to a Ni-NTA
column and proteins were eluted with a buffer containing 20 mM NaH2PO4, 250 mM NaCl, 250
mM imidazole, pH 7.4. Following thrombin or TEV digestion to remove the His6-tag, proteins
were additionally purified using either HiLoad Superdex 75 (for UBL1, UBL3) or HiLoad
Superdex 200 (for UBL12, UBL45) columns (GE Healthcare). Final samples used for NMR
experiments contained 0.8-1.2 mM of purified protein, 20 mM NaH2PO4, 250 mM NaCl, 2 mM
DTT, pH 7.0. The

15

N/13C-labeled UBL1 sample additionally contained 0.5 mM PMSF, 1 mM

benzamidine and 1 mM TCEP.
NMR spectroscopy and structure calculation.

1

H-15N HSQC spectra for all C-USP7

constructs were recorded on 800 MHz (1H) Agilent VNMRS spectrometer at 25°C. All
experiments for the UBL1 structure calculation were acquired on 600 MHz and 800 MHz (1H)
Bruker Avance spectrometers at 25ºC. The data were processed with NMRPipe (140) and
analyzed with Sparky (141) and CARA (142). The backbone and side-chain resonance
assignments of the uniformly 15N/13C-labeled UBL1 domain were performed using standard 2D
1

H-15N HSQC,

1

H-13C HSQC and 3D HNCA, HNCO, HBHA(CO)NH, CBCA(CO)NH,
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HC(C)H- and (H)CCH-TOCSY experiments (102). Sequence specific resonance assignment of
the UBL1 was done using ABACUS software (143,144). Nearly complete UBL1 NMR
resonance assignment was obtained with 93.3% of all expected chemical shifts assigned. NMR
distance restraints were obtained from 3D

15

N- and

13

C-edited NOESY-HSQC experiments

(102). H-bond restraints were added on the basis of NOE analysis. Backbone dihedral φ and ψ
angle restraints were derived from the analysis of

15

N, 1HN,

13

C,

13

C and

13

CO

chemical shifts using TALOS+ (106). Structures were calculated using CYANA (107). A total of
200 structures of UBL1 were calculated and 20 structures with the lowest energy were selected
and refined using CNS (145).
The backbone resonance assignments of the

15

N/13C-labeled deuterated UBL12 construct in

its free and ICP0-bound forms were performed using 2D 1H-15N TROSY and TROSY-based 3D
HNCA, HNCOCA, HNCO, HNCACO, HNCACB and

15

N-edited NOESY-HSQC (102)

recorded on 800 MHz (1H) Agilent VNMRS spectrometer at 25°C. The data were processed with
NMRPipe (140) and analyzed with CcpNmr Analysis (146).
NMR Studies of Protein Dynamics. The backbone 15N relaxation experiments for the

15

N-

labeled UBL1 were performed at 25°C on 500 MHz (1H) Agilent VNMRS spectrometer as
described elsewhere (118,147). All experiments were performed on a C576S UBL1 mutant
generated using QuikChange Kit (Agilent) to avoid slow cysteine-induced dimerization.

15

N R1

and R1ρ relaxation rates were measured from a series of eight spectra recorded at different
relaxation delays. Relaxation rates were extracted from exponential fits of peak intensities.

15

N

R2 were obtained from longitudinal R1 and rotating-frame R1ρ rates (119) measured at a spin-lock
field strength of 1592.4 Hz. The

15

N{1H} NOE experiment was carried out in an interleaved

manner by recording 2D 15N-1H spectra with and without 1H saturation period of 2.5 s using an
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inter-scan delay of 8 s. Heteronuclear NOE values were calculated as ratios of peak intensities in
corresponding 2D 1H–15N correlation spectra. Errors in NOE values were calculated based on
peak intensities and the measured spectral noise levels.
NMR binding experiments. ICP0 binding to individual USP7 UBL domains was assessed by
a series of titration experiments monitored by recording 800 MHz 1H-15N HSQC spectra of the
domains. Peptide GPRKCARKTRH corresponding to the ICP0 residues 617-627 was custom
synthesized (GenScript). The titrations were performed by gradual addition of the unlabeled
peptide to ~0.5 mM 15N-labeled UBL domain samples (up to 1:10 protein to peptide ratio). Both
the wild-type UBL1 and C576S mutant constructs were tested, and gave the identical results.
Frequency (chemical shift) perturbations were calculated for each amino acid residue as
i=(N2+H2 )1/2, where N and H are 15N and 1H frequency differences between ICP0bound and free states, respectively. The obtained i values were mapped onto the surface of the
crystal structure of the UBL12 tandem (PDB ID: 2YLM) (71).
Isothermal Titration Calorimetry (ITC). The affinity of USP7 UBL12 – ICP0 interaction was
determined by ITC. Measurements were performed with a Nano ITC instrument (TA
Instruments) in a buffer containing 20 mM NaH2PO, 100 mM NaCl, 2 mM β-mercaptoethanol,
pH 7 at 25°C. ICP0 peptide at a concentration of 686 μM was titrated into 85 μM UBL12. A total
of 20 injections were made with 300 second time intervals in between. ITC data were analyzed
with NanoAnalyze software (TA Instruments). Data fitting was performed using an
“independent” model after correcting for the heat produced by ICP0 dilution.
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In vivo studies:
Cell lines and Viruses. Vero and HFF-1 cells were purchased from the ATCC. HFF-1 cells
were maintained in DMEM supplemented with 10% fetal bovine serum and used between
passages 5 and 10. Vero cells were maintained in DMEM supplemented with 5% fetal bovine
serum. Strain 17+ was used as wild type HSV-1. Virus in1863 is derived from strain 17+ and
was obtained from Chris Preston (MRC Virology Unit, Glasgow, Scotland). This virus contains
the lacZ gene under the control of the HCMV promoter/enhancer inserted in the tk gene.
Growth yield of HSV-1 on shUSP7 cells. Lentivirus generation and virus infection were done
as previously described (148). Briefly, the pLKO.1 system was used to package lentiviruses and
deliver shRNA into target cells. HFF-1 cells were infected with lentiviruses expressing shRNA
against

GFP

(GCAAGCUGACCCUGAAGUUCA)

or

USP7

targeting

sequence

(GGCAACCTTTCAGTTCACT) and selected with 2 g/mL puromycin. 72 hours post-lentiviral
infection cells were infected with HSV-1 (in1863) at multiplicities of infection (MOI) of 0.1
PFU/cell. Progeny virus was collected at 24 hours post infection and titers were determined on
Vero cells by staining with crystal violet or X-gal for β-galactosidase-positive plaques as
previously described (148).
Western blot analysis was used to visualize USP7 and ICP0. Ku70 was used as a loading
control. After lentiviral transfection cells were infected with HSV-1 at an MOI of 2 PFU/cell.
Four hours post infection cells in 35mm dishes were lysed in 2X SDS sample buffer (4% SDS,
20% glycerol, 100mM Tris pH 6.8, 100mM DTT, 10% β-mercaptoethanol, 1X protease inhibitor
cocktail (Roche), and 0.1% bromophenol blue) and boiled for 5 minutes. Proteins were resolved
by SDS-PAGE and transferred to PVDF membranes. Membranes were blocked for 1 hour in 5%
non-fat dry milk dissolved in TBST. Primary antibodies were diluted in blocking solution and
47

incubated overnight at 4°C. Primary antibodies used include monoclonal mouse ICP0 (5H7)
(1:1,000; Abcam), polyclonal rabbit USP7 (H200) (1:1,000; Santa Cruz), and monoclonal mouse
Ku70 (Ab-4) (1:5,000; NeoMarker).

2.4. Results
2.4.1. Isolated USP7 UBL domains can be studied independently in solution
The full-length USP7 as well as the C-USP7 have long represented a challenge for structural
studies because of their rapid degradation during recombinant expression in E. coli (149). As a
consequence, difficulties in C-USP7 production hampered investigation of its structure and
function. The recent crystal structure of the isolated C-USP7 produced in insect cells (71)
revealed the domain organization of the C-USP7 and confirmed that it consists of five ubiquitinlike domains. In order to produce stable constructs of the C-USP7 suitable for studies in solution
we have tested bacterial expression of all individual UBL domains and their combinations in E.
coli. We found that the isolated UBL1 and UBL3 express well and result in stable soluble
proteins. In contrast, UBL2, UBL4 and UBL5 are unstable and degrade rapidly when expressed
on their own. However, the two-domain combinations UBL12 and UBL45 express well and are
stable and soluble. These results are in agreement with the C-USP7 crystal structure, which
shows extensive interactions between UBL1 and UBL2 as well as between UBL4 and UBL5.
1

H-15N HSQC NMR spectra of UBL1, UBL12, UBL3 and UBL45 are shown in Figure 2.1B.

The high quality of spectra and good chemical shift dispersion suggest that isolated UBL
domains and/or their combinations described above represent independently folding units that
can be used for structural and functional studies.
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2.4.2. Solution structure of the USP7 UBL1 domain
Figure 2.2 shows the solution NMR structure of the USP7 UBL1 domain (residues 537-664).
According to secondary structure prediction obtained from the backbone 1H,

15

N and

13

C NMR

chemical shifts using TALOS+ program (106), UBL1 adopts a characteristic ubiquitin-like βgrasp fold formed by β1-β2-α3-310-β3-β4-α4-α5-β5 elements (Figure 2.2A, top panel). The
bottom panel on Figure 2.2A shows order parameters S2 for the backbone amide groups of the
domain predicted from NMR chemical shifts using Random Coil Index (RCI) approach (150).
High S2 values of 0.8 – 0.9, indicative of limited backbone flexibility, were obtained for a
majority of the residues. The exceptions are a linker connecting the first two helices with the first
β-strands of the β-grasp fold and two large loops: loop I and loop II. The final ensemble of the 20
lowest energy structures (Figure 2.2B) displays root mean square deviation (rmsd) of 1.96 ± 0.44
Å for the backbone and 2.70 ± 0.38 Å for all heavy atoms (see Table 2.1 for structural statistics).
As expected, the overall structure of the domain is well defined in the NMR ensemble with the
exception of the two loops. (Figure 2.2B). The structure consists of a long kinked N-terminal αhelix (helices α1 and α2) followed by a β-grasp fold (Figures 2.2C and D). The α3-helix is
packed against an anti-parallel β-sheet ( that forms a barrel-like structure
(Figure 2.2D). In this barrel, the β4-strand is very short and is stabilized by a single hydrogen
bond between the backbone amide group of Leu638 and carboxyl of Leu622 from the β3-strand.
The N-terminal helix α1 does not belong to the ubiquitin-like fold and, in the context of the fulllength USP7, connects C-USP7 with the catalytic domain of the enzyme. Although the sequence
similarity of the USP7 UBL1 to ubiquitin is only 21%, it closely resembles a ubiquitin fold (PDB
ID: 1UBQ) with the backbone rmsd between the UBL1 and ubiquitin of 2.4 Å for regular
secondary structure elements. Significant differences, however, are observed in the loop regions.
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Thus, the UBL1 loop I that connects the β1- and β2-strands (residues 571-591) as well as loop II
between the β3- and β4-strands (residues 625-637) are notably longer than those of ubiquitin.
The hydrophobic patch equivalent to the ubiquitin Ile44 patch (151) is also present in UBL1 and
is centered around Trp623 (Figure 2.2D).
Figure 2.2E shows an overlay of the solution (red) and crystal (blue; PDB ID: 2YLM)
structures of the UBL1 domain. The UBL1 NMR structure is in good agreement with the crystal
structures of the entire C-USP7 (PDB ID: 2YLM) and the UBL12 tandem (PDB ID: 4PYZ) with
the backbone rmsd between NMR and crystal structures of 2.40 Å and 2.35 Å, respectively. The
most significant difference is in the loop conformations. The long loop II connecting the β3- and
β4-strands is poorly defined in the solution structure with only short and medium-range (|i-j|<5)
NOEs observed in this region (Figure 2.2F). This is in contrast to the crystal structure where
residues 625-635 form type-I -hairpin. The position of the hairpin is stabilized by interaction
with the UBL2 domain, including inter-domain salt bridges formed by residues Arg628 and
Asp764, as well as Arg634 and Glu737. Similarly, the position of loop I connecting - and β2strands (residues 571-591) is poorly defined in our solution structure, while in the crystal
structure it is stabilized by several inter-domain hydrogen bonds with the UBL2 residues.
Additionally, in the crystal structure, the relative position of the two long loops is constrained by
a hydrogen bond between the backbone HN group of Lys633 (loop II) and the OD2 group of
Asp582 (loop I), while in the NMR ensemble the loops sample multiple conformations. Overall,
the observed differences between the two structures may result from additional domains present
in the X-ray structure and the fact that NMR is sensitive to protein dynamics in solution.
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2.4.3. Backbone dynamics of the USP7 UBL1 domain
To confirm flexible conformations of the loops we have investigated the extent of
conformational dynamics of the UBL1 domain using backbone
measurements, including

15

N R1 and R2 rates and heteronuclear

15

15

N NMR relaxation

N{1H} NOE values

(118,119,147). These data report on Brownian rotational diffusion of a protein and its
conformational flexibility on the pico- to nanosecond time scales. 15N R1 and R2 relaxation rates
and 15N{1H} NOEs suggest that UBL1 is a rigid molecule with increased sub-nanosecond timescale flexibility of the two long UBL1 loops, as evidenced by a decrease in 15N{1H} NOE values,
lower R2 rate and elevated R1 rates for amino acid residues located in loops I and II (Figure 2.3).
Additionally, relaxation rates and NOEs suggest that the N-terminal α-helix that does not belong
to the β–grasp fold is also highly dynamic on the sub-nanosecond timescale.

2.4.4. USP7 is required for the efficient HSV-1 infection in HFF-1 cells
As a first step toward understanding the mechanism of substrate recognition by the C-USP7,
we have characterized its interaction with the ICP0 E3 ligase from HSV-1. ICP0 was the first
discovered and remains the best studied substrate of the USP7 that interacts exclusively with the
enzyme's C-terminus (70). ICP0 is a 775 amino acid residue long immediate early protein that is
expressed immediately after infection. Although ICP0 doesn’t interact with DNA directly, it acts
as a promiscuous activator for all three temporally regulated kinetic classes of viral genes
(reviewed in (54)). It was previously shown that ICP0 self-ubiquitination promotes its own
degradation; however, the formation of a complex with cellular USP7 stabilizes ICP0 and
rescues it from proteasomal degradation (55,152). Mutations that abolish the USP7 binding lead
to ICP0 destabilization during HSV-1 infection in U2O2 cells (55). Moreover, treatment of HeLa
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cells with siRNA against USP7 leads to a defect in ICP0 accumulation and reduced expression of
many ICP0 target genes, including ICP4 and UL42 (153). Furthermore, ICP0 interaction with
USP7 causes migration of the latter from the nucleus to the cytoplasm where it inhibits the NFkB dependent inflammatory cytokine response to protect HSV-1 from innate immunity (131).
Altogether, these data suggest that USP7 not only plays an essential role in regulation of
ICP0 levels in the infected cell, but also is required for establishment of successful HSV-1
infection. This makes USP7/ICP0 binding interface an attractive target for the development of
antiviral therapeutics. Therefore, we have explored the effect of a USP7 knockdown on the
efficiency of HSV-1 infection. Although ICP0 is not essential for virus replication in cultured
cells, ICP0-null mutant viruses grow poorly at low MOI. Because this effect is cell type
dependent, we have utilized limited-passage human diploid fibroblasts since they are sensitive to
the presence of ICP0 (reviewed in (54)). HFF-1 cells were infected with lentiviruses expressing
shRNA against either USP7 or GFP (control) followed by HSV-1 infection at an MOI 2
PFU/cell. The knockdown of USP7 was confirmed by a Western blot (Figure 2.4C). As
expected, ICP0 levels were severely decreased in cells lacking USP7 compared to cells
expressing shRNA against GFP. In addition, cells were infected with HSV-1 at a lower MOI of
0.1 PFU/cell. Progeny virus was collected at 24 hours post infection and formation of plaques
was monitored on Vero cells (Figures 2.4A and B). We observed that viral growth was reduced
100-fold in cells expressing shRNA against USP7 compared to control cells treated with shRNA
against GFP. These results suggest that the presence of USP7 in the cell and its interaction with
ICP0 are essential for establishment of successful lytic infection at low MOI in HFF-1 cells.
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2.4.5. The first two USP7 UBL domains (UBL12) are responsible for interaction with ICP0
The minimal ICP0 region required for interaction with USP7 was previously defined by R.
Everett et al. as residues 619-626 (152). This short peptide contains several Lysine and Arginine
residues, which make it highly positively charged. On the other hand, the region of USP7
responsible for interaction with ICP0 was roughly defined using limited proteolysis to reside
within residues 599-801 (70). This region contains a part of UBL1, the entire UBL2 and a part of
the UBL3 domains. To determine the domain(s) of C-USP7 responsible for interaction with ICP0
we have performed a series of NMR binding experiments. Isolated

15

N-labeled UBL1, UBL12

and UBL3 domains of the USP7 were gradually titrated with the unlabeled ICP0 peptide
(residues 617-GPRKCARKTRH-627) and binding-induced changes in peak positions in 1H-15N
HSQC spectra of the domains were monitored. As seen in Figures 2.5B and C, no peak shifts
were observed for the UBL1 and UBL3, indicating that these domains alone are not sufficient for
interaction with the ICP0 peptide. In contrast, the addition of ICP0 peptide to the

15

N UBL12

caused progressive changes in the positions and intensities of a number of peaks in its 1H-15N
HSQC spectrum indicative of specific ICP0 binding (Figure 2.5A).
In the course of titration with ICP0, the peaks in the NMR spectrum of UBL12 do not move
gradually, but rather disappear and then show up in new positions in the spectrum, indicative of a
slow on the NMR time-scale binding process. Therefore, to measure UBL12 – ICP0 binding
affinity and determine thermodynamic parameters for this interaction we have employed
isothermal titration calorimetry (ITC) (Figure 2.5D). The results indicate that UBL12 binds ICP0
in 1:1 stoichiometry. The best fit of the titration curve was obtained with an independent site
model with a dissociation constant (KD) of 14.6 ± 1.3 μM and enthalpy (∆H) of -24.5 ± 0.7
kcal/mol, resulting in entropy (ΔS) of -60.2 cal/(mol K) and Gibbs Free energy (ΔG) of -6.6
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kcal/mol at 25°C. The high ΔH value suggests that the reaction is enthalpy-driven with primary
contributions to the complex stabilization likely resulting from electrostatic interactions and/or
hydrogen bonds.

2.4.6. Mapping of the UBL12-ICP0 binding site
As seen in Figure 2.5A, a large number of peaks have shifted in 1H-15N HSQC spectrum of the
USP7 UBL12 as a result of ICP0 peptide binding. Due to slow on the NMR time scale binding,
the backbone resonances of the UBL12 in complex with ICP0 cannot be assigned by tracing
peak shifts in the UBL12 spectrum during the titration. Therefore, to quantify ICP0-induced
changes in peak positions and thus identify the UBL12 amino acid residues responsible for ICP0
recognition we have assigned the backbone resonances of the free and ICP0-bound forms of the
UBL12.
Figure 2.6A summarizes the extent of the UBL12 chemical shift assignment: circles below
the amino acid sequence correspond to assigned peaks in the 1H-15N HSQC spectra of the free
and ICP0-bound UBL12 constructs. UBL1 and UBL2 portions of UBL12 are colored in blue and
green, respectively. A total of 74% of expected NMR resonances of free UBL12 and 82%
resonances of ICP0-bound UBL12 have been assigned. The remaining peaks were broadened
beyond detection. The residues with missing assignments in either free or ICP0-bound UBL12
are marked by stars and arrows, respectively, above the amino acid sequence. Most of these
residues are missing in the spectrum of free UBL12 and appear only after ICP0 binding. Such a
behavior points to changes in the UBL12 conformation and dynamics as well as changes in
chemical environment of the nuclei on the interaction interface associated with the substrate
recognition.
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ICP0 binding led to substantial frequency (chemical shift) changes for the vast majority of
the UBL12 amide resonances (Figures 2.5A and 2.6F) with the largest perturbations (>150 Hz)
observed for residues Gly631, Leu638, Val685, Leu699, Ile709, Ser710, Ser752, Leu757 and
Asp758. The complex formation noticeably improved the quality of the spectrum, suggesting
that ICP0 binding stabilizes the UBL12 tandem (Figure 2.5A, bottom panel). As a result, a
number of intense peaks appeared in the UBL12 spectrum upon ICP0 binding. While the
backbone amide resonances for 171 out of 230 non-proline residues were observed for the free
protein, 25 additional peaks were assigned for the complex (Figure 2.6A). The vast majority of
these new peaks correspond to residues located either on the UBL1/UBL2 interface or in its
close proximity (Glu572, Phe575, His578, Gln579, Asn581, Asp582, Ile620, Gln626, Arg628,
Asn630, Thr632, Glu663, Thr664, Val665, Met686, Asn700, Tyr701, Tyr706 and Val738) (Figure
2.6D). In addition, 8 peaks in 1H-15N HSQC spectrum of the UBL12 disappeared upon ICP0
binding, pointing to changes in the UBL12 conformation and/or dynamics caused by complex
formation. These peaks correspond to residues Asp680, Lys681, Asp682, Gly763, Asp764 and
Ile765 located on the UBL1/UBL2 interface and residues Glu759 and Leu760 located in the loop
between the β4- and β5-strands of the UBL2.
Overall, mapping binding-induced frequency (chemical shift) changes onto the UBL12
structure (71) identified residues sensitive to ICP0 binding in both UBL1 and UBL2 domains.
The regions of the UBL1 and UBL2 with NMR peaks affected by ICP0 addition are shown on
the protein surface in Figures 2.6C and D. The UBL1 residues exhibiting pronounced frequency
(chemical shift) changes are mainly located in loops I and II. The residues of UBL2 affected by
ICP0 binding are located in two distinct regions. The first region includes a hydrophobic patch
formed by residues in strands β1, β2, β3 and β5 of the UBL2 β-sheet. This face of the UBL2
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domain makes extensive contacts with UBL1, which protect this patch from solvent exposure
(Figure 2.6D). The second region is solvent exposed and includes residues from the two loops:
the UBL2 loop connecting the β2-strand with the following -helix, and the loop connecting the
β4- and β5-strands (Figures 2.6C and E). These loops form a negatively charged cluster on the
UBL2 surface, which provides a binding interface for the positively charged ICP0 peptide.

2.5. Discussion
Owing to USP7 involvement in maintenance of several important tumor suppressors and key
viral proteins, it has emerged as a potential therapeutic target for treatment of cancer and
infections caused by DNA viruses (154). Therefore, the mechanisms of USP7 specificity toward
its diverse substrates are of significant interest.
While functions of the USP7 N-terminal TRAF and catalytic domains were previously
characterized, the functions of its UBL domains remain largely unknown. Roughly, UBLs within
the USP family of proteins can be divided into three groups: N-terminal,

C-terminal or

embedded in the USP catalytic core (155). The USP7 UBL domains belong to the third group of
the C-terminal UBLs. Previous studies revealed that UBLs of USP7 enhance its enzymatic
activity, since even small truncations of the extreme C-terminus dramatically decrease USP7
catalytic activity (71,83). Furthermore, it was recently shown that the UBL domains can function
as a binding platform for several USP7 substrates. However, the precise location of the C-USP7
substrate binding sites remained unknown (50,70,83).
USP7 is unique within the USP family, since, unlike other family members, it contains a
tandem array of five UBL domains. As a consequence of the large size of the USP7 C-terminus,
it is challenging to study all five tandem UBL domains together. Here we show that this complex
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system can be simplified by the isolation of stable individual UBL domains and/or constructs
containing two consecutive UBL domains. Our NMR data reveal that these constructs can be
studied in isolation in solution, providing new insights into the C-USP7 structure, dynamics and
substrate specificity. Although there are two available X-ray crystal structures of C-USP7 (PDB
IDs: 2YLM, 4PYZ), these structures provide little information about protein dynamics. In this
study we focused on the UBL1 domain and UBL12 tandem. We have: (i) determined the threedimensional NMR structure of the UBL1 domain and characterized its dynamic properties, (ii)
narrowed down the ICP0-binding region of the USP7 to the UBL12 domains, and (iii) obtained
high-resolution NMR mapping of the USP7 binding site for ICP0.
Once inside the cell, HSV-1 encounters a hostile environment created by host proteins that
are intrinsically antiviral. HSV-1 encodes proteins such as ICP0 intended to inactivate cellular
antiviral mechanisms (54). The interaction between ICP0 and USP7 is essential to prevent ICP0
degradation during the infection, and in this study, we have structurally and functionally
characterized this interaction. As a first step, we have investigated the effect of USP7 ablation on
the efficiency of HSV-1 lytic infection. We utilized shRNA to generate USP7 knockdown cells
and demonstrated that in cells lacking USP7 virus growth is severely reduced. These results
suggest that the USP7-ICP0 interaction is important for the establishment of effective lytic HSV1 infection in HFF-1 cells.
Next, we used solution NMR to structurally characterize the ICP0 – USP7 interaction, and
have shown that USP7 binds ICP0 via its first two C-terminal UBL domains, providing evidence
that the USP7 UBL domains function as a substrate interacting platform. The ICP0 peptide used
in this study was previously identified as a minimal USP7-binding region of ICP0 (152). This
peptide is composed of eleven amino acid residues, six of which are positively charged and three
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are polar (Figure 2.7B). Thus, of the two USP7 regions affected by ICP0 binding, the one located
at the UBL2 β-sheet is unlikely to directly interact with ICP0 because it consists of mainly
hydrophobic residues buried on the UBL1/UBL2 interface. On the other hand, the second region
encompassing the UBL2 loops, one between the β2-strand and the following α-helix and the
other between the β4- and β5-strands, has a negatively charged surface and is more likely to
directly bind positively charged ICP0 peptide. The high enthalpy of complex formation (-24.5 ±
0.7 kcal/mol) measured by ITC provides further evidence of the electrostatic nature of UBL12 –
ICP0 interaction.
NMR chemical shift mapping revealed that the binding of the two proteins is likely mediated
by electrostatic interactions. This is in agreement with previous mutational analysis of ICP0,
which identified Arg619, Lys620, Lys624 and Arg626 as residues critical for interaction with
USP7 (152) (Figure 2.7A). Interestingly, although the UBL1 domain alone does not interact with
ICP0 (Figure 2.5B), it exhibits extensive binding-induced chemical shift changes in the context
of the UBL12 construct (Figure 2.6F). Notably, UBL1 residues involved in ICP0 binding belong
to the two long flexible loops located in the close proximity of the UBL1 - UBL2 interface,
supporting the notion that these two domains may function in tandem. The presence of UBL2
may constrain conformation of the UBL1 flexible loops, as seen in crystal structures of the CUSP7 UBL domains. Overall, our data suggests that UBL12 may undergo micro- to millisecond
opening/closing events, resulting in the observed line broadening and/or disappearance of peaks
on the interface of UBL1 and UBL2 domains. As evident from chemical shift mapping, most of
the UBL12 biding site for ICP0 is located on the UBL2 surface with an additional participation
of residues from loop II of the UBL1. We speculate that the substrate binding may lock the two
domains in a closed conformation, thus limiting micro- to millisecond conformational sampling
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and quenching exchange contributions to transverse relaxation. This model could explain the
chemical shifts changes and line narrowing on the inter-domain interface observed upon ICP0
binding.
The HSV-1 ICP0 has never been structurally characterized, although it was shown to contain
an N-terminal RING domain similar to one from an immediate-early protein of equine herpes
virus. (156,157). The USP7-binding motif of ICP0 is located within the molecule’s C-terminus
(residues 619-626). We used Jpred (158) to predict the secondary structure of the HSV-1 ICP0
and found that its C-terminal region is predicted to contain a structured domain with an
 arrangement (Figure 2.7A). Furthermore, we have compared the HSV-1 ICP0
protein with its orthologues from other Alphaherpesvirinae subfamily viruses using SIB Blast
followed by multiple sequence alignment in ClustalW (159) and conservation score calculation
using ConSurf server (160,161) and found that the ICP0 sequence has two highly conserved
regions. The first region includes the N-terminal RING domain characteristic of E3 ubiquitin
ligases, while the second contains a yet uncharacterized C-terminal domain (CTD). Figure 2.7A
shows a multiple sequence alignment of the ICP0 CTD. Remarkably, the USP7 binding motif
(residues 619-626) is one of the best conserved regions within the ICP0 C-terminus and it is
predicted to form an α-helix. According to a helix wheel projection, this helix is amphipathic
(positively charged on one side and neutral on the other), which may facilitate its interaction with
a negatively charged cluster on the UBL2 surface (Figure 2.7B). Other predicted secondary
structure elements of the ICP0 CTD are also conserved, supporting the notion that ICP0-like
proteins harbor a structured CTD in addition to the N-terminal RING domain. High amino acid
conservation in the ICP0 region involved in USP7 binding implies that ICP0 interaction with the
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USP7 is not unique to HSV-1 but may represent a common feature shared by other members of
the Herpesvirus family.
The fact that the five non-homologous USP7 UBL domains can interact with multiple USP7
targets suggests that the UBL domains serve as a versatile binding platform and endow the
enzyme with specificity to its diverse substrates. However, until now, none of the C-USP7
substrate binding sites has been characterized at high resolution. In this work, for the first time,
we have structurally and functionally characterized the interaction of the C-USP7 with its first
identified target – HSV-1 ICP0 protein. Our results, along with future studies of other C-USP7
substrate-binding sites, may unravel determinants of the USP7 specificity towards its substrates
and provide a structural basis for the future development of new therapeutic strategies to prevent
livelong HSV-1 infection and virus expansion among human population.
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Table 2.1. NMR structural statistics of USP7 UBL1 domain.
Summary of restraints
NOE distance restraints
Short range (|i-j|<=1)
Medium range (1<|i-j|<5)
Long range (|i-j|>=5)

1358
576
1107

Total
3041
Dihedral angles (φ and ψ)
187
Hydrogen bonds
32
Deviation from experimental restraints
NOE (Å)
0.022±0.0
03
Dihedral restraints
1.757±0.1
(degrees)
23
Deviation from idealized geometry
Bonds (Å)
0.019
Angles (degrees)
1.3
Ramachandran plot statistics
Most favored regions
77.2%
Additionally allowed regions
21.8%
Generously allowed regions
0.8%
Disallowed regions
0.2%
RMSD from mean structure (Å)
All residues
Backbone atoms
1.96±0.44
Heavy atoms
2.70±0.38
Residues in ordered regions1
Backbone atoms
0.62±0.09
Heavy atoms
1.25±0.14

1

The following secondary structure elements were included as ordered regions in the RMSD
calculation: 539-548, 551-554, 556-570, 592-595, 602-613, 617-619, 621-624, 649-652, 658663.
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Figure 2.1. Isolated USP7 UBL domains can be studied independently in solution. A.
Schematic representation of the domain arrangement of the human USP7 protein. B. 2D 1H-15N
HSQC spectra of the UBL1 (blue), UBL12 (green), UBL3 (black) and UBL45 (red) domains.
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Figure 2.2. Solution NMR structure of the USP7 UBL1 (residues 537-664). A. The top panel
shows TALOS+ derived probabilities of α-helix and β-sheet formation, marked as P(α) and P(β),
respectively. The bottom panel shows RCI-based backbone amide order parameters, S2. B. The
backbone representation of the ensemble of 20 NMR lowest-energy structures of the USP7
UBL1. C. Amino acid sequence of the USP7 UBL1 domain with cartoon representation of its
secondary structure elements shown at the top. Helices are colored in red, β-strands are shown in
green. D. Ribbon representation of the UBL1 structure with secondary structure elements and
loops I and II labeled. E. Superposition of solution (red) and crystal (blue; (PDB ID: 2YLM)
structures of the UBL1. F. NOE connectivity plot of UBL1. Flexible loops I and II are labeled
and shown in grey.
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Figure 2.3. The backbone dynamics of UBL1 from 15N relaxation. A. 15N R1, R2 relaxation
rates and 15N{1H} heteronuclear NOE values shown as a function of the UBL1 residue number.
Secondary structure elements are shown at the bottom. B. Mapping of heteronuclear 1-NOE
values onto the UBL1 structure. 1-NOE values are mapped as a color gradient (blue to magenta)
and ribbon radius. Dynamic regions correspond to intense magenta color and thicker ribbon. All
experimental relaxation data were acquired at 500 MHz (1H) and 25 °C.
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Figure 2.4. USP7 is required for successful establishment of HSV-1 lytic infection. HFF-1
cells were infected with lentiviruses expressing shRNA against USP7 (shUSP7) in order to
downregulate cellular USP7. shRNA against GFP (shGFP) was used as a control. A-B. After
selection, knockdown cells were infected with HSV-1 at an MOI of 0.1 PFU/cell. Progeny virus
was collected at 24 hours post infection and titers were determined on Vero cells by staining with
either crystal violet (A) or X-gal for β-galactosidase-positive plaques (B). In B, values
correspond to the average of three independent experiments and error bars correspond to one
standard deviation. C. Efficiency of USP7 knockdown and ICP0 stability were tested by Western
blot analysis. USP7 knockdown cells were infected with HSV-1 at an MOI of 2 PFU/cell and
cell lysates were prepared at 4 hours post infection and subjected to Western blot analysis for
ICP0 and USP7. Ku70 serves as a loading control.
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Figure 2.5. NMR and ITC analysis of the USP7 UBL domain interactions with the ICP06171
15
627 peptide. Overlay of H- N HSQC spectra of the UBL12 (A), UBL1 (B), and UBL3 (C)
domains before (red) and after addition of the unlabeled ICP0 peptide (residues 617-627) to a
final protein:peptide ratio of 1:10 (blue). In A, the signals of UBL12 with chemical shift
perturbations over 100 Hz are labeled. Among these, the peaks corresponding to residues located
on the ICP0-binding interface are labeled with asterisks. The bottom panel shows changes in line
shapes for selected UBL12 peaks upon ICP0 binding. D. ITC profiles for UBL12 binding to
ICP0. The left panel shows heat change upon ligand addition; the right panel shows an integrated
ITC isotherm and its best fit to an independent site model.
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Figure 2.6. Analysis of ICP0 binding to the USP7 UBL12 tandem. A. Completeness of the
backbone assignment for the free and ICP0-bound UBL12. Here and later UBL1 and UBL2
domains are colored in shades of blue and green, respectively. Circles below the protein
sequence represent amino acid residues with assigned NMR resonances in 1H-15N HSQC spectra
of the free (light circles) and ICP0-bound UBL12 (dark circles). Open spaces indicate residues
with unassigned amide peaks. Asterisks indicate UBL12 residues with assigned amide peaks in
the bound state only, while arrows indicate residues with assigned amide peaks in the free state
only. B. Ribbon representation of the UBL12 (pdb ID: 2YLM) (71). C. Mapping of the
frequency differences between the free and ICP0-bound UBL12 i=(N2+H2 )1/2 on the
UBL12 surface. The color gradient corresponds to values, with larger changes shown by
more intense color. D. Mapping of the UBL2 residues located on the UBL1/UBL2 interface and
affected by ICP0 binding. As in C (top view) but rotated about the z-axis by 90°, for clarity,
UBL1 is shown as orange ribbon. E. Close-up view of the UBL12 ICP0-binding interface. F.
Per-residue amide frequency differences between the free and ICP0-bound states of the UBL12
(Hz as a function of residue number. Residues with peaks missing in one of the two spectra
(free or bound) are shown as bars with the maximum  of 650 Hz to indicate that these
residues are sensitive to ICP0 binding. Prolines and residues with missing amide group
assignment in both spectra are shown as empty spaces. Secondary structure elements are shown
at the top.

68

Figure 7. The C-terminal region of ICP0 may contain a structured domain. A. Sequence
alignment of the HSV-1 ICP0 (residues 604-775) and a number of its viral orthologues
performed in ClustalW (159). Viruses are Human Herpesvirus 1 (HSV1), Chimpanzee alpha-1
herpesvirus (ChHV), Human Herpesvirus 2 (HSV2), Cercopithecine Herpesvirus 1 (CeHV1),
Cercopithecine Herpesvirus 16 (CeHSV16), Macropodid Herpesvirus 1 (MaHV1) and Saimiriine
Herpesvirus 1 (SHV1). Residues are colored according to conservation scores calculated using
the ConSurf server (160,161). Secondary structure elements predicted in Jpred (158) for the
HSV-1 ICP0 are shown at the top. Arrows above the alignment indicate residues critical for
USP7 binding identified in previous mutagenesis analysis (152). B. HSV-1 ICP0 peptide
(residues 617-627) shown in a helical wheel projection created using the EMBOSS Pepwheel
program. Hydrophobic residues are shown as grey spheres, polar residues as diamonds and basic
residues as blue spheres.

69

CHAPTER 3

Mechanism of USP7 inhibition by small-molecule compounds

Alexandra Pozhidaeva, Feng Wang, Jian Wu, Phuong Nguyen, Joseph Weinstock, Suresh
Kumar, Jean Kanyo, Dennis Wright and Irina Bezsonova

This chapter was submitted as a research article titled "USP7-specific Inhibitors Target and
Modify the Enzyme’s Active Site via Distinct Chemical Mechanisms" to Cell Chemical Biology.

Authors contributions: AP and IB conceived the project and designed in vitro experiments. AP
performed protein purification, carried out and analyzed all NMR experiments, and wrote the
manuscript. AP and IB performed computational molecular docking. J Weinstock designed USP7
inhibitors used in the study. J Wu synthesized the inhibitors. SK designed cellular experiments
while FW and PN performed and analyzed them. JK performed LC-MS/MS experiments and JK,
AP and IB analyzed the results. DW proposed the chemical mechanism of USP7 inhibition. JK,
SK, J Weinstock and IB reviewed and edited the manuscript.

70

3.1. Abstract
USP7 is a deubiquitinating enzyme that plays a pivotal role in multiple oncogenic pathways
and therefore is a desirable target for new anti-cancer therapies. However, the lack of structural
information about the USP7 – inhibitor interactions has been a critical gap in the development of
potent inhibitors. Using a multidisciplinary approach, we obtained new and unexpected insights
into the mechanisms of USP7 activation and inhibition by small-molecule compounds that can
aid this development. USP7 is unique among other USPs in that its active site is catalytically
incompetent and is postulated to rearrange into a productive conformation only upon binding to
ubiquitin. Here we show that, contrary to previous reports, ubiquitin binding alone is not
sufficient to induce active site rearrangement and leaves the enzyme in an unproductive
conformation. Using a combination of NMR spectroscopy, mass spectrometry and computational
modeling we found that inhibitors P22077 and P50429 covalently modify the catalytic cysteine
of USP7 via distinct chemical mechanisms and induce a conformational switch in the catalytic
domain associated with active site rearrangement. Cell-based enzymatic activity assays
confirmed that the inhibitors inactivate the full-length protein in cells. This work represents the
first experimental insights into USP7 activation and inhibition and provides a structural basis
needed for rational development of highly potent anti-cancer therapeutics.

3.2. Introduction
The Ubiquitin-proteasome system (UPS) is required for the tightly controlled degradation
and turnover of a majority of the proteins in eukaryotic cells. An enzymatic cascade of three
classes of enzymes: E1 activating enzyme, E2 conjugating enzyme and E3 ligase work together
to ubiquitinate a substrate and target it to the proteasome, where it is cleaved into short peptides.
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The targeting of a protein to degradation in turn can be reversed by deubiquitinating enzymes
(DUBs) that remove ubiquitin chains from their substrates (2). Inhibition of UPS components
represents a promising therapeutic strategy to control cellular levels of proteins that lack
enzymatic activity and thus cannot be inhibited (90). E3 ligases and DUBs directly interact with
proteins targeted for (de)ubiquitination and determine substrate specificity of UPS. Therefore,
their inhibition has emerged as a new approach to modulate stability of distinct proteins, such as
oncoproteins and tumor suppressors (22,162,163). Ubiquitin-specific protease 7 (USP7), also
known as Herpes virus-associated ubiquitin-specific protease (HAUSP), is a cysteine protease
that belongs to the USP family of DUBs in humans (53). It is widely known for its central role in
the DNA damage response in which it regulates protein levels of the tumor suppressor p53 in
response to genotoxic stress (24). In unstressed cells, USP7 preferably interacts with and
stabilizes HDM2, an E3 ligase responsible for poly-ubiquitination of p53 and targeting it for
degradation. During DNA damage, however, ATM-dependent phosphorylation of HDM2
reduces its affinity for USP7. As a consequence, p53 is available to interact with USP7, resulting
in stabilization of p53 and initiation of the p53-dependent DNA damage response (25-27). In
addition to p53, USP7 has been shown stabilize proteins involved in DNA replication, epigenetic
DNA

alterations,

apoptosis

and

cell

cycle

control

(30,34,37,39,47,63,125,164,165).

Microdeletions and mutations in the USP7 gene lead to neurodevelopmental disorders in humans
characterized by intellectual disability, autism spectrum disorder, epilepsy and hypogonadism
(132).
Dysregulation of USP7 expression has been reported in number of human malignancies,
including human prostate cancer (51), ovarian cancer (87) and non-small cell lung cancer
(NSCLC) (86,136). The role of USP7 in oncogenesis and tumor suppression makes it an
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attractive pharmaceutical target for inhibition by small-molecule compounds (154). Early studies
in human colon cancer xenograft models showed that downregulation of USP7 suppresses cell
proliferation and delays tumor growth due to p53 stabilization in the absence of cellular stress
(166). High-throughput screening (HTS) efforts led to the discovery of the first semi-specific,
uncompetitive and reversible inhibitor of USP7 (HBX 41,108) that stabilizes p53 and inhibits
cell growth in HCT116 colon cancer cells (91). Later, more specific USP7 compounds were
reported (92) along with a family of dual USP7/USP47 inhibitors (compounds 1 - 14) (93).
Inhibition of USP7 by P5091 (compound 1) was shown to cause apoptosis of multiple myeloma
cells and prolonged survival in animal xenograft models (94). Optimization of P5091 led to the
discovery of P22077 (compound 4) that inhibited neuroblastoma growth (96) and P50429
(compound 14) that inhibited the proliferation of HCT-116 cells (93). Although all of the above
compounds show antitumor properties in various cancer cell lines and animal models, none is
very potent and all require further optimization.
USP7 consists of an N-terminal substrate-binding TRAF-like domain, five C-terminal
regulatory ubiquitin-like (UBLs) domains, and a central catalytic core that binds ubiquitin and
removes it from the substrate (70,71,138). The catalytic domain of USP7 adopts a papain
protease-like fold that binds ubiquitin. This fold contains Thumb, Palm and extended Fingers
regions similar to those of other USPs (72,75). Importantly, because all previously reported
USP7 inhibitors were discovered using HTS, it is not clear whether the inhibitors bind to the
active site of the enzyme or whether they bind to a region distinct from the active site, acting
allosterically to induce a conformational change that leads to enzyme inactivation. Furthermore,
given the structural conservation of the catalytic domains within the family of 58 USP enzymes,
it is not clear how specificity for USP7 can be achieved (11).
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In this study we uncover the mechanism of USP7 inhibition by small-molecule compounds
as well as provide new insights into the mechanism of the enzyme’s activation. We have taken
advantage of NMR spectroscopy, a powerful tool for studying protein-ligand interactions, and
developed a robust assay to test binding of USP7 inhibitors to its catalytic domain in solution.
We performed a backbone NMR resonance assignment of the catalytic domain and mapped
surface binding sites for two USP7 inhibitors P22077 and P50429, the derivatives of a lead
compound that previously showed antitumor potential (93). Interestingly, our NMR and mass
spectrometry data reveal that both compounds occupy the active site of the enzyme and
covalently modify the catalytic Cys223 residue. We suggest that these small molecules directly
inhibit the catalytic activity of USP7 by preventing the cleavage of the isopeptide bond between
the substrate and ubiquitin. The efficacy of these irreversible inhibitors was also confirmed using
full-length USP7 in Jurkat cells. Our study, the first elucidation of the mechanism of action for
any USP7 inhibitor, provides the foundation for rational design of more potent and selective
USP7 inhibitor-based therapeutic agents.

3.3. Experimental procedures
Protein expression and purification. cDNA encoding the catalytic domain of the human
USP7 (residues 208-560) was sub-cloned into pET28a-LIC Vector (Structural Genomics
Consortium) downstream from an N-terminal His6-Tag and a thrombin cleavage site. A
2

H/13C/15N – labeled catalytic domain was expressed in Escherichia coli BL21 (DE3) grown at

37°C in 100% D2O-based M9 minimal medium supplemented with 15NH4Cl and 13C/2H -glucose
as the sole source for nitrogen and carbon respectively. Protein expression was induced at an
OD600 ~ 0.8 by adding 1mM IPTG. Cells were harvested after 16 hours of incubation at 20°C
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and lysed by sonication in extraction buffer containing 20 mM NaH2PO4, 250 mM NaCl, 10 mM
imidazole, pH 7.4. Cell lysates were clarified by centrifugation at 15000 rpm for 45 min and
applied to a Ni-NTA resin (Thermo Scintific). Recombinant protein was eluted with extraction
buffer containing 250 mM imidazole. Following thrombin digestion to remove the His6-tag, the
catalytic domain was additionally purified by size exclusion chromatography using HiLoad
Superdex 200 column (GE Healthcare) in sample buffer containing 20mM Tris-HCl, 100mM
NaCl, 2mM DTT, pH 7.5. For NMR experiments the protein sample additionally contained 10%
D2O.
NMR spectroscopy. All NMR data including spectra for backbone resonance assignment and
chemical shift perturbation experiments were collected on an 800 MHz (1H) Agilent VNMRS
spectrometer equipped with a cryoprobe at 30°C. The data were processed with NMRPipe (140)
and analyzed with CcpNmr Analysis (146). NMR experiments collected for backbone resonance
assignment of USP7 catalytic domain included standard 2D 1H-15N TROSY-HSQC, TROSYbased 3D HNCA, HNCOCA, HNCO, HNCACO, HNCACB and

15

N-edited NOESY-HSQC

(101,102). To assess ubiquitin binding, unlabeled ubiquitin was gradually added to 0.3 mM
2

H/13C/15N – labeled catalytic domain of USP7 at ratios of up to 1:3 (protein to substrate). To

monitor interactions of USP7 with its inhibitors, compounds P22077 or P50429 were dissolved
in 100% DMSO and gradually added to 0.42 mM 2H/13C/15N – labeled catalytic domain up to a
1:5 protein-to-inhibitor ratio and a final DMSO concentration of 5%. In all experiments changes
in chemical shifts were monitored by acquiring 2D 1H-15N TROSY spectra. During inhibitor
binding experiments a spectrum of the free catalytic domain in sample buffer additionally
containing 5% DMSO was used as a reference spectrum.
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For the USP7 catalytic core – ubiquitin complex, observed frequency perturbations for each
amino acid residue were calculated using combined shift change of the amide nitrogen and
proton obs=(N2+H2 )1/2, where N and H are

15

N and 1H frequency differences

between free and bound states in Hz. The dissociation constant for the complex of the catalytic
domain with ubiquitin KD=[P][L]/[PL] (where [P], [L] and [PL] are concentrations of the free
protein, free substrate and the complex respectively) was extracted by nonlinear least-square
fitting of global chemical shift change plotted versus ligand concentration using the following
equation:
∆ωobs = ∆ωmax

(𝐾D + [L]t + [P]t ) − √([𝑃]t + [L]t + 𝐾D )2 − 4[P]t [L]t
2[P]t

where [P]t and [L]t are the total protein and ligand concentrations and ∆max is the chemical shift
difference at saturation. A total of 199 assigned, well resolved non-overlapped peaks were used
for the analysis. The titration data analysis was performed using SciDAVis.
Protein – ligand docking. Induced fit (flexible) and covalent docking of the complexes of the
USP7 catalytic domain with DUB inhibitors P22077 and P50429 was performed using ICM-Pro
(Molsoft). ICM method uses Monte-Carlo simulations based global optimization of flexible
ligand positions in the space of grid potential energy maps calculated for a protein receptor
(167). During induced fit docking, pockets were first automatically identified on the X-Ray
structure of the USP7 catalytic core (PDB ID: 4M5W) (75). The inhibitor binding pocket for
calculation of grid potential maps was chosen and further adjusted based on experimental NMR
results. Full side-chains of residues within the search box were allowed to be flexible including
residues 218-219, 222-224, 226, 291-292, 461-465 and 482 of P22077 and residues 218-227,
291-296, 351, 405-411, 416-418, 456, 460-466, 481-482 and 514-515 – during docking of
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P50429. The thoroughness level was set to 5. For covalent docking, chemical reactions for both
of the compounds were sketched manually. Covalent adducts were identified based on MS
results and represented products of the chemical reactions. Cys223 was chosen as the modified
residue. Structures with the lowest predicted ICM scoring function accounting for ligand size,
protein – ligand van der Waals interactions, conformational changes, changes in solvation
electrostatic energy and hydrophobic free energy gain were chosen for analysis.
Mass Spectrometry. Samples used for intact mass determination and LC-MS/MS were
prepared by incubating 300 μg of the purified catalytic domain with either a 5-fold molar excess
of P22077 or P50429 in the sample buffer containing 5% DMSO, or with vehicle (5% DMSO)
overnight at room temperature. Following incubation, the protein samples were dialyzed in water
to remove salts and excess of the small molecules. To determine the intact mass of the USP7
catalytic core and its complexes with inhibitors, samples (~100 µg, 30 µl) were mixed with 200
µl of 50% methanol containing 0.1% formic acid and analyzed by direct infusion on a Thermo
Scientific Orbitrap Fusion Tribrid mass spectrometer. The instrument was operated in Intact
Protein mode with an ion routing multipole pressure of 1mTorr. Spectra were acquired at 120K
and 240K resolution. The isotopically resolved data were processed using Thermo Scientific
Protein Deconvolution 4.0 software.
For LC-MS/MS, the intact protein samples (~10ug) were dried using SpeedVac prior to
dissolving and denaturing in 8M urea, 0.4M ammonium bicarbonate. The urea concentration was
adjusted to 2M by the addition of water, and the proteins were digested with trypsin (Promega) at
37ºC for 16 hours. Samples were desalted using a C18 Ultra microspin column (The Nest
Group) and peptides were eluted with 80% acetonitrile containing 0.1% trifluoroacetic acid
(TFA), dried and reconstituted in 7% formic acid/0.1% TFA and then diluted with additional
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0.1% TFA to a final protein concentration of 0.01µg/µl. LC-MS/MS analysis was performed on
a Thermo Scientific Q Exactive Plus equipped with a Waters nanoAcquity UPLC system using a
Waters Symmetry® C18 180µm x 20mm trap column and a ACQUITY UPLC PST (BEH) C18
nanoACQUITY Column (1.7 µm, 75 µm x 250 mm) for peptide separation. Trapping was done
at flow rate of 5µl/min in 97% Buffer A (100% water, 0.1% formic acid) for 3 min. Peptide
separation was performed at 330 nl/min with the following gradient of Buffer B (100%
acetonitrile, 0.1% formic acid) in Buffer A for 90 minutes: 3% B at initial conditions; 5% B at 1
minute; 35% B at 50 minutes; 50% B at 60 minutes; 90% B at 65-70; and back to initial
conditions at 71 minutes. MS was acquired in profile mode over the 300-1,700 m/z range using 1
microscan; 70,000 resolution; AGC target of 3E6; and a full max ion time of 45 ms. MS/MS was
acquired in centroid mode using 1 microscan; 17,500 resolution; AGC target of 1E5; full max
ion time of 100 ms; 1.7 m/z isolation window; normalized collision energy of 28; and 200-2,000
m/z scan range. Up to 20 MS/MS were collected per MS scan on species with an intensity
threshold of 2E4, charge states 2-6, peptide match preferred, and dynamic exclusion set to 20
seconds. MASCOT Distiller software was used to generate peak lists which were searched
against the UBP7_HUMAN sequence as well as the Swiss-Protein database with taxonomy
restricted to E. coli using the MASCOT algorithm (Matrix Science). Search parameters used
were peptide mass tolerance of 10 ppm; MS/MS fragment tolerance of +0.25 Da; allow up to two
missed cleavages; variable modification of methionine oxidation and custom modifications
configured for the moieties added by the compounds.
Cell Culture. Human T lymphocyte cell line Jurkat (p53MUT) was maintained in Roswell
Park Memorial Institute (RPMI) 1640 Medium, supplemented with 10% FBS and 2mM Lglutamine, and 50 units/mL penicillin/streptomycin.
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Western Blotting. Jurkat cells were treated with USP7 inhibitors for 24 hours with indicated
doses, harvested and washed once with ice-cold PBS. Cell pellets were lysed using modified
RIPA lysis buffer (50mM Tris-HCl, pH 7.5, 150mM NaCl, 1% NP40, 1% sodium deoxycholate,
2mM EDTA, 10% glycerol, Protease inhibitor cocktail (Sigma, 1:500), 50µM PR-619 (Pan DUB
inhibitor, LifeSensors). Protein estimation was carried out using the Bradford method (Bio-Rad).
Twenty five µg of cell lysates were separated on 10% SDS-PAGE gel, transferred to PVDF
membrane and probed with primary antibodies against DNMT1 (Cell Signaling) HDM2 (Santa
Cruz), UHRF1 (Santa Cruz) and Actin (Sigma). Blots were developed using Millipore ECL or
Pierce ECL depending on the sensitivity requirements and images were captured and quantified
using the LI-COR Odyssey Fc imaging system. For repeated analysis of Western blots,
membranes were stripped using Restore Western Blot Stripping buffer (ThermoFisher).
Immunoprecipitation. Immunoprecipitation and measurement of USP7 activity were
performed as reported previously (94) with slight modifications. Jurkat cells treated with DMSO
or USP7 inhibitors were washed with ice cold PBS and lysed using NP40 lysis buffer (50mM
Tris-HCl, pH 7.5, 150mM NaCl, 1%(v/v) NP40, 10%(v/v) glycerol, 1mM PMSF) and precleared using 30µl of protein G-sepharose (Invitrogen) for 1 hour at 4oC. 500µg of pre-cleared
cell lysates were incubated with Protein G sepharose beads pre-loaded with 0.5µg of anti-USP7
antibody (Progenra) for 1 hour. Beads were washed twice with lysis buffer containing 2mM βmercaptoethanol and USP7 activity was determined using Ub-CHOP2 reporter assays
(LifeSensors). DMSO treated cell lysates were incubated with beads alone as a control. 5µl of
beads from the immunoprecipitation was analyzed by Western blotting with anti-USP7 antibody
to determine relative levels of USP7.
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3.4. Results
3.4.1. NMR studies of the 41kDa catalytic core of USP7 in solution
Structural information about a protein target and its interaction with lead compounds is the
key for successful rational drug design and optimization. Although several crystal structures are
available for the catalytic core of USP7 and USP7-ubiquitin complexes (PDB IDs: 1NB8, 1NBF,
4M5W) (72,75), structures of the enzyme with any known inhibitors have not been obtained. The
relatively large size of the catalytic domain (41kDa) has also hindered its investigation in
solution. We have overcome this hurdle by using full protein deuteration in combination with
TROSY-based NMR experiments designed for large biological systems (101). A 2D 1H-15N
TROSY-HSQC spectrum displayed good signal dispersion indicative of well-structured domains
(Figure 3.1). The quality of the NMR data facilitated backbone resonance assignment, a
prerequisite for mapping of inhibitor binding sites.
Sequential assignment using a standard triple-resonance NMR spectroscopy approach was
achieved for a total of 83% of the backbone atoms (NH, CO, Cα and Cβ), with 81 % of amides
assigned (Figure 3.2A). The absence of several peaks and the presence of weak peaks prevented
a higher percentage of resonance assignments. In particular, 61 of the 343 non-proline residues
resonances could not be identified in the 1H-15N TROSY-HSQC spectrum. Approximately onehalf of the missing signals correspond to residues located in β-strands β8, β10 and β11 that are a
part of an anti-parallel β-sheet buried in the interior of the protein. The absence of these signals is
likely explained by the difficulty of deuterium – proton exchange in the hydrophobic core of the
protein. Another cluster of missing resonances belongs to residues Lys217 – Ser227 from the
non-structured and likely flexible N-terminus. Overall, the stability and behavior of the USP7
catalytic domain in solution indicate that this domain is well suited for NMR spectroscopy.
80

Furthermore, the nearly complete backbone assignment provides confidence that NMR
spectroscopy is a powerful tool for probing USP7 – substrate/ligand interactions.

3.4.2. Interaction of the USP7 catalytic core with ubiquitin
USP7 is postulated to recognize the ubiquitin moiety conjugated to its substrates via a direct
interaction between the catalytic domain of the enzyme and ubiquitin. According to previous
structural studies, this interaction causes a dramatic structural rearrangement of the USP7 active
site, resulting in activation of the enzyme (72). However, despite the report of a structure for the
USP7 catalytic core covalently modified with ubiquitin aldehyde, an interaction with free
ubiquitin could not be confirmed using SPR experiments, suggesting that the interaction is very
weak (71). Compared to other biophysical approaches, NMR spectroscopy has the advantage of
being sensitive to weak and transient interactions (168). Consequently, we used this method to
detect USP7/ubiquitin binding in solution and follow the anticipated structural changes. Our
chemical shift perturbation experiments showed that the direct interaction between USP7
catalytic domain and ubiquitin occurs on a fast-to-intermediate exchange timescale, resulting in
gradual changes in the NMR spectra of the 2H/15N/13C-labeled catalytic core upon titration with
unlabeled ubiquitin (Figure 3.2B). These gradual chemical shift changes in the 1H-15N TROSYHSQC spectrum simplified the assignment of resonances of the catalytic domain complexed with
ubiquitin and allowed quantification of binding affinity and mapping of the binding site. Overall,
addition of ubiquitin caused prominent peak perturbations for a number of USP7 residues with
peaks for Tyr331, Lys378, Arg343, Asp346, Glu371, Gln372, Ala381, Gln387 and Val 393
exhibiting shifts over 100 Hz (Figure 3.2C). The NMR titration curve fit a two-state binding
model (Figure 3.2E), confirming that the USP7 catalytic domain can bind to ubiquitin with low
affinity (KD of 105.7 ± 15.9 μM). NMR chemical shift mapping revealed that the residues most
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sensitive to ubiquitin binding are located in β-strands β1, β2, β4, β5, β6 and β7 that form the
ubiquitin-binding Fingers of the USP7 catalytic domain (Figure 3.2D), consistent with the crystal
structure of the domain complexed with ubiquitin aldehyde (PDB ID: 1NBF) (72). Surprisingly,
the active site of the enzyme was not perturbed by ubiquitin, suggesting that ubiquitin binding
alone does not cause the active site rearrangement necessary for catalysis (Figure 3.2C).

3.4.3. Mapping of the small-molecule binding site
The USP7/USP47 inhibitors P22077 and P50429 are analogs of P5091, a lead compound that
showed antitumor potential in cancer cell lines and mice xenograft models (93,94). Both
inhibitors are trisubstituted thiophenes with 5-(2,4-difluorophenyl)thio, 4-nitro, and 2-acetyl
substituents

in

P22077

and

5-(3,5-dichloropyridyl)thio,

4-cyano

and

2-(4-

(methylsulfonyl)phenyl)-NH substituents in P50429 (insets in Figures 3.3A and B, respectively).
P50429 exhibits ten-fold more potent inhibition of USP7 compared to P22077 (IC50 = 0.42 μM
versus 8.0 μM) (93). In order to understand the reason for the increased potency of P50429 and
to develop compounds with even greater potency and target specificity, one must know how
these compounds bind to USP7. We, therefore, set out to structurally characterize the binding of
P22077 and P50429 to the enzyme’s catalytic core by performing NMR titrations in which
increasing amounts of each compound were gradually added to the 2H/15N/12C-labeled catalytic
domain up to a final protein-to-inhibitor molar ratio of 1:5. Upon addition of P22077, residues
Gly215, Leu229, Glu248, Gly284, Thr287, Leu304, Asp305, Asp349 and Gly458 exhibited the
most significant chemical shift changes (Figure 3.3A). Compound P50429 caused large chemical
shift changes for residues Thr280, Leu304, Met407, Phe409, Met410, Gly458, Gly462 and
Asp483 (Figure 3.3B). Notably, the intensity of a few peaks significantly decreased (>60%) upon
addition of either of the compounds indicating that the corresponding amino acid residues are
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also sensitive to inhibitor binding. These residues included Lys281, Ser282, Phe283, Trp285,
Asn306, Asn460, Gly462, Gly463 and Tyr465 sensitive to P22077 and Lys281, Ser282, Phe283,
Gly284, Trp285, Asn306, Asn460, His464 and Tyr465 sensitive to P50429. Although these
residues could not be unambiguously assigned in the bound state, they are shown on histograms
in Figure 3.3 as having negative chemical shift values of -10 Hz to emphasize their role in
binding. Overall, addition of either compound caused chemical shift perturbations and decreases
in intensity only for a few peaks in the spectra (18 and 17 peaks for P22077 and P50429
respectively) indicating a small binding footprint on the surface of USP7 and suggesting that no
major global conformational changes occur upon binding. Moreover, a very similar set of
residues was affected by addition of both compounds with the exception of residues Met407,
Phe409 and Met410 that lie within a loop connecting β8- and β9-strands and are sensitive to
P50429 only.
Chemical shift perturbations of more than 40 Hz for P22077 and more than 30 Hz for P50429
were considered significant and were mapped onto the structure of USP7 catalytic domain (PDB
ID: 1NBF). Chemical shift mapping revealed that residues sensitive to addition of either of the
two DUB inhibitors cluster in two small regions on the surface of the protein (Figures 3.3C and
D). The first set of residues affected by binding surrounds the catalytic cleft (Figure 3.3E). These
include Gly458, Asn460, Gly462, Gly463 and Tyr465 located in β10- and β11-strands as well as
the loop connecting them, and Asp349 from the loop between strands β2 and β3. Additionally,
this region contains two residues from the flexible N-terminus, Gly215 and Leu216, as well as
Leu229 from the first helix α1, indicating that the mostly unassigned N-terminus is also sensitive
to inhibitor binding (Figure 3.3E). Importantly, the catalytic cleft is mostly formed by
hydrophobic residues with the catalytic Cys223 situated at its bottom. Consistent with this

83

finding, both compounds are hydrophobic in nature. Furthermore, the pocket is large enough
(~1075 Å3) to easily accommodate either of these small molecules. The second region consists of
residues 281 – 285 and Thr287 located in the loop connecting helices α4- and α5 (referred to as a
“switching loop”) and residues 304 – 306 located in helix α5, which is involved in active site
rearrangement into the catalytically productive conformation (72). Although this region is
sensitive to the presence of the inhibitors, only the catalytic cleft is involved in a direct
interaction, as was confirmed by MS (see below).
To elucidate the position of the inhibitors in the active site of USP7, we utilized an induced
fit docking approach (ICM-Pro) that allows flexibility of side-chains of residues located in the
binding site. The resulting structural models of the complexes of the catalytic core with P22077
and P50429 are shown in Figures 3.3F and G, respectively. Overall, the compounds are similarly
positioned in both models. The 2,4-difluorobiphenyl group in P22077 (3,5-dichloropyridyl group
in P50429) inserts deeply into a cavity formed by residues Asn218, Gly220, Ala221, Thr222,
Cys223, Asn226, His464, Tyr465 and Asp482. Thiophene is perpendicular to the aromatic rings
and turned such that the sulfur is located in the bottom of the pocket and the electronwithdrawing groups, -nitro in P22077 and -cyano in P50429, are exposed to solvent. The second
aromatic, methylsulfonyl phenyl group in P50429 further penetrates the catalytic cleft and
interacts with residues from the loop connecting strands β8 and β9. This is consistent with the
data obtained from the NMR titration experiments in which chemical shift perturbations for
residues Met407, Phe409 and Met410 located in the loop connecting β8- and β9-strands were
observed only upon binding to P50429. These additional contacts might contribute to tighter
binding of P50429 compared to P22077, suggesting new strategies for improvement of potency.
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3.4.4. Mechanism of USP7 inhibition by DUB inhibitors P22077 and P50429
The presence of a doubly deactivated, highly electron-deficient thiophene ring in both of the
USP7 inhibitors used in this study suggested that the molecules might react directly with
nucleophilic residues, such as cysteine, thus leading to covalently modified adducts. The USP7
catalytic domain has seven cysteine residues that could potentially be modified. Addition of an
excess of DTT to the catalytic core incubated with either P22077 or P50429 compounds did not
cause any changes in the NMR spectra (data not shown) excluding the possibility of disulfide
bond formation between a cysteine thiol group in the protein and the thioether linker in the
small-molecule inhibitors. To investigate whether these compounds bind USP7 reversibly or
covalently modify the protein we performed intact protein MS analysis of the free and inhibitortreated catalytic domain (Figure 3.4A). The deconvoluted spectrum of the free catalytic domain
showed a major peak with an average mass of 41062.25 Da (calculated mass is 41088.4 Da). The
intact masses of both complexes with the inhibitors were greater relative to the free protein.
These results indicate that both compounds covalently modify USP7, since the measurements
were taken in 50% methanol, where the protein would be expected to be largely denatured.
Moreover, mass shifts of 169 Da and 146 Da for P22077 and P50429, respectively, were smaller
than the corresponding molecular weights of the compounds (315.322 Da for P22077, 484.411
Da for P50429), suggesting that significant parts of the small molecules are lost during final
modification of the enzyme.
To investigate whether these compounds covalently modify the catalytic and/or other
cysteine residues within USP7 we performed LC-MS/MS experiments on tryptically digested
samples. The fragment ions in the MS/MS scans were compared to theoretical fragments via a
database search to identify peptides. A variable modification of cysteine was configured for each
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inhibitor based on the added net mass determined by the intact mass study. Over 90% of the
protein sequence coverage was achieved for the free and inhibitor-treated protein samples,
including all seven cysteine residues. Virtually all identified tryptic peptides 218NQGATCYMNSLLQTLFFTNQLR-239 from samples treated with either P22077 or P50429
exhibited a mass shift of 169 Da and 146 Da, respectively, compared to the same peptide from
the unmodified protein. Importantly, the residue harboring the modification was almost
exclusively assigned to catalytic Cys223 (Figures 3.4B and C). The data for P50429 was
remarkably clear cut, with every peptide encompassing Cys223 identified as containing the
inhibitor-based modification, while peptides containing other cysteine residues were rarely
identified as modified. The putative 169 Da adduct for P22077 was more promiscuous, with
Cys223 modified in all but one instance and other cysteines occasionally modified as well.
Altogether, the MS results in combination with NMR-based mapping of the binding site
strongly suggest that both of the compounds occupy the active site of USP7 catalytic domain and
further selectively covalently modify the catalytic Cys223 residue, irreversibly blocking its
enzymatic activity. Figure 3.5 shows the proposed mechanisms of USP7 active site modification.
The observed mass shift of 169 Da for P22077-modified protein is consistent with an average
molecular weight of 1-(4-nitro-thiophen-2-yl)-ethanone group (3 in Figure 3.5). The mass shift
of 146 Da in the case of P50429 corresponds to an average molecular weight of 3,5dichloropyridyl group of the molecule (7 in Figure 3.5). Element composition of the proposed
modifications was supported by analysis of MS/MS isotope patterns. Therefore, despite the
overall scaffold structural similarity of the compounds (93), each compound modified the USP7
catalytic core in a specific manner. P22077 (1) transfers the central thiophene onto the catalytic
cysteine though a postulated mechanism involving initial nucleophilic attack on the thiophene to
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give an intermediate thio-orthoester (2) which collapses though expulsion of difluorothiophenol
(4) to form the re-aromatized adduct (3). Although P50429 (5) is also poised for a similar
substitution reaction, the reaction follows a different course as a result of the substitution of the
phenyl ring in (1) for the pyridyl ring in (5), which renders the ring prone to nucleophilic attack.
A similar addition/elimination process occurs through the intermediacy of (6) to transfer the
pyridyl ring to the enzyme as in (7), with the thiophenyl moiety (8) serving as the leaving group.

3.4.5. Inhibition of endogenous full-length USP7 by DUB inhibitors P2077 and P50429 in
Jurkat cells
To determine if irreversible inhibition is also achieved against full-length USP7 in the
context of live cells, we pre-treated Jurkat cells with either DMSO or graded concentrations of
the compounds for 4 hours and monitored the activity of immunoprecipitated USP7 using UbEKL reporter assay. As seen in Figure 3.6A, the inhibitors showed dose dependent inhibition of
USP7 catalytic activity, with strong inhibition at a dose of 10 μM. Notably, total DUB activity
measured in cell lysates was not significantly affected by these treatments (Figure 3.6B),
indicating their cellular selectivity, in agreement with previously published results (93,169).
The cellular effect of USP7 inhibition can be assessed by monitoring levels of its known
protein targets. We used Western blotting of Jurkat cells to evaluate the effect of P22077 and
P50429 on the stability of DNA methyltransferase DNMT1 and E3 ligase UHRF1 (39), both
essential for maintenance of genomic DNA methylation, as well as HDM2. Compared to cells
treated with DMSO, treatment with either compound resulted in dose-dependent decreases for all
three substrates (Figure 3.6C). Thus, these compounds not only inhibit the isolated catalytic
domain in vitro but also effectively inhibit full-length USP7 in cells, as evidenced by the
destabilization of USP7 substrates.
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3.5. Discussion
Dysregulation of the ubiquitin-proteasome system has been reported in multiple human
pathologies. Thus, targeting the UPS is considered a promising therapeutic strategy to treat
cancer, cardiovascular, neurodegenerative and immunological disorders. Two FDA approved
proteasome inhibitors, Bortezamib and Carfilzomib, are currently used for treatment of multiple
myeloma (170,171). More recently, other components of the UPS, such as E2 conjugating
enzymes, E3 ligases and DUBs have been exploited as potential targets for drug discovery.
Inhibition of USP7 is of special interest because of its role in turnover of multiple proteins
involved in DNA replication and repair, epigenetic regulation of gene transcription, immune
responses and cell cycle control. Here we report the first structural characterization of the
molecular mechanism of USP7 inhibition by small-molecule compounds.
Ubiquitin binding alone is not sufficient for rearrangement of the catalytic core of USP7. By
assigning NMR resonances of the catalytic domain of USP7, we developed a powerful tool for
studying this challenging dynamic system in solution. We have shown that even transient and
short lived interactions of USP7 can now be detected, along with evidence of conformational
dynamics. Specifically, our NMR studies of the binding between the isolated catalytic domain
and its only known substrate, ubiquitin, revealed that, contrary to previous reports, this
interaction alone is not sufficient for active site rearrangement. According to the crystal
structures, binding of ubiquitin to Fingers causes conformational changes in the catalytic domain
that result in realigning of the catalytic triad into a competent conformation (72). In contrast, our
results show that residues involved in such rearrangement are not sensitive to ubiquitin binding
in solution. Specifically, no significant chemical shift changes were detected for residues located
in helix α5, which moves by ~3Å during active site reorganization, as well as for the loops
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connecting helices α4- and α5, and strands β10 and β11. Furthermore, upon ubiquitin binding the
chemical shifts of residues surrounding the catalytic cleft are not perturbed. This indicates that
the C-terminal tail of ubiquitin alone does not enter the catalytic cavity of the enzyme in
solution. The active conformation of the catalytic domain in complex with ubiquitin aldehyde
captured in the crystal structure (72) is likely induced by the covalent attachment of ubiquitin to
the catalytic cysteine of USP7, which irreversibly traps the C-terminal tail of ubiquitin inside the
catalytic cleft. There might be several reasons why free ubiquitin does not rearrange the active
site of the isolated catalytic domain. Perhaps, presence of other USP7 domains or a ubiquitinated
substrate, or both are required. Indeed, there is mounting evidence that the C-terminal UBL
domains of USP7 may play an important role in activation of the enzyme (71,83,84).
Furthermore, binding of a ubiquitinated substrate rather than isolated ubiquitin might be needed
for efficient activation of the enzyme. In the absence of a protein substrate, ubiquitin binds to the
Fingers of the catalytic core of USP7 but does not insert its flexible tail into the catalytic cleft
and, therefore, does not cause the rearrangement of the active site required for catalytic activity.
The presence of a substrate may ensure proper positioning of the isopeptide bond between
ubiquitin and the substrate inside the catalytic cleft. The importance of the ubiquitinated
substrate for the enzyme’s activation suggests that targeting the USP7 substrate binding sites
may provide an effective and highly specific approach to inhibiting USP7 in the future.
USP7 inhibitors selectively target and modify its active site. To investigate the molecular
mechanism of USP7 inhibition we used NMR spectroscopy to map a binding site for two
USP7/USP47-specific DUB inhibitors P22077 and P50429 on the structure of its catalytic
domain. The results of chemical shift perturbation experiments showed that both compounds
share the binding site located in the USP7 catalytic cleft. Surprisingly, residues from helix α5
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and the “switching loop” were also affected by addition of the inhibitors. As mentioned above,
these residues are involved in the active site realignment observed in the crystal structure of the
USP7 catalytic core in complex with ubiquitin aldehyde. Remarkably, NMR frequency changes
in this region of the protein were unique for the complexes with the inhibitors and were not
detected in titrations with ubiquitin. The fact that the inhibitors bind to the cavity that
accommodates the C-terminus of ubiquitin in the crystal structure together with the observed
chemical shift changes in helix α5 and the “switching loop” suggest that binding of the
compounds to USP7 causes a conformational rearrangement of the active site similar to that
caused by ubiquitin aldehyde (72). These findings additionally highlight the significance of the
interaction between the ubiquitin flexible tail and the active site for realignment of the latter. The
inhibitors appear to mimic this interaction, causing conformational changes in the active site.
The chemical structure of DUB inhibitors P22077 and P50429 suggest that these compounds
can covalently modify cysteine residues. Our LC-MS/MS and intact mass determination
experiments have confirmed this suggestion. The catalytic domain of USP7 contains seven
cysteines, four of them surface exposed and, therefore, have a chance of being modified by
reactive small-molecule compounds. Strikingly, we have shown that both compounds
specifically modify only the catalytic Cys223. This result is consistent with NMR experiments
showing that the compounds cause chemical shift perturbations for residues in the catalytic
cavity. The molecular scaffold of the compounds allows the specific binding and presence of
doubly deactivated thiophene, leading to modification of Cys223 situated at the bottom of the
catalytic cleft. The reaction is possible due to the realignment of the active site upon inhibitor
binding, which results in deprotonation of the cysteine thiol group by catalytic His464. Structural
models of the complexes obtained with an induced fit docking algorithm provide strong
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complimentary evidence of the inhibitors position in the catalytic cleft favorable for nucleophilic
attack of deprotonated Cys223 on the thiophene ring. Notably, although both compounds are
chemically similar and possess the basic structure of a trisubstituted thiophene, MS experiments
revealed that specific substructures of each inhibitor had been transferred to the protein and
indicated an intriguing divergence in the reactivity profile of the two inhibitors (Figure 3.5). The
preference for attack on the pyridine in P50429 may relate to either reduced electrophilicity of its
thiophene relative to the thiophene in P22077 (nitro/acetyl versus cyano/carboxamido) or a more
optimal trajectory for attack in the bound state. Figures 3.7A and B depict Cys223 modified by
compounds P22077 and P50429 and surrounding residues. In general, the docked poses of
thiophene and pyridyl rings are similar. The rings have hydrophobic interactions with
surrounding residues Tyr224, Met292 and Phe409 and an electrostatic interaction with His456.
The only hydrogen bond is between the oxygen atom within the acetyl group and the alphahydrogen atom of Gly462 (Figure 3.7A). Notably, as both reactions proceed through a
nucleophilic aromatic substitution reaction to deliver an S-arylated cysteine, the adducts are
likely much more stable than those formed from more reversible Michael-type reactions on
deactivated alkenes and, therefore, are expected to produce a longer duration of inhibition.
DUB inhibitors P22077 and P50429 selectively inhibit full-length USP7 in cells. MS data
revealed that P22077 and P50429 form covalent adducts to the active site cysteine in in vitro
reactions using the isolated catalytic domain of USP7. Full-length USP7 is a large (1102 amino
acid residues) protein consisting of seven domains proposed to adopt a compact conformation
during the enzyme activation (71) that may possibly interfere with the inhibitor binding. Our
experiments in Jurkat cells showed that both compounds inhibit the catalytic activity of
endogenous full-length USP7. Furthermore, P50429 proved to have more potency against USP7,
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in agreement with previous studies (93). In particular, at 10 μM, P50429 inhibited USP7 by
~70% compared to ~55% for P22077.
Stabilization of p53, along with growth arrest of tumor cells, are well-known effects of USP7
inhibition (91,92,94). However, it was suggested that p53-independent pathways might also be
involved in the cytotoxic effects of the USP7 inhibitors (94). UHRF1 and DNMT1, recently
discovered substrates of USP7, are critical for maintenance of genomic DNA methylation during
replication (39). Therefore, we explored the effect of P22077 and P50429 on the stability of
UHRF1, DNMT1, and HDM2 in Jurkat cells. The dose dependent decreases in the levels of all
three substrates suggests that, their stability is compromised by deubiquitination. While
degradation of HDM2 leads to stabilization of p53, the degradation of UHRF1 and DNMT1
might cause methylation defects in newly synthetized DNA. These downstream effects may
contribute to the overall cytotoxic activity of these compounds.
Unique catalytic site environment may explain USP7/USP47 inhibitor selectivity. USP7 belongs
to a superfamily of USP cysteine proteases consisting of 58 proteins with structurally conserved
catalytic cores, which makes development of USP7-specific inhibitors challenging. Indeed, the
two compounds tested in this work are the most specific among the currently available USP7
inhibitors; however, they both can inhibit USP7 and its close homolog USP47 (172). The fact
that inhibitors P22077 and P50429 bind to the conserved catalytic cleft of USP7 is intriguing and
raises the question of how this specificity is achieved. In an effort to address this question, we
performed protein sequence alignment using PROMAL (173), followed by calculation of
conservation score (ConSurf) (161) for a set of USP enzymes that are selectively inhibited by
P22077 (USP7 and USP47), as well as enzymes USP2, USP4, USP5, USP8, USP9X, USP15,
USP20 and USP28, not susceptible to inhibition by P22077 (169). As expected, the majority of
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the residues in the catalytic cavity are highly conserved with calculated ConSurf scores of 8 and
9 out of 9 (Figure 3.7C). Interestingly, the alignment also revealed a few residues that are
conserved between USP7 and USP47 but varied in other USPs. Specifically, Gln219 of USP7 is
present only in USP47, while other proteins contain a hydrophobic amino acid residue at the
equivalent position. Acidic amino acid residues equivalent to Asp289 in USP7 are also found in
USP47 (Glu246) but replaced by residues with a neutral sidechain in USP2, USP4, USP5, USP8,
USP9X, USP15 and USP28, and by basic arginine in USP20. Additionally, the positively
charged His294 in USP7 has a ConSurf score of 8 and is conserved in USP47 and USP9X, in
contrast to glutamine at the equivalent position in all other analyzed USPs. The hydrophobic side
chain of USP7 Ala221 that is near the catalytic Cys223 is preserved in USP47 (Met175) and
USP9X (Ala1564) but changed to polar asparagine in others. Finally, Gln405 in USP7 is
conserved among USP47, USP9X and USP5. Other proteins have histidine at the equivalent
positions, with the exception of USP28, which has aspartate. Overall, although some of these
residues are not unique for USP7 and USP47, only these two enzymes contain all five. This
distinct residue combination creates a network of hydrophobic and electrostatic interactions
unique to the active sites of USP7 and USP47, which may provide the basis for the observed
specificity of inhibitors.
It is also possible that USP7-specific inhibitors preferentially target its unique, misaligned
active site for initial binding. Indeed, catalytic triads in all existing structures of the USP catalytic
domains, with the exception of USP7, are found in the catalytically competent conformation
even in the absence of ubiquitin (76-79). In this light, the structure of the catalytic core of USP47
also inhibited by P22077 and P50429 is a subject of great interest.
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Altogether, our results reveal the molecular mechanisms of USP7 inhibition by DUB
inhibitors P22077 and P50429. We showed that inhibitors specifically bind to the catalytic cleft
of the enzyme and subsequently modify the catalytic cysteine residue. The modification of the
cysteine thiol group irreversibly inhibits the enzymatic activity of USP7 by preventing formation
of anionic sulfur and its following nucleophilic attack on the C-terminal carbonyl carbon of
ubiquitin.
Previously, only X-ray crystallography was used to structurally characterize the catalytic
domains of USP proteins. We have shown that these large enzymes can be successfully studied
in solution. Such studies may provide a unique insight into dynamic conformational changes and
transient interactions within the molecule. More importantly, these studies will facilitate
compound optimization and the discovery of more potent and specific inhibitors of USP7 and
other pharmacologically important USPs.
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Figure 3.1. Backbone resonance assignment of USP7 catalytic domain. 2D 1H-15N TROSYHSQC spectrum of the USP7 catalytic domain with sequence specific assignments indicated. A
central region of the spectrum indicated by a box is expanded in the inset for clarity.
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Figure 3.2. The isolated USP7 catalytic domain binds ubiquitin. A. Completeness of the
backbone assignment of the catalytic domain. Circles below the protein sequence represent
amino acid residues with assigned amide NMR resonances. Secondary structure elements are
shown and labeled above the protein sequence. B. NMR chemical shift perturbations, in1H15
N TROSY-HSQC spectra of the catalytic domain caused by addition of increasing amounts of
ubiquitin. C. A plot of per-residue NMR chemical shift differences between free and ubiquitinbound states of USP7. The Palm, Fingers and Thumb regions of the catalytic domain are
indicated above the plot. D. Solvent accessible surface of the Fingers region of the catalytic
domain colored according to NMR chemical shift perturbations from C. The shade of violet
represents the degree of chemical shift changes in response to ubiquitin binding. Ubiquitin is
shown in cyan. E. Normalized global chemical shift change corresponding to the fraction of
bound catalytic domain plotted as a function of catalytic domain to ubiquitin ratio. KD of the
binding was estimated from least-square fit of cumulative chemical shift change.
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Figure 3.3. DUB inhibitors P22077 and P502429 occupy the active site of USP7. A and B.
Per-residue NMR chemical shift perturbations,, caused by addition of inhibitors P22077 (A)
and P50429 (B) to the USP7 catalytic core. Amino acid residues exhibiting chemical shift
changes greater than 40 Hz for P22077 and 30 Hz for P50429 are labeled. Residues unassigned
in the bound state, for which NMR peaks gradually disappear upon binding to P22077 and
P50429, are shown with a negative value of -10 Hz and colored in red and blue,
respectively. Chemical structures of the compounds are shown as insets. C. Mapping of chemical
shift differences from A on the surface of the catalytic domain. The color gradient from grey to
magenta corresponds to  values observed upon P22077 addition. The residues with negative
values are shown in red D. Mapping of  from B on the surface of the catalytic domain.
Chemical shift differences are colored with a gradient from gray to cyan according to the 
value. The residues with negative are shown in blue. E. Close-up view of the USP7 region
affected by P22077 addition. Residues sensitive to binding are labeled and their side-chains are
shown as spheres. The color code is the same as in C, ubiquitin is shown in beige. F and G. The
structural models of the USP7 catalytic core in complex with P22077 (F) and P50429 (G). The
binding pocket is shown as a surface and colored by electrostatic charge distribution (red is
negative, blue is positive and green is hydrophobic). The compounds are colored by element: C –
gray, S – yellow, N – blue, O – red, F – orange, Cl – green.
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Figure 3.4. Inhibitors P22077 and P50429 covalently modify catalytic Cys223 residue in the
USP7 active site. A. Centroid mode deconvoluted mass spectra of intact free (top), P22077bound (middle) and P50429-bound (bottom) catalytic domain. Average intact masses of the
significant peaks are shown. The mass difference between unmodified and the inhibitor –
modified protein is labeled. B. MS/MS spectrum of peptide corresponding to residues 218 – 239
modified by P22077 (m/z = 1366.6, [M+2H]2+). C. MS/MS spectrum of the same peptide
modified by P50429, (m/z = 903.4, [M+3H]3+). The b-ions denote N-terminal fragment ions and
y-ions represent C-terminal fragment ions. Ions matched to the peptide sequence are shown in
red.
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Figure 3.5. Proposed mechanisms of chemical reaction between Cys223 of USP7 and
inhibitors P22077 (1-4) and P50429 (5-8). See text for details.
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Figure 3.6. P22077 and P50429 inhibit USP7 activity in cells. A. Jurkat cells were pretreated
with either DMSO or the compounds at indicated concentrations for 2 hours and cell lysates
were subjected to USP7 immunoprecipitation followed by western blotting (top panel) and USP7
activity measurement using the Ub-CHOP2 reporter assay (bottom panel). B. Total DUB activity
in cell lysates from A measured in a similar manner. C. Endogenous levels of USP7 substrates
DNMT1, UHRF1, HDM2 monitored in Jurkat cells pretreated with either DMSO or the
compounds at indicated concentrations for 24 hours. Western blotting with antibodies against
Actin serves as a loading control.
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Figure 3.7. Specificity determinants of dual USP7/USP47 inhibitors. A and B. Structural
models of the USP7 active site with Cys223 covalently modified by P22077 (A) and P50429 (B)
obtained by covalent docking (ICM-Pro). The surrounding residues are labeled and their sidechains are shown in green. The small molecules are colored by element as in Figures 2F and G.
C. Surface representation of the USP7 catalytic domain with residues conserved among USPs
shown in maroon and residues unique for USP7 and USP47 shown in blue. Conservation scores
were calculated using ConSurf server (161) and only highly conserved residues (with scores 9
and 8) are shown. The USP proteins used for the score calculation included USP2, USP4, USP5,
USP7, USP8, USP9X, USP15, USP20, USP28, and USP47.
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4.1. Abstract
Rev1 is a translesion synthesis (TLS) DNA polymerase essential for DNA damage tolerance
in eukaryotes. In the process of TLS, stalled high-fidelity replicative DNA polymerases are
temporarily replaced by specialized TLS enzymes that can bypass sites of DNA damage
(lesions), thus allowing replication to continue or postreplicational gaps to be filled. Despite its
limited catalytic activity, human Rev1 plays a key role in TLS by serving as a scaffold that
provides access of Y-family TLS polymerases pol, , and  to their cognate DNA lesions and
facilitates their subsequent exchange to pol that extends the distorted DNA primer-template.
Rev1 interaction with the other major human TLS polymerases, pol, ,  and the regulatory
subunit Rev7 of pol, is mediated by the Rev1 C-terminal domain (Rev1-CT). We used NMR
spectroscopy to determine the spatial structure of the Rev1-CT domain (residues 1157-1251) and
its complex with Rev1 interacting region (RIR) from pol (residues 524-539). The domain forms
a four-helix bundle with a well-structured N-terminal -hairpin docking against helices 1 and 2,
creating a binding pocket for the two conserved Phe residues of the RIR motif that upon binding
folds into an -helix. NMR spin-relaxation and NMR relaxation dispersion measurements
suggest that free Rev1-CT and Rev1-CT/pol-RIR complex exhibit s-ms conformational
dynamics encompassing the RIR binding site, which might facilitate selection of the molecular
configuration optimal for binding. These results offer new insights into the control of TLS in
human cells by providing a structural basis for understanding the recognition of the Rev1-CT by
Y-family DNA polymerases.
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4.2. Introduction
Reactive products of cellular metabolism and external genotoxic agents such as ultraviolet
(UV) irradiation cause persistent damage to the genomic DNA, which is constantly removed
through various DNA repair mechanisms (174). Unavoidably, however, some DNA
modifications (lesions) are present during S-phase, creating blocks for progression of the DNA
replication machinery since spatially constrained active sites of high-fidelity replicative DNA
polymerases cannot accommodate most types of DNA damage. To circumvent this problem,
organisms in all kingdoms of life have evolved DNA damage tolerance pathways employing
specialized translesion synthesis (TLS) DNA polymerases that can insert nucleotides across
DNA lesions, thereby allowing replication to proceed while temporarily leaving DNA damage
unrepaired (35,175-179). Growing evidence suggests that an additional important component of
TLS DNA polymerase action is to fill postreplicational gaps opposite lesions at the end of the
cell cycle so that double strand breaks are not generated during the next round of DNA
replication (180-184).
The most intensively studied TLS polymerases are the Y-family enzymes Rev1, pol, pol,
pol and the B-family polymerase pol (a complex of the catalytic Rev3 subunit with Rev7)
(35,175-179). TLS polymerases lack 3'5' proofreading exonuclease activity, possess more
accommodating active sites than replicative DNA polymerases, and make a relatively limited
number of contacts with the template base and incoming nucleotide (185). These features allow
them to insert nucleotides across from a wide variety of DNA lesions that would stall a
replicative DNA polymerase. However, the ability to replicate through altered bases comes at an
expense of fidelity. The nucleotide misincorporation rates of TLS polymerases copying
undamaged DNA are ca.10-1-10-4, much higher than the misincorporation rates of 10-6-10-8
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observed for pol and pol, the main replicative DNA polymerases (175,176,186). Consequently,
the access of these error-prone TLS enzymes to primer termini is carefully regulated.
Certain TLS polymerases are specialized for the efficient and relatively accurate insertion of
nucleotides opposite particular lesions (35,178,179), termed cognate lesions. Examples of
cognate lesions include thymine-thymine cyclobutane pyrimidine dimers (T-T CPDs) for
pol(187,188) and N2-dG adducts, such as N2-benzo[a]pyrene-dG (BaP-dG) adducts, for
pol(189,190) Although these TLS polymerases can also replicate over certain non cognate
lesions as well, they do so in a more error-prone manner. Furthermore, the bypass of many DNA
lesions, including bulky BaP-dG adducts, cisplatin (cisPt) adducts, and [6-4] photoproducts ([64]PP), is accomplished via the coordinated consecutive action of two different TLS DNA
polymerases (191-193). An inserter TLS polymerase (e.g. pol,  or ) incorporates a nucleotide
across the site of DNA damage. This inserter polymerase is then replaced by another TLS
enzyme that extends from the distorted primer terminus positioned across from the lesion. This
extender role is frequently carried out by pol, which is recruited to the primer terminus in a
process mediated by Rev1 (176,194,195). Rev1/pol-dependent TLS is responsible for most of
the DNA damage-induced mutagenesis in eukaryotic cells and contributes to spontaneous
mutagenesis as well (194,195). On the other hand, certain DNA lesions such as cyclobutane
pyrimidine dimers (CPDs) or abasic sites can be effectively bypassed by a single TLS enzyme.
For example, pol alone can efficiently replicate through T-T CPD, one of the common types of
UV induced lesions, in an essentially error-free manner (187,188). Xeroderma pigmentosum
variant (XPV) individuals, who lack pol function are highly UV-sensitive and cancer-prone
(188). They exhibit increased UV-induced mutagenesis due to more error-prone polymerases
carrying out TLS in the absence of the more accurate pol (196).
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Protein-protein interactions play critical roles in controlling the access of TLS polymerases to
their cognate DNA lesions and facilitating polymerase switching during bypass replication
(35,177-179). Beyond their catalytic cores, Y-family TLS enzymes possess auxiliary domains
and motifs that are important for their efficient interactions with one another and with the DNA
(35,178,179). TLS polymerases possess ubiquitin-binding motif (UBM) or ubiquitin-binding
zinc finger (UBZ) domains in addition to the proliferating cell nuclear antigen (PCNA)
interacting motifs (197). These ubiquitin-binding domains play a role in the recruitment of TLS
DNA polymerases to PCNA processivity clamps that have been mono-ubiquitinated at Lys164 in
a Rad6/Rad18-dependent fashion in response to DNA damage (198). The PCNA-interacting
protein (PIP) box motifs of pol, , and  additionally contribute to the interaction with monoubiquitinated PCNA, while Rev1, which lacks a consensus PIP-box motif, instead utilizes its Nterminal BRCT (BRCA1 C-terminus), its polymerase associated (PAD) or UBM domains for
PCNA binding (199-201). In addition, as discussed in the detail in this paper, the C-terminal
parts of vertebrate pol, ,  contain Rev1-interacting regions (RIRs), consisting of short peptide
motifs containing two consecutive phenylalanines that bind to the Rev1 C-terminal domain
(Rev1-CT) (202).
The human Y-family Rev1 polymerase is a 1251 amino acid (aa) protein that is notable for
its role, along with pol, in most DNA damage induced mutagenesis (203-205). The Rev1
catalytic activity, however, is limited to inserting dCMP opposite a G template or certain types of
DNA lesions, and thus is insufficient to explain its role in introducing mutations (205-207).
Subsequent studies revealed that Rev1 possesses a “second function” besides its catalytic ability
that is important for TLS and mutagenesis (208). This second, and more important, function of
Rev1 proved to be the recruitment and coordination of other DNA polymerases during the
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process of TLS via specific protein-protein interactions (35,178,179). Thus, Rev1 serves as a
scaffold that provides access for the Y-family polymerases , , and to their cognate DNA
lesions, and can also facilitate the subsequent exchange to pol, which then extends the distorted
DNA primer terminus opposite the lesion. Remarkably, previous studies of intermolecular
interactions of Rev1 fragments using yeast two-hybrid assays, co-immunoprecipitation and
cellular co-localization revealed that Rev1’s interaction with the other three Y-family TLS
polymerases, pol, , and  and with pol as well is mediated by a relatively small 100 aa Rev1CT domain (202,209-211). The human Y-family polymerases ,  and  bind the Rev1-CT with
RIR peptide motifs that contain two consecutive Phe residues (202). Such motifs are absent in
the Rev3 and Rev7 subunits of pol also known to interact with the Rev1-CT in vertebrates (209212), suggesting that their mode of Rev1-CT binding is different from that of polymerases , 
and . Previous reports suggest that the loss of S. cerevisiae Rev1-CT has a detrimental effect on
cell survival and results in a decrease of mutagenesis after DNA damage (213). Although the
crystal structure of the central polymerase domain of both human and yeast Rev1 have been
solved, the critically important protein-protein interaction Rev1-CT domain was removed to
facilitate crystallization (214,215).
The versatility of Rev1-CT interactions renders characterization of this module critical for
understanding the underlying mechanisms of TLS. Here we report high-resolution spatial
structures of the human Rev1-CT domain (residues 1157-1251) and its complex with Rev1
interacting region (RIR) from pol (residues 524-539) determined by solution NMR
spectroscopy, as well as a detailed characterization of conformational flexibility of the free
Rev1-CT domain and the complex on various time-scales using 15N NMR spin-relaxation (216)
and 15N NMR relaxation dispersion measurements (217). The functional importance of particular
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amino acids to this interaction is demonstrated through the use of yeast two-hybrid analysis.
Taken together, these data provide a rigorous structural basis for understanding Rev1 interactions
with human Y-family TLS polymerases.

4.3. Experimental Procedures
Protein sample preparation for NMR spectroscopy. The gene encoding human Rev1-CT
domain (residues 1158-1251 of Rev1 inserted after the cleavage site for TEV protease ENLYFQG), codon optimized for expression in E. coli, was custom synthesized (GenScript) and
sub-cloned into pET-28b(+) vector (Novagen) using NdeI - BamHI restriction sites.
The recombinant human Rev1-CT was over-expressed in E. coli BL21(DE3) cells.

15

N/13C

labeled protein for NMR spectroscopy was produced by growing cells transformed with Rev1CT plasmid in minimal M9 medium using 15NH4Cl and 13C-glucose as sole nitrogen and carbon
sources, respectively. Cells were grown at 37 oC to OD600 of 0.6-0.8 followed by induction of
protein expression by 1 mM IPTG overnight at 20 oC. After harvesting, the bacterial pellets were
re-suspended in loading buffer containing 50 mM NaH2PO4, 250 mM NaCl, 10 mM imidazole, 1
mM PMSF, pH 7.4. After the cells were lysed by sonication, the soluble fraction was loaded onto
a Ni2+ affinity column and incubated for 1 h at 4oC. After an extensive wash with the loading
buffer, the protein was eluted with the buffer of the same composition, but containing 250 mM
imidazole. The His-tag was removed by TEV cleavage for 4 h at 20oC or overnight at 4oC in the
presence of 2 mM DTT and 0.5 mM EDTA, followed by protein purification on a HiLoad
Superdex 75 column (GE Healthcare). After concentration, the final sample of free Rev1-CT
domain contained 0.9 mM

15

N/13C labeled protein, 50 mM NaH2PO4, 100 mM NaCl, 0.25 mM

EDTA, 5 mM DTT, 0.05% NaN3, 10% D2O, pH 7.0. Protein cleavage with TEV protease leaves
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an N-terminal Gly residue, so that the resulting Rev1-CT domain included residues 1157-1251 of
human Rev1 with Pro1157 mutated to Gly. The consistency of the protein sample was confirmed
by MALDI-TOF mass spectroscopy.
The complex of 15N/13C labeled Rev1-CT domain with a custom synthesized (GenScript) 16
aa unlabeled peptide that encompasses one of the two RIR regions of pol (residues 524-539;
QSTGTEPFFKQKSLLL) (202) was prepared by gradually titrating 25 mM peptide solution into
0.9 mM protein sample. The binding was monitored by recording 1H-15N HSQC spectra at each
step of the titration. The final sample of the complex contained 0.9 mM

15

N/13C Rev1-CT -

unlabeled pol-RIR mixed in 1:1 molar ratio, 50 mM NaH2PO4, 100 mM NaCl, 0.25 mM
EDTA, 5 mM DTT, 0.05% NaN3, 10% D2O, pH 7.0. At this protein concentration, about 89% of
the protein and the peptide are in the bound state, estimated assuming dissociation constant KD =
13 M for the complex reported in previous studies (202).
NMR resonance assignment and protein structure calculation. NMR spectra for the free
15

N/13C Rev1-CT domain and its complex with the unlabeled pol-RIR peptide were collected at

15 oC on Agilent VNMRS spectrometers equipped with cold probes operating at 11.7 and 18.8 T
magnetic fields (500 and 800 MHz 1H frequencies). The backbone and side-chain
1

15

N, 13C and

H resonances of Rev1-CT domain were assigned from 2D 1H-15N HSQC, 1H-13C HSQC and 3D

HNCA, HNCACB, HNCO, HBHA(CO)NH, HC(C)H-TOCSY, (H)CCH-TOCSY,

15

N-edited

NOESY-HSQC and 13C-edited NOESY-HSQC (150 ms mixing time) spectra (102). Two sets of
experiments were performed (i) for the free 15N/13C Rev1-CT domain and (ii) for 15N/13C Rev1CT - unlabeled pol-RIR complex. The assignments of 1H NMR resonances for pol-RIR
peptide in complex with

15

N/13C Rev1-CT domain were obtained from 2D

15

N,13C-filtered

TOCSY, COSY and NOESY (250 ms mixing time) spectra (218), containing intra-molecular 1H109

1

H correlations from the unlabeled peptide, collected in both 90% H2O/10% D2O and in 100%

D2O buffers (COSY spectrum was recorded in D2O buffer only). In addition, we have recorded
3D

13

C-edited

15

N,13C-filtered NOESY-HSQC spectrum, containing inter-molecular NOE

correlations between

15

N/13C Rev1-CT domain and the unlabeled pol-RIR peptide used for

structure determination of the complex (218). NMR spectra were processed with NMRPipe (140)
and analyzed with CARA software (219). Nearly complete backbone 95% (94%) and side-chain
90% (90%) resonance assignments were obtained for the free Rev1-CT domain (the complex).
Structure calculations for the Rev1-CT domain and Rev1-CT/pol-RIR complex were
performed in CYANA software (107). The restraints for the backbone dihedral  and  angles
were derived from the backbone 1H, 15N and 13C chemical shifts using TALOS+ program (106).
Intra-molecular 1H-1H distance restraints for the free and bound forms of Rev1-CT were
obtained from 3D

15

N- and

13

C-edited NOESY-HSQC spectra, while inter-molecular distance

restraints and restraints within the pol-RIR peptide were derived from 3D
filtered NOESY-HSQC and 2D

15

13

C-edited

15

N,13C-

N,13C-filtered NOESY experiments, respectively. Intra-

molecular NOE correlations for Rev1-CT domain in free and bound states were assigned
automatically in CYANA, while protein-peptide and inter-peptide NOEs were assigned
manually. Hydrogen bond restraints were added on the basis of NOE analysis. A total of 200
structures of the free Rev1-CT domain and the complex were generated, followed by refinement
of 20 final lowest-energy structures by short constrained molecular dynamic simulations in
explicit solvent using CNS software (145). Table 4.1 summarizes NMR based restraints used for
structure calculation of Rev1-CT domain and the complex along with structure refinement
statistics.
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NMR characterization of protein dynamics. The backbone 15N R1, R2 (CPMG) and 15N{1H}
NOE NMR relaxation measurements for the Rev1-CT domain and its complex with pol-RIR
peptide were performed on a 11.7 T Agilent VNMRS spectrometer at 15 oC using the pulsesequences of Farrow et al. (117). The delay between 180o refocusing pulses of CPMG sequence
in 15N R2 experiment was set to  = 1 ms, corresponding to CPMG frequency CPMG = 1/(2) of
500 Hz. 15N R1 and R2 rates and their uncertainties were obtained from exponential fits of peak
intensities in a series of 8 2D 1H-15N correlation spectra recorded at different relaxation delays.
15

N R2 rates were numerically corrected to take into account small systematic contributions due

to off-resonance effects of CPMG refocusing pulses (220). 15N{1H} NOE values were calculated
as ratios of peak intensities in corresponding 2D 1H-15N correlation spectra recorded with and
without 1H saturation using 8 s delay between scans to ensure full recovery of

15

N longitudinal

magnetization. To account for possible systematic uncertainties in measured NMR relaxation
data the minimal errors of 2% for

15

N R1, R2 rates and 0.05 for

15

N{1H} NOE values were

assumed.
Overall rotation diffusion tensors for the free Rev1-CT domain and Rev1-CT/pol-RIR
complex and overall rotation correlation time R = 1/(2(Dx + Dy + Dz)) (Di, i = x,y,z are
eigenvalues of rotation diffusion tensor) were calculated from
program DASHA (221). Specifically,

15

15

N R1 and R2 data using the

N R1 and R2 rates were globally fit to the models

assuming an isotropic, axially symmetric and fully anisotropic rotational diffusion tensor (216).
Included in these calculations were the residues with (i) non-overlapped cross-peaks in 1H-15N
correlation spectra, (ii)

15

N{1H} NOE > 0.6 and (iii)

15

N R2/R1 ratios within mean  2 standard

deviations. In both cases the model of axially symmetric anisotropic rotation diffusion was
selected according to F-test at 10% significance level, resulting in R = 8.96  0.07 ns (10.45 
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0.06 ns) and Dx/Dz = Dy/Dz = 0.91  0.02 (0.84  0.01) for the free Rev1-CT domain (Rev1CT/pol-RIR complex).
Pico- to nanosecond conformational dynamics of the Rev1-CT domain in free and bound
forms were assessed from the analysis of

15

N relaxation data using the Lipari-Szabo model-free

approach (115,216) performed in DASHA software (221). At this stage of the data analysis the
parameters of molecular overall rotation were fixed to previously determined values, and 15N R1,
R2 and

15

N{1H} NOE data were fit on a per-residue basis using the models of spectral density

function including the following adjustable parameters: (i) {S2}, (ii) {S2, e}, (iii) {S2, Rex}, (iv)
{Sf2, Ss2, s} and (v) {S2, e, Rex}, where S2, Sf2 and Ss2 (S2 = Sf2Ss2) are generalized order
parameters describing angular amplitudes of internal motions of N-H vectors, e, s are
correlation times for fast ps and slower ns time-scale internal motions, Rex (below referred to as
Rex,mf) is the contribution to transverse relaxation rate R2 due to s-ms conformational exchange.
Model selection was performed based on the values of 2 penalty function, describing goodness
of relaxation data fit, according to the protocol of Mandel et al. (222) (significance levels of 5%
and 20%, respectively, were assumed for 2 and F-test).
The residues in free Rev1-CT domain and its complex with pol-RIR peptide exhibiting
micro- to millisecond conformational exchange were identified based on Rex,mf values obtained
in model-free analysis of 15N relaxation data (115,216). The CPMG sequence used in the 15N R2
experiment suppresses exchange contribution to R2 provided that 2CPMG >> kex and 2CPMG
>> , where kex and  are exchange rate constant and frequency difference between the
exchanging states (223). Therefore, Rex,mf primarily reflect contributions to R2 due to fast s-ms
conformational exchange with kex ≥ 2CPMG accompanied by changes in NMR chemical shifts.
To quantify Rex contributions to

15

N R2 due to slower ms time-scale exchange we have
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performed

15

N CPMG relaxation dispersion measurements (217,224), where the effective

transverse relaxation rates R2,eff were obtained as a function of CPMG.

15

N relaxation dispersion

profiles for the free Rev1-CT and Rev1-CT/pol-RIR complex were recorded at 11.7 T (the free
domain and the complex) and 18.8 T (the complex only) magnetic fields with the pulse-sequence
of Hansen et al. (225), using a constant relaxation period T = 30 ms and CPMG ranging from 33
to 1000 Hz. Relaxation dispersion data measured at 11.7 T were least-square fit to a model of
two-state conformational exchange as described elsewhere (226). The best-fit dependencies of
R2,effclc(CPMG) were used to estimate exchange contributions Rex,rd = R2,effclc(33Hz)R2,effclc(533Hz) to

15

N R2 that complement model-free derived Rex,mf measured at CPMG of 500

Hz.
Yeast two-hybrid analysis. Studies of protein-protein interactions in the yeast two-hybrid
system were performed in the PJ69-4A strain of yeast (227). DNA fragments encoding the Cterminal fragment of human Rev1 (amino acids from 1131-1249) and full-length human polη
(amino acids from 1-713), were subcloned into the pGAD-C1 (GAL4 AD) and the pGBD-C1
(GAL4 BD) plasmids marked with leucine and tryptophan auxotrophy, respectively. The assay
was performed by growing strains harboring the two plasmids in 3 ml of media lacking leucine
and tryptophan for 2 days at 30°C and spotting 5µL of cells on selective media plates lacking
leucine and tryptophan (-LW) and on medium also lacking adenine and histidine (-AHLW) to
score positive interactions. Interactions were scored after 3 days of growth at 30 °C.
Site-directed mutations for yeast two-hybrid analysis were generated according to the
protocol of the Quikchange Mutagenesis kit (Stratagene), except that we used an annealing
temperature of 50 °C and an extension time of 2min/kb. Mutations were verified by sequencing.
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4.4. Results and Discussion
4.4.1. The Rev1 C-terminus is a structured domain that binds human Y-family DNA
polymerases
Previous studies established that the C-terminal ~100 aa region of DNA polymerase Rev1
(Rev1-CT) is critical for DNA damage tolerance in eukaryotes (209-211). However, removal of
a fragment of Rev1 containing this region does not alter the dCMP transferase activity of yeast
Rev1 in vitro (228), supporting the notion that Rev1 plays a non-catalytic, structural role in
translesion synthesis (TLS) by coordinating the action of other TLS polymerases through
protein-protein interactions (35,177-179,229). The binding of the human and mouse Rev1-CT
domain with each of the other vertebrate Y-family polymerases, pol,  , and with Rev7, the
regulatory subunit of pol has been demonstrated by multiple experimental techniques, including
yeast two-hybrid assays, co-immunoprecipitation, and cellular co-localization (202,209-211).
Although the Rev1-CT domain is highly conserved in eukaryotes, its ability to bind other Yfamily DNA polymerases has only evolved in higher organisms (230), in contrast to the Rev1CT/Rev7 interaction, which has been reported in eukaryotes from yeast to humans (35).
Secondary structure prediction and sequence alignment of Rev1-CT from different species
suggested that the domain likely consists of four amphipathic helices, which would have the
potential for forming a four-helix bundle, and identified several conserved motifs that seemed
likely to be involved in the hydrophobic core of the domain and whose mutation impairs the
function of yeast REV1 gene in vivo (213).
Despite the wealth of biochemical and mutational data, the detailed atomic-level picture of
Rev1-CT interactions with other TLS polymerases has remained obscure due to the lack of a
high-resolution spatial structure of this domain. In order to determine the solution NMR structure
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of the human Rev1-CT domain (residues 1157-1251) we have expressed and purified

15

N/13C

labeled protein and performed its backbone and side-chain resonance assignment using a
standard set of triple-resonance NMR experiments (102). Figure 4.1A shows the 1H-15N HSQC
spectrum of the free Rev1-CT domain (red) recorded at 11.7 T field at 15 oC, revealing a single
set of well dispersed NMR resonances indicative of a structured protein domain. NMR chemical
shifts obtained at this stage of the data analysis provide a plentiful source of information on local
protein structure and conformational dynamics. Thus, secondary structure prediction based on
the backbone 1H, 15N and 13C chemical shifts using TALOS+ program (106) (Figure 4.1B, red)
confirmed that the domain consists of four -helices, referred to below as H1 to H4. Order
parameters S2 for the backbone amide groups of the free Rev1-CT (Figure 4.1C, red) that
describe the main chain conformational flexibility (S2 = 1 for fully restricted, 0 for unconstrained
motions) were empirically predicted from the backbone chemical shifts using Random Coil
Index (RCI) approach (150,231). High S2 observed throughout the protein sequence suggest
rather limited mobility of the domain on ps-ns to s time-scale (231). In contrast, the free Rev1CT domain seems to be dynamic on a time-scale from s to ms. At temperatures above 20-25 oC
the quality of Rev1-CT spectra deteriorate significantly due to extensive line-broadening
indicative of s-ms conformational exchange. Decreasing the temperature to 15 oC improves
spectra quality, although the resonances from loops between helices H1-H2 and H3-H4 still
remain broadened, some beyond the level of detection.
The Rev1-CT domain has been previously shown to form medium to weak affinity
complexes with short peptide motifs (Rev1 interacting regions, RIRs) from human Y-family
DNA polymerases ,  and  containing two consecutive Phe residues (Figure 4.1D) with
dissociation constants (KD) ranging from 8 to 69 M (202). One RIR motif was identified in
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each of human pol and pol, while two motifs were found in human pol (Figure 4.1D). In
order to elucidate the structural basis for Rev1-CT interactions with human Y-family DNA
polymerases, we have performed NMR studies of the Rev1-CT complex with a 16 amino acid
peptide containing one of the two RIR motifs of human pol (residues 524-539, line 1 in Figure
4.1D). Figure 4.1A shows 1H-15N HSQC spectrum of the Rev1-CT/pol-RIR complex (blue)
superimposed on the spectrum of the free domain (red). The backbone and side-chain NMR
resonance assignments for 15N/13C labeled Rev1-CT in complex with the unlabeled pol peptide
were obtained as described above for the free domain, while 1H resonances of the peptide were
assigned from a set of filtered 2D 1H-1H experiments. The analysis of the backbone 1H, 15N and
13

C chemical shifts of Rev1-CT domain bound to pol-RIR peptide suggests that neither

secondary structure (Figure 4.1B, blue) nor backbone amide order parameters S2 that report on
main chain dynamics (Figure 4.1C, blue) change significantly upon the complex formation. On
the other hand, NMR resonances from H1-H2 and H3-H4 loops exhibit somewhat less
broadening due to s-ms conformational exchange. Chemical shift changes upon complex
formation are observed in the region of the Rev1-CT domain comprising helices H1 and H2, as
well as in the N-terminal part preceding helix H1, suggesting that this part of the domain is
involved in Y-family polymerase binding.
Titrations of Rev1-CT domain with increasing amounts of pol-RIR peptide monitored by
1

H-15N HSQC spectra suggest that the binding process is slow on the NMR time-scale. Namely,

peaks corresponding to free Rev1-CT decrease in intensity and ultimately disappear, while peaks
of the bound form show up in new places in spectra and increase in intensity with increasing
peptide concentration (as illustrated in the inset to Figure 4.1A for Leu1171). In the case of twostate chemical exchange between equally populated states, two peaks are observed in the NMR
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spectrum of a nucleus if the forward and reverse rates k for the process are slower than /23/2
(coalescence point), where  is frequency difference between the exchanging states (232).
Separate peaks as close as 0.03 ppm (1H) corresponding to free and bound Rev1-CT are observed
in 11.7 T 1H-15N HSQC spectra recorded at about 1:0.5 protein/peptide ratio, suggesting that
association kon[L] ([L] is concentration of free peptide) and dissociation koff rates for Rev1CT/pol-RIR interaction are slower than ~33 s-1. Assuming the previously reported KD = 13 M
(202) and total protein and peptide concentrations [P0] = 0.9 mM and [L0] = 0.45 mM,
respectively, one can estimate the upper limit for kon of Rev1-CT/pol-RIR association as
2.7∙106 M-1s-1, which is of the same order of ~106 M-1s-1 expected for diffusion controlled protein
association (233). This observation suggests that the Rev1-CT/pol-RIR association is likely
somewhat slower than diffusion controlled, potentially pointing to a barrier crossing event due to
rearrangements of interaction partners.

4.4.2. Structure of the free Rev1-CT domain
Figure 4.2 shows the spatial structure of the human Rev1-CT domain (residues 1157-1251)
as determined by solution NMR spectroscopy. The ensemble of 20 least-energy structures of the
domain (Figure 4.2A) is in excellent agreement with the input experimental data, displaying
mean pairwise RMSD for the backbone atoms of regular secondary structure elements of 0.53 Å,
and exhibiting minimal violations of distance/torsion angle restraints and deviations from
idealized molecular geometry (Table 4.1). As expected, the domain adopts a four-helix bundle
fold with helices H1, H2, H3 and H4 spanning the residues 1165-1178, 1184-1199, 1203-1219
and 1224-1243, respectively (Figure 4.2B). The N-terminal 8 residues (1157-1164) of the
domain preceding -helix H1 form a rigid type I' -hairpin stabilized by two hydrogen bonds
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between Leu1159 and Ala1162 (NH1159-CO1162, CO1159-NH1162). The -hairpin tightly packs
against helices H1 and H2, resulting in multiple long-range NOE contacts between Leu1159 Val1163 and Asn1166, Asp1167, Val1168, Leu1172 in -helix H1, and between Leu1159 and
Gln1189 in -helix H2. Two hydrophobic residues in the -turn, Ala1160 and Gly1161, together
with hydrophobic side chains of Leu1171, Trp1175 from helix H1 and negatively charged
Asp1186 from helix H2 form a pocket on the surface of the domain (Figure 4.2C, left plot)
capable of accommodating the FF residues of RIR motifs of Y-type DNA polymerases (see
below). It is notable that this region comprised of residues from the N-terminal -hairpin and
helices H1 and H2, exhibits the largest NMR chemical shift change upon pol-RIR peptide
binding. Figure 4.2C shows electrostatic charge distribution color mapped onto the surface of
Rev1-CT domain. In addition to hydrophobic/negatively charged pocket described above located
between helices H1 and H2 there is a large positively charged patch on the opposite side of the
molecule formed by side-chains of Lys1169 and Arg1173 from helix H1 and Lys1211, Lys1214
and Arg1215 from helix H3.
Side-chains of residues with solvent exposure less than 5% and an accessible surface area
less than 10 Å2 that form the core of the Rev1-CT domain are shown in Figure 4.2B and are
listed in the figure caption. Beyond side-chains buried in the hydrophobic core of the four-helix
bundle, several residues form the interface between the N-terminal -hairpin and -helices H1
and H2. Recently, extensive sequence alignment of Rev1-CT domains from multiple eukaryotic
species identified five conserved 5-6 residue regions within Rev1 C-terminus, referred to as
rev1-108 to rev-112 (213). Alanine-patch mutations of four of these regions (rev1-108 - rev1111) in yeast Rev1-CT completely abrogate the function of the REV1 gene in cell survival after
DNA damage induced by UV or methanesulfonate (MMS) exposure (213). It is interesting to
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note that each of the rev1-108, rev1-110 and rev1-111 regions in the human Rev1-CT contain 2
to 4 residues from the core of the domain (see caption to Figure 4.2). Simultaneous mutations of
multiple core residues, therefore may cause significant destabilization of the domain. Provided
that the core of Rev1-CT is conserved among eukaryotic species, this observation explains why
mutations of rev1-108, rev1-110 and rev1-111 in yeast are equivalent to loss of the whole
domain, and, once again, underlines the importance of the Rev1-CT domain for DNA damage
tolerance in eukaryotes.
4.4.3. Structure of the Rev1-CT/pol-RIR complex
The finding that vertebrate Rev1-CT directly interacts with the three Y-family DNA
polymerases, pol,  and  sparked a search for Rev1 binding sequences (RIR motifs) in
eukaryotic Y-family DNA polymerases (202,209-211). This search proved non-trivial. As shown
in Figure 4.1D, there is limited sequence homology among the four RIR regions found in human
Y-family polymerases. Based on mutational analysis and truncations of RIR containing peptides
Ohashi et al. (202) described the minimal RIR region as yyyFFxxxx (underlined in Figure 4.1D),
where F is a phenylalanine residue, y is any amino-acid, and x is any amino acid but a proline.
The two consecutive Phe residues are conserved among RIR regions, and substitution of any of
them to Ala results in complete abrogation of RIR - Rev1-CT binding. In 3 of 4 RIRs found in
human Y-family enzymes (Figure 4.1D) the FF sequence is preceded by Ser whose mutation in
pol decreases, but does not abolish Rev1-CT interaction (202). Intriguingly, while there is no
obvious sequence conservation in the region C-terminal to the FF motif, studies of the truncated
RIR peptides suggest that at least four residues must follow the FF sequence in order to
efficiently bind Rev1-CT. Mutation of any of the four residues to Ala has no effect on Rev1
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interaction, yet substitution of any of them to Pro results in a complete loss of Rev1 interaction,
suggesting that main chain conformation of RIR peptides is important for binding rather than
specific side-chain contacts (beyond those formed by FF residues) (202).
To ascertain the mechanism of Rev1 recognition of Y-family DNA polymerases, we have
determined the solution NMR structure of the Rev1-CT domain complex with an RIR containing
peptide from human pol (residues 524-539) shown in Figure 4.3. The ensemble of 20 leastenergy structures (Figure 4.3A) agrees well with the input experimental restraints (Table 4.1),
exhibiting mean pairwise RMSD for the backbone atoms of regular secondary structure elements
of 0.62 Å (Rev1-CT)/0.27 Å (pol peptide). Structure comparison of the free and bound forms of
Rev1-CT domain (Figure 4.3B) reveals no noticeable structural changes in the domain upon
pol-RIR binding. Interestingly, in the complex with Rev1-CT, the pol-RIR peptide forms an
-helix starting at Phe531 and continuing all the way to the C-terminal Leu539. The two
phenylalanine residues, Phe531 and Phe532, are located in the first turn of the helix facing Rev1CT domain surface. As anticipated from the mutational analysis of Rev1-CT/pol-RIR
interaction, the majority of contacts between Rev1-CT and pol-RIR peptide involve the two
Phe residues, displaying extensive inter-molecular NOE connectivities in

13

C-edited

15

N,13C-

filtered NOESY-HSQC spectrum (218) (Figure 4.4). Both aromatic side-chains become buried
upon Rev1-CT binding. The ring of Phe532 deeply penetrates into the binding pocket on Rev1CT surface formed by residues Ala1160, Gly1161 from the N-terminal -turn, Leu1171,
Trp1175 from helix H1, and Asp1186, Gln1189 from helix H2, while the ring of Phe531 packs
against Thr1178 and Ile1179 on the domain surface (Figures 4.3C and D). Notably, the pocket is
already preformed in the free form of Rev1-CT domain (Figure 4.2C). As a result, Phe531 and
Phe532 contribute 110 and 180 Å2, respectively, to the ~600 Å2 interaction surface between
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Rev1-CT domain and pol-RIR peptide. The pol-RIR -helix is tilted towards helices H1 and
H2 of Rev1-CT (Figures 4.3A and B), with the backbone amides of Phe531, Phe532 and Lys533
in the first turn of the -helix facing the negatively charged surface of the Rev1-CT domain
(Figure 4.2C). The key residue in Rev1-CT that interacts with the above amide groups of polRIR peptide is a highly conserved Asp1186 from the helix H2, which is surface exposed in the
free domain, but becomes completely buried upon complex formation. Strikingly, as also
discussed more fully below, mutation of Asp1186 to alanine completely eliminates the binding
of the full-length pol to the Rev1-CT in the yeast two-hybrid system (Figure 4.5). The carboxyl
of the Asp1186 side-chain participates in charge-dipole interactions with the backbone amides of
Phe531 (whose 1HN resonance is shifted to 11.1 ppm) and Phe532 of pol-RIR peptide, and is
also proximal to the side-chain NH group of Trp1175 and the backbone amide of Met1183 from
the H1-H2 loop of Rev1-CT domain (Figure 4.3D). It is not an unusual feature for a buried
ionizable side-chain in a protein to be involved in interactions with the backbone / side-chain
dipole or oppositely charged side-chain group (234). Residues Lys531, Ser532 and Leu539 from
the two turns of the pol-RIR -helix following the FF sequence interact with Ala1160 and
Gly1161 from the N-terminal -hairpin of Rev1-CT, while Thr528 and Glu529 preceding the FF
pair pack against the side-chains of Pro1182 and Met1183 in the H1-H2 loop.
The spatial structure of the Rev1-CT/pol-RIR complex (Figure 4.3) reveals that the two
consecutive phenylalanine residues, Phe531 and Phe532, of the pol RIR motif are responsible
for the majority of specific inter-molecular interactions and are crucial for the complex
formation. Accordingly, mutation of these critical Phe531 and Phe532 residues to glycine within
the pol RIR nearly completely eliminates interaction with the Rev1-CT via the yeast twohybrid system described below (Figure 4.5A). We also observe a relatively weaker binding when
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the Phe483 and Phe484 residues within the first RIR of pol were mutated to glycine, consistent
with an earlier report that all four phenylalanine residues within the two pol RIRs contribute to
Rev1-binding (202).
Another important interaction involves the backbone amide groups of Phe531 and Phe532
from the N-terminal face of the pol-RIR -helix and negatively charged Asp1186 of Rev1-CT
completely buried on the binding interface. The fact that the pol-RIR peptide adopts an helical conformation provides a rationale for the previously published mutational data (202). It is
clear that the helix is needed to maintain proper orientation of the two aromatic rings of the FF
sequence that fit into the binding pocket on the Rev1-CT surface, as well as to position the
backbone amides of the first -helix turn towards the side-chain of Asp1186 in Rev1-CT.
Mutational data suggest that at least four residues following the FF sequence are necessary to
maintain the -helical conformation secured by hydrogen bonds between residues i and i+4.
Alanine is highly favorable in -helices (235), so that substitution of residues C-terminal to the
FF sequence with Ala maintains -helical conformation of RIR peptide and, therefore, has little
effect on Rev1-CT binding. In contrast, mutation to a helix-breaking Pro (235) disrupts the helix of RIR motif and thereby abolishes Rev1-CT interaction. The -helix of RIR motifs found
in Y-family DNA polymerases starts with the FF sequence following the N-cap Ser or Pro
(Figure 4.1D). Pro is often found in N-cap positions of protein -helices (236), while Ser is
known as one of the most favorable N-cap residues (along with Asn, Asp, Cys and Thr) (237).
Therefore, it is not surprising that Ser to Ala substitution in the pol-RIR motif results in
weakening of Rev1-CT binding (202). Although Thr528 and Glu529 preceding the FF sequence
interact with the side-chain of Met1183 of Rev1-CT (Figure 4.3), these and other residues from
the N-terminal part of pol-RIR peptide exhibit no well-defined conformation and are likely of
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little importance for interaction with Rev1-CT. Therefore, based on our analysis of the Rev1CT/pol-RIR structure (Figure 4.3) Rev1 binding motif can be re-defined as nFF(4h), where n is
an N-cap residue, F is phenylalanine and 4h are at least four residues that form an -helix.
4.4.4. Corroboration of Rev1-CT/Pol-RIR interface by yeast two-hybrid assays
Having elucidated the structure of the human Rev1 C-terminus in complex with the polηRIR, we employed a yeast two-hybrid system to monitor the interaction between the proteins.
The region encoding the human Rev1-CT and full-length polη was fused to the Activation
Domain (AD) and the Binding Domain (BD) of the GAL4 transcription factor, respectively. The
presence of the constructs after transformation into the PJ69-4A strain of yeast was ensured by
growth on selective media plates lacking leucine and tryptophan (-LW). Interactions between the
two proteins activate the expression of the HIS3 and ADE2 reporter genes, both driven by
promoters responsive to the Gal4 transcription factor. These interactions were scored by growth
on selective media plates additionally lacking adenine and histidine (-AHLW). We determined
that a longer Rev1-CT construct of ~120 amino acids, rather than the 95 amino acid Rev1-CT
fragment that was used in structure determination, reproducibly recapitulated the interaction with
polη. Consistent with earlier data, the interaction between the Rev1-CT and full-length polη
resulted in robust growth of the strains in –AHLW selective media plates (Figure 4.5A). In
contrast, no growth was observed in strains expressing the Rev1-CT and the BD alone, showing
that the interaction is specific between the two proteins.
Having established a strong interaction between the Rev1-CT and polη we asked if mutations
of residues within the N-terminal β-hairpin and -helices H1, H2 of Rev1-CT affect the
interaction with polη. To extend and validate our predictions from the Rev1-CT/polη-RIR
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complex, we created a series of point mutations within the Rev1-CT and examined its interaction
with polη via the yeast two-hybrid assay. As shown in Figure 4.5B, the Rev1-CT mutations
L1159A, L1171A, L1172A, W1175A and D1186A completely abrogate the interaction, whereas
the mutations E1174A, T1178A and M1183A severely diminish binding to polη. The mutant
proteins containing A1160G, I1179A and Q1189A substitutions, however, show an interaction
similar to wild-type Rev1-CT. Among the set of residues in Rev1-CT that show complete loss of
binding, Leu1159 lies on the interface between the N-terminal β-hairpin and helices H1 and H2
that create a binding pocket for the Phe531 and Phe532 residues of the pol-RIR, and likely is
important for stabilization of the β-hairpin. The key residue Leu1171 interacts with Phe532 and
is exposed in the free Rev1-CT but becomes buried upon binding the polη-RIR. Its mutation to
alanine, therefore, completely eliminates the interaction with the polη-RIR. Leu1172, however,
forms part of the hydrophobic core of the Rev1-CT so a change to alanine, while rendering it
incompetent to bind polη, is likely due to a destabilization of the Rev1-CT itself. Similarly
Trp1175, one of the key residues on the binding interface between the Rev1-CT and polη
interacts with Phe532, but is partially buried in the free domain and, therefore, participates in
stabilization of the hydrophobic core. Like L1172A, the W1175A mutation likely significantly
destabilizes the Rev1-CT domain. Strikingly, Asp1186, a crucial residue for the Rev1-CT - polRIR interaction is almost completely buried on the binding interface. It interacts with the
backbone amide groups of Phe531 and Phe532 from the first turn of pol-RIR -helix and,
consequently, mutation of this negatively charged amino acid to alanine abrogates interaction
with the polη-RIR, as evidenced by a complete lack of growth of yeast strains harboring these
plasmids on selective media plates lacking AHLW (Figure 4.5B).
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The weaker polη-RIR interacting residues Glu1174 and Thr1178 in the Rev1-CT are located
in the -helix H1 at the periphery of pol-RIR binding interface, while Met1183 is located in the
loop between helices H1 and H2 and interacts with N-terminal residues of the pol-RIR
preceding the conserved Phe531 and Phe532. Their mutation to alanine results in a significantly
reduced growth of yeast strains carrying the plasmids on –AHLW plates. Surprisingly, mutation
of Ala1160, which makes contacts with the two turns of the pol-RIR -helix following the FF
motif, and Ile1179, Gln1189 located on the periphery of the interface and interacting directly
with Phe531 and Phe532, had no effect on binding to the Rev1-CT in the yeast two-hybrid assay
(Figure 4.5B). Taken together, these results show that residues Leu1171, Glu1174, Thr1178,
Met1183 and Asp1186 of Rev1-CT make contacts with pol that contribute to stabilization of
the complex between the two proteins.
4.4.5. Conformational dynamics of Rev1-CT domain and Rev1-CT/pol-RIR complex
Protein conformational flexibility plays an important role in molecular recognition, often
conferring upon protein domains the ability to bind multiple targets (238,239). Pre-sampling of
multiple interconverting conformers enables rapid selection of molecular configuration optimal
for binding. On the other hand, loss of conformational mobility and/or ordering upon binding
imposes an entropic penalty that weakens molecular interaction, thereby modulating specificity
of recognition by allowing more selective binding. Not surprisingly, a number of molecular
complexes have been described involving flexible and/or disordered interaction partner(s) that
only fold into an ordered structure upon binding (239). The interaction between the Rev1-CT and
the Y-family DNA polymerases pol, , and  seems to fall into this category. The Rev1
interacting regions (RIRs) of pol, pol, pol are mapped outside structured domains of the
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enzymes (35,178,179) and likely adopt -helical conformation only upon binding the Rev1-CT
domain. Although the Rev1-CT is shown to be well structured, NMR line broadening in the H1H2 and H3-H4 loops, as well as in parts of helices H1 and H2 points to ms-s conformational
rearrangements of RIR interaction interface. Therefore, to elucidate the role of Rev1-CT
flexibility in Y-family DNA polymerase recognition we have examined ps-ns and ms-s timescale conformational dynamics of free and pol-RIR bound forms of the domain using 15N spinrelaxation (216) and 15N CPMG relaxation dispersion (217) measurements.
Figure 4.6A (top plots) shows

15

N R1, R2 relaxation rates and

15

N{1H} NOE values for the

Rev1-CT domain (red) and Rev1-CT/pol-RIR complex (blue) measured at 11.7 T magnetic
field, 15 oC. NMR spin-relaxation data were analyzed using the Lipari-Szabo model-free
approach (115,216) to extract order parameters S2 (Figure 4.6A, bottom plot) and correlation
times (data not shown), describing angular amplitudes and time-scales of fast ps-ns internal
motions of the backbone NH vectors, respectively, along with parameters of overall rotational
diffusion of the molecule. As expected, overall rotation correlation time R for the complex
(10.45  0.06 ns) exceeds R for the free domain (8.96  0.07 ns) by 17%, closely matching the
increase of molecular size upon Rev1-CT (95 aa) - pol-RIR (16 aa) complex formation.
Uniformly high order parameters S2 > 0.8 are observed for the backbone amide groups of the
free Rev1-CT domain and the complex (Figure 4.6A), stemming from fast (fs-ps) restricted
thermal flexibility of the protein backbone (S2 = 1 for fully constrained, 0 for unrestricted
motions). The exceptions are 5-6 residues in the C-terminal part of the domain and residues from
the H3-H4 loop, exhibiting a lower S2 pointing to increased ps-ns mobility. The experimental S2
values (Figure 4.6A) are in line with those predicted from the backbone chemical shifts using
RCI approach (150,231) (Figure 4.1C), albeit the later are underestimated in loop regions.
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Interestingly, the experimental S2 for the backbone amides in the N-terminal -hairpin are about
as high as in the regular secondary structure elements (Figure 4.6A), confirming that the Nterminal part adopts a rigid conformation in both free and bound forms of the Rev1-CT domain.
Overall, 15N relaxation data analysis suggests that ps-ns time-scale internal motions of the Rev1CT domain are restricted and that ps-ns dynamics of the domain does not change upon pol-RIR
binding.
Along with order parameters S2 and correlation times of internal motions, model-free
analysis of

15

N relaxation data allows extraction of exchange contributions Rex,mf to transverse

relaxation rates R2 that report on s-ms conformational dynamics accompanied by changes in
15

N chemical shifts (216). The extracted Rex,mf primarily originate from faster s-ms processes,

since the CPMG sequence in our

15

N R2 experiment suppresses contributions to R2 due to ms

exchange with kex << 2CPMG and  << 2CPMG (where kex is exchange rate constant,  is
frequency difference between the exchanging states; CPMG frequency CPMG in our

15

N R2

experiment was set to 500 Hz) (223). To additionally quantify contributions to 15N R2 rates due
to slower ms time-scale conformational exchange, we have performed

15

N CPMG relaxation

dispersion experiments (217,224,225) that measure effective transverse relaxation rates R2,eff as a
function of CPMG, and quantified Rex,rd = R2,effclc(33Hz) – R2,effclc(533Hz) that complement Rex,mf
obtained in model-free analysis of

15

N relaxation data. The sum Rex,mf + Rex,rd provides an

approximation for total exchange contribution Rex to 15N R2 in free-precession limit.
15

N R2 rates plotted vs. residue number (Figure 4.6A) reveal that residues in (and adjacent to)

H1-H2 and H3-H4 loops in the free Rev1-CT domain and in the complex exhibit enhanced

15

N

R2 caused by significant s-ms exchange contributions Rex,mf that were quantified using modelfree analysis of

15

N spin-relaxation data (115,216).
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15

N CPMG relaxation dispersion

measurements (217,224,225) that were used to identify amide groups involved in slower ms
time-scale exchange not captured in Rex,mf significantly extend the list of residues in free and
bound forms of Rev1-CT undergoing s-ms conformational rearrangements. Figure 4.6B shows
examples of

15

N CPMG relaxation dispersion profiles for the backbone amide groups of

Gly1161, Leu1171, Trp1175 and Asp1186 that form the pol binding site of Rev1-CT. In is
clear that for these residues R2,eff (CPMG) profiles reach a plateau at CPMG~500 Hz where the
exchange contribution to R2 is effectively suppressed by the CPMG sequence. Figure 4.6C
shows total exchange contribution Rex = Rex,mf + Rex,rd to 15N R2 rates (at 11.7 T magnetic field)
mapped onto structures of free Rev1-CT domain (top) and the complex (bottom), with residues
involved in faster s-ms and slower ms dynamics marked, respectively, in cyan and magenta.
Remarkably, the region exhibiting extensive s-ms conformational exchange in both free and
bound states of Rev1-CT encompasses the binding site for the pol-RIR motif formed by
residues from the N-terminal -hairpin, the two last turns of -helix H1, the H1-H2 loop, and
two first turns of -helix H2. Although s-ms exchange contributions Rex generally decrease
upon complex formation, the binding interface remains dynamic on s-ms time-scale in Rev1CT/pol-RIR complex. Interestingly, Rex contribution to

15

N R2 increase upon complex

formation for Gly1161 from the N-terminal -hairpin of Rev1-CT (Figure 4.6B), which directly
interacts with pol-RIR -helix.
Beyond intramolecular processes, ms time-scale exchange observed in the Rev1-CT/polRIR complex may be caused by an on-off equilibrium between free and bound forms of the
protein (240). From the upper limits of kon (2.7x106 M-1s-1) and koff (33 s-1) obtained as described
above one can derive the upper estimate for the exchange rate constant of the on-off equilibrium
kex = kon[L] + koff ~ 300 s-1 at the condition of our
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15

N CPMG dispersion experiment (0.9 mM

total protein, 0.9 mM total peptide concentrations; free ligand concentration [L] ~ 11% of 0.9
mM at KD = 13 M (202)). Even at a relatively slow kex of 100-300 s-1 the exchange between
free and bound forms of Rev1-CT may cause noticeable exchange contributions to transverse
relaxation rates. To elucidate whether the observed ms time-scale exchange in the complex can
be solely explained by on-off equilibrium between free and bound forms of Rev1-CT we have
additionally recorded

15

N CPMG dispersion profiles at 18.8 T magnetic field, and globally fit

11.7 and 18.8 T relaxation dispersion data to a model of two-state conformational exchange
(Figure 4.7A), resulting in a population of the second (minor) state pB = 5.9 ± 0.4% and
exchange rate constant kex = 585 ± 23 s-1. This is about two times faster than the estimated 300 s1

upper limit of the exchange rate constant for the Rev1-CT/pol-RIR binding equilibrium.

Interestingly,

15

N chemical shift differences obtained from CPMG relaxation dispersion data,

disp, are in good agreement with

15

N chemical shift differences between free and pol-RIR

bound forms of Rev1-CT, spec (Figure 4.7B), with the exception of few residues on the
binding interface (such as Trp1175). In addition, significant contributions Rex,mf to 15N transverse
relaxation rates R2 due to faster s-ms dynamics have been obtained in 'model-free' analysis of
15

N relaxation data for the binding site residues 1175-1179 (Figures 4.6A and C). Taken

together, these data suggest that conformational exchange observed on the binding interface of
the Rev1-CT - pol-RIR complex may include contributions from both on-off equilibrium
between free and bound forms of Rev1-CT and intra-molecular dynamic process(es).
The analysis of 15N spin-relaxation and 15N CPMG relaxation dispersion data established that
free and pol-RIR bound forms of Rev1-CT domain are rigid on ps-ns time scale, but exhibit
significant s-ms conformational dynamics encompassing the RIR binding site. Transitions to
low-populated states occurring on s-ms time-scale observed on the intermolecular interface of
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the complex may point to the existence of multiple modes of Rev1-CT/pol-RIR binding. Such a
plasticity of interaction interface in the bound state might prove beneficial for minimizing the
entropic penalty of the complex formation (239). On the other hand, s-ms sampling of multiple
conformational states in the free Rev1-CT domain may facilitate selection of a molecular
configuration(s) that enables efficient binding of RIR motifs (238,239), exhibiting surprisingly
little sequence conservation among Y-family DNA polymerases (Figure 4.1D).

4.5. Concluding Remarks
In this study, we have made a significant contribution to our understanding of how Rev1
regulates TLS in human cells through its interactions with the Y-family TLS polymerases pol,
, and  by (i) solving the structure of Rev1’s important C-terminal domain, (ii) revealing the
structural details of how the RIR of pol binds to Rev1’s C-terminal domain, and (iii) showing
that the RIR binding site of the Rev1 C-terminal domain displays conformational dynamics on
the s-ms time scale that may facilitate the selection of the molecular configuration optimal for
binding. We have also been able to redefine the Rev1 binding motif, RIR, as nFF(4h), where n is
an N-cap residue, F is phenylalanine and 4h are at least four residues that form an -helix.
The interactions that Rev1 makes with the Y-family DNA polymerases pol, , and  enable
a later acting form of TLS control that acts subsequent to the Rad6/Rad18-mediated
monoubiquitination of PCNA that is triggered by a variety of types of DNA damage (184,241).
The Rev1-CT is not important for the recognition of monoubiquitinated PCNA nor is it
necessary for recruitment to nuclear foci after DNA damage (229,242). Reciprocally, the RIR
sequences of pol are not necessary for recruitment to UV-induced nuclear foci, since its Cterminal 120 amino acids which do not include either of the RIRs are sufficient for its
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localization (243). Nor are the RIR sequences necessary for damage-induced foci formation by
pol (202) or pol (244). Thus the interactions that the Y-family TLS DNA polymerases pol, ,
and  make with the Rev1-CT represent another level of regulation beyond that of PCNA
monoubiquitination that helps to ensure that these inherently error-prone DNA polymerases do
not introduce mutations by gaining access to primer termini in undamaged DNA. Subsequent
polymerase exchanges that are mediated through the interactions that each of these TLS
polymerases make with Rev1’s C-terminal domain could possibly also help with the process of
matching each polymerase with its cognate lesion over which it can replicate relatively
accurately. Example of cognate lesions include thymine-thymine cyclobutane pyrimidine dimers
for pol, N2-BPDE-dG lesions for pol, and dA for pol (35,174). Polymerase exchange
mediated by the Rev1 C-terminal domain could also help exchange a non functional TLS
polymerase for an alternative TLS polymerase (245). Evidence has been reported indicating that,
in higher eukaryotes, a component of TLS can also proceed in the absence of PCNA
monoubiquitination (246). In these cases, the interactions that Rev1 makes with other TLS DNA
polymerases might be particularly important in facilitating and regulating TLS (209,211,247).
The exchanges that Rev1 likely facilitates between pol, , and  are apparently made possible
by the s-ms conformational dynamics of the region of the Rev1-CT that interacts with their
RIRs.
In TLS events requiring the coordinated consecutive action of two DNA polymerases, the
Rev1 C-terminal domain can also serve to facilitate the exchange from an inserter DNA
polymerase to the extender DNA polymerase pol via its interaction with the accessory subunit
Rev7. Recent evidence indicates that human Rev1 recruits pol through an interaction with Rev7
as it does in yeast (248). Rev7 clearly interacts differently with the Rev1-CT than do pol, , and
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 since it lacks an RIR and the Rev1-binding interface of Rev7 appears be a portion of the
surface of a five-stranded -sheet of Rev7 rather than a disordered peptide (249). Although pol
can accurately replicate UV-irradiated DNA independently of Rev1, pol-Rev1 interactions are
involved in suppressing spontaneous mutations, probably by promoting accurate TLS past
endogenous lesions (250).
Although TLS DNA polymerases can act at the replication fork, there is a growing body of
evidence in both yeast and mammalian cells that a substantial amount of TLS occurs at
postreplicational gaps caused by lesions rather than at active replication forks (180-184,251). In
fact, in yeast TLS occurs efficiently if it is constrained to occur during G2/M by manipulating
the cell cycle dependence of Rad6/Rad18-dependent monoubiquitination (180,182). Of particular
interest is the observation that in S. cerevisiae Rev1 is synthesized at extremely low levels during
G1 and most of S phase, but then is expressed at fifty-fold higher levels during G2/M (251).
Thus, most of the Rev1-pol interactions that occur in S. cerevisae via interactions of the Rev1
C-terminal domain with Rev7 are naturally confined to postreplicational gaps during G2/M
(183,252). Given the growing body of evidence that a significant amount of TLS takes place
during G2/M in mammalian cells (181), it seems likely that a substantial fraction of the
interactions between the Rev1 C-terminal domain and other TLS DNA polymerases similarly
take place at postreplicational gaps.
Knowledge of the structure of the Rev1-CT should also make it possible to clarify the
molecular details of the interactions that Rev1 makes during interstrand crosslink repair and may
make it possible to gain additional insights into the relationship between interstrand crosslink
repair and Fanconi anemia (253). Since inhibition of TLS can help to improve chemotherapy
(254,255), it is possible that searching for inhibitors that target specific protein-protein
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interactions required for TLS might be an alternative to searching for inhibitors that selectively
inhibit only one TLS DNA polymerase out of the 15 DNA polymerases found in human cells
(256).

Accession codes
Atomic coordinates of the Rev1-CT domain and the Rev1-CT/polh-RIR complex were
deposited to Protein Data Bank (PDB entries 2LSY, 2LSK). The backbone and side chain NMR
resonance assignments were deposited to BioMagResBank (BMRB entries 18455, 18434).
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Table 4.1. NMR-based restraints used for structure calculation of Rev1-CT domain and Rev1CT/pol-RIR complex, and structure refinement statistics.
Free Rev1-CT

Rev1-CT/pol complex

Total NOE distance restraints

1853

1526

Short range (|i-j|<=1)

1013

856/53a

Medium range (1<|i-j|<5)

468

315/9a

Long range (|i-j|>=5)

372

221/0a

-

51/21b

Dihedral angles restrains (φ and ψ)

180

152 / 26a

Hydrogen bonds

46

40/4a

NOE (Å)

0.02

0.02

Dihedral restraints (degrees)

1.1

1.3

Bonds (Å)

0.02

0.02

Angles (degrees)

1.1

1.2

90.1%

90.3%

Summary of restraints

Intermolecular

Structure refinement statistics
Deviation from NMR-based restraints

Deviation from idealized geometry

Ramachandran plot favorable
RMSD, pairwise (Å)
All residues

Rev1-CT

pol-RIR

Backbone atoms

0.87±0.16

1.08±0.19

2.58±1.03

Heavy atoms

1.35±0.14

1.83±0.23

3.40±1.00

Backbone atoms

0.53±0.11

0.62±0.12

0.27±0.08

Heavy atoms

1.08±0.10

1.51±0.22

1.38±0.26

Residues in regular secondary structure
elementsc

a - intra-molecular restraints for Rev1-CT / pol peptide
b - upper/low distance restraints
c - residues 1165-1178, 1184-1199, 1203-1219, 1224-1243 in Rev1-CT, 532-539 in pol.
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Figure 4.1. The Rev1-CT forms a structured domain that binds DNA polymerase η. A. 1H15
N HSQC spectra of free 15N/13C Rev1-CT domain (red) and the 15N/13C Rev1-CT complex
with the unlabeled pol-RIR peptide (blue) recorded at 11.7 T magnetic field, 15 oC. The inset
shows the peak of Leu1171 in 1H-15N HSQC spectra of a titration series recorded at different
ratios of peptide to protein. B. Probability of -helix, P(helix), in the free (red) and pol-RIR
bound (blue) Rev1-CT domain predicted from backbone chemical shifts using TALOS+ program
(106) plotted vs. residue number. C. Order parameters S2 for the backbone amide groups of the
free (red) and pol-RIR bound (blue) Rev1-CT domain predicted from the backbone chemical
shifts using RCI approach (150,231). D. Alignment of 16 aa peptides comprising RIR regions of
human pol, ,  used by Ohashi et al. (202) to identify the minimal motif required for Rev1-CT
interaction (underlined). The two consecutive Phe residues shown in the box are the only
residues conserved in all four RIR regions found in human Y-type DNA polymerases.
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Figure 4.2. Three-dimensional structure of the human Rev1-CT domain (residues 11571251) determined by solution NMR spectroscopy. A. Superposition of the backbone folds of
20 final lowest-energy structures obtained in CYANA (107) followed by refinement in explicit
solvent by CNS software (145). B. Ribbon representation of the Rev1-CT structure showing the
positions of four -helixes of the domain. Side chains are shown for residues that form core of
the domain with less than 10% surface exposure and 10 Å2 accessible surface area (averaged
over 20 best structures), including Leu1159, Ala1162 from the N-terminal -hairpin, Val1168,
Leu1172 (rev1-108), Ile1176 (rev1-108) from -helix H1, Val1190 (rev1-110), Tyr1193 (rev1110), Cys1194 (rev1-110), Leu1197, Ile1198 from -helix H2, Leu1206 (rev1-111), Val1209
(rev1-111), Ile1210 (rev1-111), Met1213, Leu1216, Met1217 from -helix H3, Trp1225,
Ala1228, Ile1232, Val1236, Leu1240 from -helix H4; underlined are residues from four
conserved 5-6 aa residue regions, referred to as rev1-108 to -111, identified by extensive
sequence alignment of Rev1-CT domains from different eukaryotic species (213). C.
Electrostatic charge distribution on the surface of the Rev1-CT domain (blue is positive, red is
negative). Encircled is a pocket on the surface of the domain that accommodates the FF residues
of RIR motifs of Y-family polymerases.
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Figure 4.3. Spatial structure of the complex of the human Rev1-CT domain (residues 11571251) with the RIR containing peptide from DNA polymerase  (residues 524-539). A.
Superposition of the backbone folds of 20 final least energy structures. Also shown are sidechains of Phe531 and Phe532 of pol critical for interaction with Rev1-CT. B. Superposition of
NMR structures of the free Rev1-CT domain (light colors) and the Rev1-CT/pol-RIR complex
(saturated colors). C and D. Interaction interface of the Rev1-CT domain complex with the polRIR peptide. Side chains of Rev1-CT residues that contribute 5 Å2 or more (averaged over 20
best structures) to the intermolecular interaction interface are shown on plot D.
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Figure 4.4. Inter-molecular NOEs observed for the Rev1-CT/polη-RIR complex. 1H-1H
cross-sections from a 13C-edited 15N,13C-filtered NOESY-HSQC spectrum of the Rev1-CT/polηRIR complex, displaying intermolecular protein-peptide NOE cross-peaks between selected
groups of the 13C/15N labeled Rev1-CT domain and 1H nuclei of the unlabeled polη-RIR peptide.
Multiple NOE connectivities are observed between the protons from the polη-RIR binding site of
the Rev1-CT domain and aromatic 1H of Phe residues of the polη-RIR motif.
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Figure 4.5. Mapping of the Rev1-CT/pol-RIR interface by yeast two-hybrid assays. The
region encoding the human Rev1 C-terminal 120 amino acid fragment (Rev1-CT) was fused to
the GAL4 Activation Domain (AD). The full-length polη-encoding region was appended to the
DNA-binding Domain (BD) of GAL4. A. Rev1 plasmids were transformed into strains harboring
BD-fused wild-type (WT) polη and the indicated mutations or into strains harboring the empty
expression plasmids (indicated by the – symbol in the figure). B. AD-appended WT Rev-CT and
the indicated mutations were transformed into strains containing BD-WT polη or the empty
expression plasmid (-). The plasmids were selected for by growth on media lacking leucine and
tryptophan (-LW) and interactions were scored by growth on plates also lacking Adenine and
Histidine (-AHLW).
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Figure 4.6. Conformational dynamics of the Rev1-CT domain and the Rev1-CT/polη-RIR
complex. A. 15N R1, R2 relaxation rates and 15N{1H} NOE values measured at 11.7 T magnetic
field, 15 oC, along with order parameters S2 (or S2 = Sf2Ss2) for the backbone amide groups
obtained in model-free analysis of 15N relaxation data for the free Rev1-CT domain (red) and the
Rev1-CT/pol-RIR complex (blue). B. Examples of experimental 15N CPMG dispersion profiles
R2,eff(CPMG) measured at 11.7 T magnetic field for selected residues of free (top plot) and polRIR bound (bottom plot) forms of Rev1-CT. C. Exchange contributions Rex = Rex,mf + Rex,rd to
15
N R2 rates measured at 11.7 T magnetic field mapped onto structures of the free Rev1-CT
domain (top) and the complex (bottom). Labeled numbers are residues with Rex > 5 s-1. Residues
exhibiting fast s-ms time scale exchange identified in model free-analysis of 15N relaxation data
(115,216) with Rex,mf contributing over 60% to a total Rex are marked in cyan. Residues
displaying slower ms time-scale exchange detected by 15N CPMG dispersion measurements
(217,224,225) with Rex,rd contributing over 60% to a total Rex are marked in magenta. Shown in
blue are residues with comparable Rex,mf and Rex,rd contributions. Phe1165, Ser1223 (free domain
and the complex) and Val1224 (the complex only) whose resonances are not detected in NMR
spectra presumably due to severe s-ms exchange line-broadening are assumed to have high Rex
values and are marked in grey.
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Figure 4.7. On-off equilibrium between free and bound forms of Rev1-CT contributes to
ms time-scale conformational exchange observed for the Rev1-CT/polη-RIR complex. A.
15
N CPMG relaxation dispersion data for the backbone amides of Trp1175 and Gln1189 of
Rev1-CT domain bound to the polη-RIR peptide recorded at 11.7T (red circles) and 18.8T (blue
circles) magnetic fields, and their best fits to a model of 2-state conformational exchange (solid
lines). Relaxation dispersion data for 77 residues of a bound form of the Rev1-CT domain
measured at two magnetic field strengths were globally fit to the model of 2-state exchange,
resulting in a population of the second (minor) state pB = 5.9 ± 0.4% and exchange rate constant
kex = 585 ± 23 s-1. B. 15N chemical shift differences obtained in the global fit of 15N CPMG
relaxation dispersion data for the Rev1-CT/polη-RIR complex, Δϖdisp, (red circles), and 15N
chemical shift differences between the free and polη-RIR bound forms of the Rev1-CT domain,
Δϖspec (grey impulses), plotted vs. residue number.
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CHAPTER 5

Summary and future directions
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5.1. Summary
The overall goal of this thesis was to elucidate the molecular mechanisms of USP7 substrate
specificity, its activation and inhibition. To address the specific aims, we explored the possibility
of studying USP7 using NMR spectroscopy. We optimized expression and purification
conditions for USP7 fragments including the catalytic core as well as the UBL1, UBL12, UBL3
and UBL45 C-terminal domains, performed backbone resonance assignment of the catalytic core
(Chapter 3), the UBL1 and the UBL12 domains (Chapter 2), and determined the solution
structure of the UBL1 domain described in Chapter 2. Almost complete backbone NMR
resonance assignment of the above USP7 fragments enabled structural characterization of the
enzyme interactions with its substrates and small-molecule compounds.
In Chapter 2, using NMR spectroscopy, we characterized a novel substrate-binding site
within USP7. In particular, we showed that ICP0 from HSV-1 interacts with the first two UBL
domains of USP7. The binding site is located on the surface of UBL2, which makes it the first
substrate-recognizing site discovered outside the N-terminal TRAF-like domain. In addition,
using cellular assays, we found that knockout of USP7 in HFF-1 cells negatively affects the
efficiency of HSV-1 lytic infection. Together these results provide a rationale for designing
small-molecule compounds for breaking the USP7 – ICP0 interaction that might be used for
treatment of HSV-1 infection in humans.
In Chapter 3, we described an unexpected insight into the mechanism of regulation of USP7
catalytic activity. We, for the first time, detected a weak (KD = 105.7 ± 15.9 μM) but specific
interaction between the isolated catalytic core of USP7 and free ubiquitin in solution. Consistent
with previous reports (72), we showed that ubiquitin binds to Fingers region of the enzyme.
However, strikingly, we discovered that this interaction does not induce conformational
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rearrangement of the USP7 active site that is critical for the deubiquitinase activity of the
enzyme. Therefore, contrary to previous findings (72), we revealed that ubiquitin binding alone
is not sufficient for USP7 activation and a substrate binding is likely required.
In Chapter 3, we presented the first structural analysis of USP7 inhibition by two smallmolecule compounds. We demonstrated that two USP7 inhibitors P22077 and P50429 (93) target
the catalytic cleft of the enzyme in a similar manner. Further, we uncovered the mode of action
for these inhibitors and, surprisingly, found that although P22077 and P50429 are structurally
related, they act via distinct chemical mechanisms to covalently modify the catalytic Cys223
residue. We complemented the obtained in vitro data with cellular studies showing that P22077
and P50429 specifically inhibit endogenous full-length USP7 in cells. Overall, these results
provide a structural basis for development of a new class of anti-cancer therapeutics.
Altogether, the results presented in this work aided to our understanding of how USP7
recognizes its substrates and how its catalytic activity is regulated in the cell and by available
small-molecular compounds.

Another goal of this work was to characterize the mechanism by which TLS DNA
polymerase REV1 recognizes other Y-family polymerases. We determined the spatial structures
of the free Rev1-CT domain and its complex with Polη-RIR. NMR characterization of the
protein structures and conformational dynamics, along with yeast two-hybrid assays revealed
that Polη binding to Rev1 is primarily mediated by the two conservative phenylalanine residues
of the Polη-RIR motif and amino-acid residues from the N-terminal β-hairpin of Rev1-CT. The
results allowed us to define the RIR motif as nFF(4h) where n is N-cap serine or proline residue,
F is phenylalanine and 4h are at least four residues that form an α-helix.
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5.2. Closing remarks and future directions
5.2.1. NMR spectroscopy is a powerful tool for studies of USP7
The work presented in this thesis differs from previous structural studies of USP7 in that it
employs solution NMR spectroscopy to study the enzyme. Several crystal structures of the
isolated USP7 domains were available in the literature (58,71,72) but we were the first to
determine the solution structure of one of the domains, UBL1. Most importantly, we proved the
feasibility of investigating USP7 interactions with its substrates and small-molecule compounds
in solution using NMR spectroscopy.
Here, we have developed a robust system for studies of USP7 in solution (Figure 5.1). In
addition to the assignments of USP7 catalytic core and UBL1, and UBL12 domains described
above, we also performed backbone resonance assignment of UBL3 (Figure 5.2) and UBL45
(Figure 5.3) domains. The TRAF-like domain has been previously assigned by Saridakis at al.
(58). Thus, our “divide and conquer” strategy provides nearly complete backbone resonance
assignment of the entire enzyme, which creates a powerful tool for future studies of USP7.
NMR sequence specific assignments accompanied by available crystal structures made it
possible to map substrate/inhibitor binding interfaces on the structure of USP7. Moreover,
solution NMR spectroscopy can now be used to investigate the molecular mechanisms of USP7
regulation such as inter-domain rearrangements and interactions with proteins altering the
activity of the enzyme. Furthermore, studies of the USP7 conformational dynamics are now
possible. Revealing the structural changes that occur during USP7 binding to its substrates,
regulatory factors or inhibitors will gain our understanding of how the enzyme functions and will
provide new possibilities for modulating its activity.
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5.2.2. Identification of novel substrate-binding sites within USP7
In Chapter 2, we described a novel substrate-binding site within USP7 located in its Cterminal region. Although it was previously known that C-USP7 is involved in protein-protein
interactions, the precise location of the binding sites remained unknown. We showed that a
negatively charged patch on the surface of UBL2 domain serves as an interaction site for a
positively charged peptide from a viral protein ICP0.
Our findings provided the first structural evidence that C-USP7 functions as a substratebinding platform along with the N-terminal TRAF-like domain. Two other research groups have
reported crystal structures of UBL12 in complex with ICP0 that confirmed our findings (85,257).
In addition, crystal structures of UBL1-3 complexes with UHRF1 and DNMT1 were recently
published (258,259). Interestingly, these structures revealed that both UHRF1 and DNMT1
recognize C-USP7 in a manner similar to ICP0. Specifically, these proteins have a positively
charged motif in their sequence that binds to the same negatively charged surface of UBL2 as
ICP0. Thus, our and others’ studies combined discovered the molecular mechanism of substrate
recognition by UBL12 tandem. Moreover, provided the fact that these three proteins harbor
short, ~10 amino residue sequence containing several lysines or/and arginines, the presence of
such a sequence in a USP7 substrate can be now used to predict its interaction with UBL12
tandem. Along with a search for P/AxxS motifs that bind to the USP7 TRAF-like domain, a
search for this newly described substrate feature might simplify the future mapping of
USP7/substrate binding interfaces.
USP7 interacts with and deubiquitinates over cellular 30 proteins (Table 1.1). Although the
majority of these interactions have been biochemically and functionally characterized, only five
complexes have been characterized structurally. These include complexes with p53, HDM2,
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DNMT1, UHRF1 and UbE2E1 (27,73,74,258,259). The lack of structural information about
USP7/substrate binding interfaces is a critical gap in the development of highly targeted
compounds modulating activity of USP7 towards a particular protein. Likely, several of known
USP7 binding partners will be found to interact with either the TRAF-like domain or UBL12
tandem via discovered mechanisms. However, it is already clear that structural studies of some
interactions such as HDM2 binding to the C-terminal UBL3 domain or FOX(O)4 and p53
binding to UBL45 tandem will reveal new determinants of USP7 substrate specificity. Among
others, USP7 interaction with TRIM27 E3 ligase is of the special interest. According to a
recently published study, the C-terminal region of TRIM27 directly binds to the USP7 catalytic
domain that previously was known to recognize only ubiquitin (132). Interestingly, this E3 ligase
is both the substrate of USP7 and the regulator of its catalytic activity (63,132). Therefore,
structural characterization of the complex might not only identify a novel substrate-binding site
within the USP7 catalytic domain but also uncover the molecular mechanism of USP7 regulation
by co-factors. Finally, structural characterization of USP7 interactions with histone-associated
proteins represents another interesting subject for future investigations. USP7 interacts with all
PRC1 components in vitro (reviewed in subchapter 1.1.3) but it is not clear whether these
multiple interactions occur simultaneously or competitively in the context of the intact complex
in cells. Moreover, USP7 binds several other proteins involved in post-translational
modifications of histones; however, it is not known how all these interactions are organized in
space and time. Mapping of the binding interfaces between USP7 and its substrates located on
chromatin will help to answer these questions and provide insight into not yet known functions
of USP7.
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5.2.3. Mechanism of USP7 activation
In Chapter 3 of this thesis, we found that USP7 interaction with free ubiquitin does not cause
the rearrangement of the catalytic residues into productive conformation contrary to what was
previously postulated (72). These results suggest that binding to a ubiquitinated substrate might
be needed for efficient activation of the enzyme. We hypothesize that the simultaneous
interactions of the substrate with TRAF-like/UBL domains and ubiquitin with the catalytic core
ensure the correct placement of the flexible ubiquitin tail in the catalytic cleft and promote
conformational changes in the active site necessary for cleavage of the isopeptide bond.
Furthermore, there is mounting evidence that C-terminal region of USP7 is critical for efficient
ubiquitin binding and enzymatic activity (62,71). Interestingly, even in the absence of a
substrate, a USP7 construct containing the catalytic core and C-terminal UBL domains is active
on di-ubiquitin and ubiquitin-AMC (ubiquitin fused to 7-amido-4-methylcoumarin) while the
isolated catalytic domain is not (71). These observations together with our results suggest that CUSP7 might play a role in the active site rearrangement. In addition, there is a possibility that
both, presence of the C-terminal domains and an interaction with a ubiquitinated substrate are
required for efficient activation of USP7. Thus, to fully answer the question “How is USP7
activated?” we need to determine the structure of the full-length protein and investigate the effect
of a substrate binding on the overall conformation of the enzyme.
The current model of the full-length USP7 suggests that UBL domains fold back in order to
bring the extreme C-terminal peptide required for the deubiquitinase activity towards the
catalytic domain (Figure 1.4C) (71,84). The large size of USP7 and inter-domain dynamics
makes structure determination using X-Ray crystallography challenging. Figure 5.4A illustrates
the alternative multi-disciplinary approach that might be used to overcome the challenge. We
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propose to initially identify possible inter-domain interactions using methods such pull-downs,
SPR, ITC and mutagenesis. NMR might be further used to map the inter-domain binding
interfaces. To investigate whether USP7 adopts a compact or extended conformation, or samples
both conformations, one can use small-angle X-Ray scattering (SAXS). Finally, a highresolution structure of full-length USP7 can be determined by fitting the structures of individual
domains into density maps obtained with cryo-electron microscopy (cryo-EM). A structure of
intact USP7 complexed with one of its ubiquitinated substrates might also be determined using
cryo-EM. Together, the structures of free full-length USP7 and its complexes with substrates will
provide a detailed picture of the enzyme’s action.
As the first step towards determination of the structure of fill-length USP7, we used negative
stain EM and collected microphotographs of the protein purified from insect cells. Our results
indicate that USP7 adopts a compact structure as evidenced by observed doughnut shaped
molecules (Figure 5.4B). These preliminary results provide further support for a model of the
full-length enzyme where its C-terminal and N-terminal regions closely interact with each other.
However, the high-resolution structure of intact USP7 is needed to elucidate the exact positions
of its domains relative to each other and to explain how its C-terminal peptide affects the
catalytic activity.

5.2.4. Future of USP7 inhibition by small-molecule compounds
In Chapter 3, we uncovered the mechanism of USP7 inhibition by two dual USP7/USP47
inhibitors. Despite the success of high throughput screening, the lack of structural biophysical
characterization hindered their further optimization. The work described in Chapter 3 is the first
comprehensive study that characterizes binding of the inhibitors to the enzyme as well as their
mechanism of action. Since we found that compounds P22077 and P50429 used in this study
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covalently modify the catalytic Cys223 residue, our results raise the critical for drug
development question “If the inhibitors target the highly conservative active site, how is the
specificity towards USP7 and USP47 achieved?” Our findings do not answer this question but
provide a few interesting clues. In particular, we show that the inhibitors’ binding induces
conformational changes in the unique misaligned active site of USP7 similar to those seen in the
enzyme modified by ubiquitin aldehyde (72). One possible explanation for P22077 and P50429
specificity is that they target the catalytically unproductive conformation of the USP7 catalytic
core. In this light, it would be interesting to see whether the USP47 active site is also misaligned.
Furthermore, our structural models of USP7 – inhibitor complexes in combination with
identification of conserved residues revealed a few residues in the proximity of the active site
that are unique to USP7 and USP47. However, mutagenesis studies are required to check if these
unique residues are significant for initial binding. In addition, at least one another inhibitor of
USP7, HBX 19,818, was shown to target its active site (92). This compound is highly specific
for USP7, thus its structural characterization in complex with the enzyme would significantly
contribute to the understanding of the molecular mechanism of USP7 inhibition and might
provide novel approaches to making compounds more specific.
The mapping of USP7/substrate interfaces opens a new alternative strategy for manipulating
the enzyme by targeting one of its substrate-binding sites instead of the catalytic domain. Such
compounds can potentially control stability of a specific USP7 substrate or a group of substrates.
Importantly, the success of designing compounds that break protein-protein interactions depends
on the size and structural complexity of a binding interface. It is easier to design a small
molecule resembling a linear short peptide rather than a molecule mimicking interaction with
secondary or tertiary structure elements (97). The fact that both the TRAF-like domain and
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UBL12 recognize short extended peptides is encouraging for discovery of compounds that can
interrupt USP7 binding to specific substrates. NMR spectroscopy can be a useful tool in the
development such compounds. It is widely used in fragment based drug design (FBDD) that was
proved to be a more effective approach to targeting protein-protein interactions than highthroughput screening (260). FBDD identifies initial low-complexity molecules that weakly bind
to protein/substrate interfaces; therefore, NMR backbone resonance assignment of the isolated
USP7 domains presented in this work might simplify the identification of such small molecules
in the future.

Manipulation of the ubiquitin – proteasome system might be an effective strategy for
treatment of human cancers (90); yet before targeting any of the E1, E2, E3 or DUB enzymes in
humans, we need to fully comprehend how these enzymes function and how their activity is
controlled. This thesis expands our knowledge of molecular mechanisms underlying substrate
specificity and regulation of deubiquitinating enzyme USP7. Nevertheless, this work is only the
beginning. There is still much to be learned about USP7 on the molecular level as well as in
context of the cell and the whole organism. Furthermore, there are dozens of other DUBs and
other components of UPS that are involved in vital cellular processes and need to be extensively
studied in terms of their pharmaceutical potential. Once we have a complete picture of the
interplay between various UPS participants, we will be able to take full advantage of this
fascinating cellular system to treat life-threatening human diseases.
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Figure 5.1. NMR resonance assignment of all USP7 domains provides new opportunities
for studying the enzyme in solution. 2D 1H-15N HSQC spectra of USP7 fragments including
the TRAF-like domain (pink), catalytic domain (purple), UBL1 (blue), UBL12 (green), UBL3
(black) and UBL45 (red) domains, for which backbone resonance assignment is available. NMR
resonances of TRAF-like domain have been assigned previously (58); resonance assignment of
all other fragments has been performed during studies presented in this thesis. The schematic
representation of USP7 domain organization is shown above the spectra.
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Figure 5.2. Backbone resonance assignment of the USP7 UBL3 domain. The 1H-15N HSQC
spectrum of USP7 C-terminal UBL3 domain with residue-specific assignments indicated.
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Figure 5.3. Backbone resonance assignment of the USP7 UBL45 domain. The 1H-15N
TROSY-HSQC spectrum of USP7 C-terminal UBL45 tandem with residue-specific assignments
indicated.
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Figure 5.4. Pathway towards the structure of full-length USP7. A. Multi-method approach
for determining the structure of full-length USP7. B. Negative stain electron microscopy of fulllength USP7. Left panel shows an example photomicrograph with three selected particles boxed.
The inset shows the same particles at larger magnification (100Å scale bar). Right panel shows
class averages obtained using EMAN2 (261).
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